BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Caldwell SH, Oelsner DH, Iezzoni JC, Hespenheide EE, Battle EH, Driscoll CJ. Cryptogenic cirrhosis: Clinical characterization and risk factors for underlying disease. Hepatology 1999;29:664-9. [DOI: 10.1002/hep.510290347] [Cited by in Crossref: 744] [Cited by in F6Publishing: 685] [Article Influence: 33.8] [Reference Citation Analysis]
Number Citing Articles
1 Basaranoglu M, Kayacetin S, Yilmaz N, Kayacetin E, Tarcin O, Sonsuz A. Understanding mechanisms of the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2010; 16(18): 2223-2226 [PMID: 20458758 DOI: 10.3748/wjg.v16.i18.2223] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
2 Bellentani S. The epidemiology of non-alcoholic fatty liver disease. Liver Int. 2017;37 Suppl 1:81-84. [PMID: 28052624 DOI: 10.1111/liv.13299] [Cited by in Crossref: 312] [Cited by in F6Publishing: 277] [Article Influence: 78.0] [Reference Citation Analysis]
3 Alsohaibani F, Porter G, Al-Ashgar H, Walsh M, Berry R, Molinari M, Peltekian KM. Comparison of cancer care for hepatocellular carcinoma at two tertiary-care referral centers from high and low endemic regions for viral hepatitis. J Gastrointest Cancer 2011;42:228-35. [PMID: 20809396 DOI: 10.1007/s12029-010-9200-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
4 Patel YA, Berg CL, Moylan CA. Nonalcoholic Fatty Liver Disease: Key Considerations Before and After Liver Transplantation. Dig Dis Sci. 2016;61:1406-1416. [PMID: 26815171 DOI: 10.1007/s10620-016-4035-3] [Cited by in Crossref: 38] [Cited by in F6Publishing: 29] [Article Influence: 7.6] [Reference Citation Analysis]
5 Jirillo E, Caccavo D, Magrone T, Piccigallo E, Amati L, Lembo A, Kalis C, Gumenscheimer M. Review: The role of the liver in the response to LPS: experimental and clinical findings. Journal of Endotoxin Research 2002;8:319-27. [DOI: 10.1177/09680519020080050501] [Cited by in Crossref: 11] [Cited by in F6Publishing: 6] [Article Influence: 2.2] [Reference Citation Analysis]
6 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 6.3] [Reference Citation Analysis]
7 Baffy G, Brunt EM, Caldwell SH. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace. J Hepatol 2012;56:1384-91. [PMID: 22326465 DOI: 10.1016/j.jhep.2011.10.027] [Cited by in Crossref: 536] [Cited by in F6Publishing: 505] [Article Influence: 59.6] [Reference Citation Analysis]
8 Altlparmak E, Köklü S, Yallnklllc M, Yüksel O, Cicek B, Kayacetin E, Sahin T. Viral and host causes of fatty liver in chronic hepatitis B. World J Gastroenterol 2005; 11(20): 3056-3059 [PMID: 15918189 DOI: 10.3748/wjg.v11.i20.3056] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 54] [Article Influence: 3.5] [Reference Citation Analysis]
9 Ali R, Cusi K. New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann Med. 2009;41:265-278. [PMID: 19353360 DOI: 10.1080/07853890802552437] [Cited by in Crossref: 77] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
10 Paradis V, Zalinski S, Chelbi E, Guedj N, Degos F, Vilgrain V, Bedossa P, Belghiti J. Hepatocellular carcinomas in patients with metabolic syndrome often develop without significant liver fibrosis: a pathological analysis. Hepatology. 2009;49:851-859. [PMID: 19115377 DOI: 10.1002/hep.22734] [Cited by in Crossref: 377] [Cited by in F6Publishing: 341] [Article Influence: 31.4] [Reference Citation Analysis]
11 Merat S, Malekzadeh R, Sohrabi MR, Hormazdi M, Naserimoghadam S, Mikaeli J, Farahvash MJ, Ansari R, Sotoudehmanesh R, Khatibian M. Probucol in the Treatment of Nonalcoholic Steatohepatitis: An Open-Labeled Study. Journal of Clinical Gastroenterology 2003;36:266-8. [DOI: 10.1097/00004836-200303000-00015] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.4] [Reference Citation Analysis]
12 Feldstein AE, Papouchado BG, Angulo P, Sanderson S, Adams L, Gores GJ. Hepatic stellate cells and fibrosis progression in patients with nonalcoholic fatty liver disease. Clinical Gastroenterology and Hepatology 2005;3:384-9. [DOI: 10.1016/s1542-3565(04)00616-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
13 Yang JS, Kim JT, Jeon J, Park HS, Kang GH, Park KS, Lee HK, Kim S, Cho YM. Changes in hepatic gene expression upon oral administration of taurine-conjugated ursodeoxycholic acid in ob/ob mice. PLoS One 2010;5:e13858. [PMID: 21079772 DOI: 10.1371/journal.pone.0013858] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 3.6] [Reference Citation Analysis]
14 Harada N, Soejima Y, Taketomi A, Yoshizumi T, Uchiyama H, Ikegami T, Saibara T, Nishizaki T, Maehara Y. Recurrent familial hypobetalipoproteinemia-induced nonalcoholic fatty liver disease after living donor liver transplantation. Liver Transpl 2009;15:806-9. [PMID: 19562718 DOI: 10.1002/lt.21766] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
15 Nascimbeni F, Bedossa P, Fedchuk L, Pais R, Charlotte F, Lebray P, Poynard T, Ratziu V; LIDO (Liver Injury in Diabetes and Obesity) Study Group. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol 2020;72:828-38. [PMID: 31862486 DOI: 10.1016/j.jhep.2019.12.008] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 10.0] [Reference Citation Analysis]
16 Al-osaimi AMS, Berg CL, Caldwell SH. Intermittent disconjugate gaze: A novel finding in nonalcoholic steatohepatitis and cryptogenic cirrhosis. Hepatology 2005;41:943-943. [DOI: 10.1002/hep.20675] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
17 Mousa N, Abdel-Razik A, Zaher A, Hamed M, Shiha G, Effat N, Elbaz S, Elhelaly R, Hafez M, El-Wakeel N, Eldars W. The role of antioxidants and zinc in minimal hepatic encephalopathy: a randomized trial. Therap Adv Gastroenterol. 2016;9:684-691. [PMID: 27582881 DOI: 10.1177/1756283x16645049] [Cited by in Crossref: 16] [Cited by in F6Publishing: 8] [Article Influence: 3.2] [Reference Citation Analysis]
18 Adams LA, Angulo P, Lindor KD. Nonalcoholic fatty liver disease. CMAJ. 2005;172:899-905. [PMID: 15795412 DOI: 10.1503/cmaj.045232] [Cited by in Crossref: 330] [Cited by in F6Publishing: 314] [Article Influence: 20.6] [Reference Citation Analysis]
19 Menghini R, Casagrande V, Menini S, Marino A, Marzano V, Hribal ML, Gentileschi P, Lauro D, Schillaci O, Pugliese G, Sbraccia P, Urbani A, Lauro R, Federici M. TIMP3 overexpression in macrophages protects from insulin resistance, adipose inflammation, and nonalcoholic fatty liver disease in mice. Diabetes 2012;61:454-62. [PMID: 22228717 DOI: 10.2337/db11-0613] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 5.7] [Reference Citation Analysis]
20 Saugspier M, Dorn C, Thasler WE, Gehrig M, Heilmann J, Hellerbrand C. Hop bitter acids exhibit anti-fibrogenic effects on hepatic stellate cells in vitro. Experimental and Molecular Pathology 2012;92:222-8. [DOI: 10.1016/j.yexmp.2011.11.005] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
21 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 117] [Article Influence: 11.4] [Reference Citation Analysis]
22 Enzan H, Toi M, Hayashi Y, Hamauzu T, Kuroda N, Hiroi M. Zone 3 Predominance of Histopathological Features in Nonalcoholic Steatohepatitis. In: Okita K, editor. NASH and Nutritional Therapy. Tokyo: Springer-Verlag; 2005. pp. 50-7. [DOI: 10.1007/4-431-27172-4_3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
23 Hayashi PH, Harrison SA, Torgerson S, Perez TA, Nochajski T, Russell M. Cognitive Lifetime Drinking History in Nonalcoholic Fatty Liver Disease: Some Cases May Be Alcohol Related. Am J Gastroenterol 2004;99:76-81. [DOI: 10.1046/j.1572-0241.2003.04013.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 37] [Article Influence: 2.5] [Reference Citation Analysis]
24 Laggai S, Simon Y, Ranssweiler T, Kiemer AK, Kessler SM. Rapid chromatographic method to decipher distinct alterations in lipid classes in NAFLD/NASH. World J Hepatol 2013; 5(10): 558-567 [PMID: 24179615 DOI: 10.4254/wjh.v5.i10.558] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
25 Huang X, Xu M, Chen Y, Peng K, Huang Y, Wang P, Ding L, Lin L, Xu Y, Chen Y, Lu J, Wang W, Bi Y, Ning G. Validation of the Fatty Liver Index for Nonalcoholic Fatty Liver Disease in Middle-Aged and Elderly Chinese. Medicine (Baltimore) 2015;94:e1682. [PMID: 26448014 DOI: 10.1097/MD.0000000000001682] [Cited by in Crossref: 59] [Cited by in F6Publishing: 30] [Article Influence: 11.8] [Reference Citation Analysis]
26 Lee SS, Lee Y, Kim N, Kim SW, Byun JH, Park SH, Lee MG, Ha HK. Hepatic fat quantification using chemical shift MR imaging and MR spectroscopy in the presence of hepatic iron deposition: validation in phantoms and in patients with chronic liver disease. J Magn Reson Imaging. 2011;33:1390-1398. [PMID: 21591008 DOI: 10.1002/jmri.22583] [Cited by in Crossref: 45] [Cited by in F6Publishing: 41] [Article Influence: 4.5] [Reference Citation Analysis]
27 Brunt EM. Pathology of nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:195-203. [PMID: 20195271 DOI: 10.1038/nrgastro.2010.21] [Cited by in Crossref: 318] [Cited by in F6Publishing: 297] [Article Influence: 28.9] [Reference Citation Analysis]
28 Koh WP, Wang R, Jin A, Yu MC, Yuan JM. Diabetes mellitus and risk of hepatocellular carcinoma: findings from the Singapore Chinese Health Study. Br J Cancer. 2013;108:1182-1188. [PMID: 23370206 DOI: 10.1038/bjc.2013.25] [Cited by in Crossref: 50] [Cited by in F6Publishing: 48] [Article Influence: 6.3] [Reference Citation Analysis]
29 Abdel-Razik A, Mousa N, Elbaz S, Eissa M, Elhelaly R, Eldars W. Diagnostic utility of interferon gamma-induced protein 10 kDa in spontaneous bacterial peritonitis: single-center study. Eur J Gastroenterol Hepatol. 2015;27:1087-1093. [PMID: 26020377 DOI: 10.1097/meg.0000000000000400] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
30 Martin P, DiMartini A, Feng S, Brown R, Fallon M. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology. 2014;59:1144-1165. [PMID: 24716201 DOI: 10.1002/hep.26972] [Cited by in Crossref: 429] [Cited by in F6Publishing: 324] [Article Influence: 61.3] [Reference Citation Analysis]
31 Dorn C, Kraus B, Motyl M, Weiss TS, Gehrig M, Schölmerich J, Heilmann J, Hellerbrand C. Xanthohumol, a chalcon derived from hops, inhibits hepatic inflammation and fibrosis. Mol Nutr Food Res 2010;54 Suppl 2:S205-13. [PMID: 20087858 DOI: 10.1002/mnfr.200900314] [Cited by in Crossref: 55] [Cited by in F6Publishing: 51] [Article Influence: 5.0] [Reference Citation Analysis]
32 Page JM, Harrison SA. NASH and HCC. Clin Liver Dis. 2009;13:631-647. [PMID: 19818310 DOI: 10.1016/j.cld.2009.07.007] [Cited by in Crossref: 87] [Cited by in F6Publishing: 90] [Article Influence: 7.3] [Reference Citation Analysis]
33 Wu J, Zeng C, Yang Z, Li X, Lei G, Xie D, Wang Y, Wei J, Yang T. Association Between Dietary Selenium Intake and the Prevalence of Nonalcoholic Fatty Liver Disease: A Cross-Sectional Study.J Am Coll Nutr. 2020;39:103-111. [PMID: 31157605 DOI: 10.1080/07315724.2019.1613271] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
34 Suzuki A, Angulo P, Lymp J, St Sauver J, Muto A, Okada T, Lindor K. Chronological development of elevated aminotransferases in a nonalcoholic population. Hepatology. 2005;41:64-71. [PMID: 15690483 DOI: 10.1002/hep.20543] [Cited by in Crossref: 133] [Cited by in F6Publishing: 115] [Article Influence: 8.3] [Reference Citation Analysis]
35 Flemming JA, Yang JD, Vittinghoff E, Kim WR, Terrault NA. Risk prediction of hepatocellular carcinoma in patients with cirrhosis: the ADRESS-HCC risk model. Cancer. 2014;120:3485-3493. [PMID: 25042049 DOI: 10.1002/cncr.28832] [Cited by in Crossref: 79] [Cited by in F6Publishing: 71] [Article Influence: 11.3] [Reference Citation Analysis]
36 Lackner C. Hepatocellular ballooning in nonalcoholic steatohepatitis: the pathologist’s perspective. Expert Rev Gastroenterol Hepatol. 2011;5:223-231. [PMID: 21476917 DOI: 10.1586/egh.11.8] [Cited by in Crossref: 40] [Cited by in F6Publishing: 38] [Article Influence: 4.0] [Reference Citation Analysis]
37 García-Compeán D, Jáquez-Quintana JO, González-González JA, Lavalle-González FJ, Villarreal-Pérez JZ, Maldonado-Garza HJ. [Diabetes in liver cirrhosis]. Gastroenterol Hepatol 2013;36:473-82. [PMID: 23628170 DOI: 10.1016/j.gastrohep.2013.01.012] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
38 Tsang SWC, Ng WF, Wu BPY, Chow DA, Li ETH, Wong TC. Predictors of fibrosis in Asian patients with non-alcoholic steatohepatitis. Journal of Gastroenterology and Hepatology 2006;21:116-21. [DOI: 10.1111/j.1440-1746.2005.04146.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
39 Clark JM, Brancati FL, Diehl AM. The prevalence and etiology of elevated aminotransferase levels in the United States. Am J Gastroenterol. 2003;98:960-967. [PMID: 12809815 DOI: 10.1111/j.1572-0241.2003.07486.x] [Cited by in Crossref: 880] [Cited by in F6Publishing: 827] [Article Influence: 48.9] [Reference Citation Analysis]
40 Alswat KA, Mumtaz K, Jafri W. Liver biopsy for histological assessment: The case in favor. Saudi J Gastroenterol 2010;16:133-9. [PMID: 20339188 DOI: 10.4103/1319-3767.61245] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
41 Mills SJ, Harrison SA. Comparison of the natural history of alcoholic and nonalcoholic fatty liver disease. Curr Gastroenterol Rep. 2005;7:32-36. [PMID: 15701296 DOI: 10.1007/s11894-005-0063-4] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 2.8] [Reference Citation Analysis]
42 Kim MK, Chanda D, Lee IK, Choi HS, Park KG. Targeting orphan nuclear receptor SHP in the treatment of metabolic diseases. Expert Opin Ther Targets 2010;14:453-66. [PMID: 20230197 DOI: 10.1517/14728221003652463] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
43 Berg T, Neuhaus R, Klein R, Leder K, Lobeck H, Bechstein W, Müller AR, Wiedenmann B, Hopf U, Berg PA, Neuhaus P. DISTINCT ENZYME PROFILES IN PATIENTS WITH CRYPTOGENIC CIRRHOSIS REFLECT HETEROGENEOUS CAUSES WITH DIFFERENT OUTCOMES AFTER LIVER TRANSPLANTATION (OLT): A LONG-TERM DOCUMENTATION BEFORE AND AFTER OLT: . Transplantation 2002;74:792-8. [DOI: 10.1097/00007890-200209270-00010] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
44 Tuyama AC, Chang CY. Non-alcoholic fatty liver disease: Non-alcoholic fatty liver disease. Journal of Diabetes 2012;4:266-80. [DOI: 10.1111/j.1753-0407.2012.00204.x] [Cited by in Crossref: 37] [Cited by in F6Publishing: 31] [Article Influence: 4.1] [Reference Citation Analysis]
45 Samara K, Liu C, Soldevila-Pico C, Nelson DR, Abdelmalek MF. Betaine resolves severe alcohol-induced hepatitis and steatosis following liver transplantation. Dig Dis Sci. 2006;51:1226-1229. [PMID: 16944015 DOI: 10.1007/s10620-006-8038-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
46 Rafiq N, Younossi ZM. Nonalcoholic fatty liver disease: a practical approach to evaluation and management. Clin Liver Dis. 2009;13:249-266. [PMID: 19442917 DOI: 10.1016/j.cld.2009.02.009] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 3.6] [Reference Citation Analysis]
47 Starley BQ, Calcagno CJ, Harrison SA. Nonalcoholic fatty liver disease and hepatocellular carcinoma: A weighty connection. Hepatology 2010;51:1820-32. [DOI: 10.1002/hep.23594] [Cited by in Crossref: 871] [Cited by in F6Publishing: 827] [Article Influence: 79.2] [Reference Citation Analysis]
48 Bruguera M, Sánchez Tapias JM. ¿Qué son las enfermedades hepáticas criptogenéticas? Medicina Clínica 2000;114:31-6. [DOI: 10.1016/s0025-7753(00)71178-x] [Cited by in Crossref: 3] [Article Influence: 0.1] [Reference Citation Analysis]
49 Clark JM, Diehl AM. Hepatic steatosis and type 2 diabetes mellitus. Curr Diab Rep. 2002;2:210-215. [PMID: 12643175 DOI: 10.1007/s11892-002-0085-3] [Cited by in Crossref: 74] [Cited by in F6Publishing: 75] [Article Influence: 4.1] [Reference Citation Analysis]
50 Malik SM, deVera ME, Fontes P, Shaikh O, Ahmad J. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant. 2009;9:782-793. [PMID: 19344467 DOI: 10.1111/j.1600-6143.2009.02590.x] [Cited by in Crossref: 141] [Cited by in F6Publishing: 121] [Article Influence: 11.8] [Reference Citation Analysis]
51 Lazo M, Hernaez R, Bonekamp S, Kamel IR, Brancati FL, Guallar E, Clark JM. Non-alcoholic fatty liver disease and mortality among US adults: prospective cohort study. BMJ. 2011;343:d6891. [PMID: 22102439 DOI: 10.1136/bmj.d6891] [Cited by in Crossref: 231] [Cited by in F6Publishing: 218] [Article Influence: 23.1] [Reference Citation Analysis]
52 Ishak KG. Pathologic features of chronic hepatitis. A review and update. Am J Clin Pathol. 2000;113:40-55. [PMID: 10631857 DOI: 10.1309/42d6-w7pl-fx0a-lbxf] [Cited by in Crossref: 84] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
53 Sanyal AJ;  American Gastroenterological Association. AGA technical review on nonalcoholic fatty liver disease. Gastroenterology. 2002;123:1705-1725. [PMID: 12404245 DOI: 10.1053/gast.2002.36572] [Cited by in Crossref: 701] [Cited by in F6Publishing: 659] [Article Influence: 36.9] [Reference Citation Analysis]
54 Heneghan MA, Zolfino T, Muiesan P, Portmann BC, Rela M, Heaton ND, O'grady JG. An evaluation of long-term outcomes after liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2003;9:921-928. [PMID: 12942453 DOI: 10.1053/jlts.2003.50165] [Cited by in Crossref: 33] [Cited by in F6Publishing: 30] [Article Influence: 1.9] [Reference Citation Analysis]
55 Perumpail RB, Liu A, Wong RJ, Ahmed A, Harrison SA. Pathogenesis of hepatocarcinogenesis in non-cirrhotic nonalcoholic fatty liver disease: Potential mechanistic pathways. World J Hepatol 2015; 7(22): 2384-2388 [PMID: 26464753 DOI: 10.4254/wjh.v7.i22.2384] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
56 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74-S83. [PMID: 12407579 DOI: 10.1002/hep.1840360710] [Cited by in Crossref: 195] [Cited by in F6Publishing: 127] [Article Influence: 10.3] [Reference Citation Analysis]
57 Oo YH, Neuberger J. Recurrence of Nonviral Diseases. Clinics in Liver Disease 2007;11:377-95. [DOI: 10.1016/j.cld.2007.04.012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
58 Adams LA, Lymp JF, St. Sauver J, Sanderson SO, Lindor KD, Feldstein A, Angulo P. The Natural History of Nonalcoholic Fatty Liver Disease: A Population-Based Cohort Study. Gastroenterology 2005;129:113-21. [DOI: 10.1053/j.gastro.2005.04.014] [Cited by in Crossref: 1888] [Cited by in F6Publishing: 1741] [Article Influence: 118.0] [Reference Citation Analysis]
59 Blei AT, Mazhar S, Davidson CJ, Flamm SL, Abecassis M, Gheorghiade M. Hemodynamic Evaluation Before Liver Transplantation: Insights Into the Portal Hypertensive Syndrome. Journal of Clinical Gastroenterology 2007;41:S323-9. [DOI: 10.1097/mcg.0b013e318157188e] [Cited by in Crossref: 21] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
60 Solga SF, Diehl AM. Non-alcoholic fatty liver disease: lumen-liver interactions and possible role for probiotics. J Hepatol. 2003;38:681-687. [PMID: 12713883 DOI: 10.1016/s0168-8278(03)00097-7] [Cited by in Crossref: 124] [Cited by in F6Publishing: 51] [Article Influence: 7.3] [Reference Citation Analysis]
61 Amarapurkar D, Amarapurkar A, Patel N, Agal S, Baigal R, Gupte P, Pramanik S. Nonalcoholic steatohepatitis (NASH) with diabetes: predictors of liver fibrosis. Annals of Hepatology 2006;5:30-3. [DOI: 10.1016/s1665-2681(19)32036-8] [Cited by in Crossref: 49] [Article Influence: 3.3] [Reference Citation Analysis]
62 Manton ND, Lipsett J, Moore DJ, Davidson GP, Bourne AJ, Couper RT. Non‐alcoholic steatohepatitis in children and adolescents. Medical Journal of Australia 2000;173:476-9. [DOI: 10.5694/j.1326-5377.2000.tb139299.x] [Cited by in Crossref: 93] [Cited by in F6Publishing: 88] [Article Influence: 4.4] [Reference Citation Analysis]
63 Yamamoto M, Iwasa M, Iwata K, Kaito M, Sugimoto R, Urawa N, Mifuji R, Konishi M, Kobayashi Y, Adachi Y. Restriction of dietary calories, fat and iron improves non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2007;22:498-503. [DOI: 10.1111/j.1440-1746.2006.04548.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
64 Simo KA, McKillop IH, McMillan MT, Ahrens WA, Walters AL, Thompson KJ, Kuwada TS, Martinie JB, Iannitti DA, Gersin KS, Sindram D. Does a calculated "NAFLD fibrosis score" reliably negate the need for liver biopsy in patients undergoing bariatric surgery? Obes Surg. 2014;24:15-21. [PMID: 23934335 DOI: 10.1007/s11695-013-1044-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.7] [Reference Citation Analysis]
65 Hiraoka A, Ochi M, Matsuda R, Aibiki T, Okudaira T, Kawamura T, Yamago H, Nakahara H, Suga Y, Azemoto N, Miyata H, Miyamoto Y, Ninomiya T, Hirooka M, Abe M, Matsuura B, Hiasa Y, Michitaka K. Ultrasonography screening for hepatocellular carcinoma in Japanese patients with diabetes mellitus. J Diabetes 2016;8:640-6. [PMID: 26347476 DOI: 10.1111/1753-0407.12340] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
66 Tanaka S, Iimuro Y, Hirano T, Hai S, Suzumura K, Nakamura I, Kondo Y, Fujimoto J. Safety of hepatic resection for hepatocellular carcinoma in obese patients with cirrhosis. Surg Today 2013;43:1290-7. [DOI: 10.1007/s00595-013-0706-2] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
67 Bedossa P, Kleiner DE. Pathology of Alcoholic and Nonalcoholic Fatty Liver Disease. In: Chalasani N, Szabo G, editors. Alcoholic and Non-Alcoholic Fatty Liver Disease. Cham: Springer International Publishing; 2016. pp. 223-47. [DOI: 10.1007/978-3-319-20538-0_12] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
68 Goodman ZD. The Impact of Obesity on Liver Histology. Clinics in Liver Disease 2014;18:33-40. [DOI: 10.1016/j.cld.2013.09.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
69 Joaquim M, Escobar-Henriques M. Role of Mitofusins and Mitophagy in Life or Death Decisions. Front Cell Dev Biol 2020;8:572182. [PMID: 33072754 DOI: 10.3389/fcell.2020.572182] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
70 Rockey DC, Caldwell SH, Goodman ZD, Nelson RC, Smith AD;  American Association for the Study of Liver Diseases. Liver biopsy. Hepatology. 2009;49:1017-1044. [PMID: 19243014 DOI: 10.1002/hep.22742] [Cited by in Crossref: 1217] [Cited by in F6Publishing: 1044] [Article Influence: 101.4] [Reference Citation Analysis]
71 Poordad FF. Nonalcoholic fatty liver disease: a review. Expert Opinion on Emerging Drugs 2005;10:661-70. [DOI: 10.1517/14728214.10.3.661] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
72 Polyzos SA, Kountouras J, Zavos C, Tsiaousi E. The role of adiponectin in the pathogenesis and treatment of non-alcoholic fatty liver disease. Diabetes Obes Metab. 2010;12:365-383. [PMID: 20415685 DOI: 10.1111/j.1463-1326.2009.01176.x] [Cited by in Crossref: 142] [Cited by in F6Publishing: 138] [Article Influence: 14.2] [Reference Citation Analysis]
73 Ikejima K, Takei Y, Honda H, Hirose M, Yoshikawa M, Zhang YJ, Lang T, Fukuda T, Yamashina S, Kitamura T, Sato N. Leptin receptor-mediated signaling regulates hepatic fibrogenesis and remodeling of extracellular matrix in the rat. Gastroenterology 2002;122:1399-410. [PMID: 11984526 DOI: 10.1053/gast.2002.32995] [Cited by in Crossref: 271] [Cited by in F6Publishing: 266] [Article Influence: 14.3] [Reference Citation Analysis]
74 Lang S, Martin A, Kasper P, Schramm C, Kütting F, Goeser T, Steffen HM, Demir M. Hepatocellular carcinoma surveillance with liver imaging is not associated with improved survival. Scand J Gastroenterol 2020;55:222-7. [PMID: 31990240 DOI: 10.1080/00365521.2020.1718747] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
75 Tada T, Toyoda H, Sone Y, Yasuda S, Miyake N, Kumada T, Tanaka J. Type 2 diabetes mellitus: A risk factor for progression of liver fibrosis in middle‐aged patients with non‐alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology 2019;34:2011-8. [DOI: 10.1111/jgh.14734] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 7.0] [Reference Citation Analysis]
76 Wallace DF, Subramaniam VN. Co-factors in liver disease: the role of HFE-related hereditary hemochromatosis and iron. Biochim Biophys Acta. 2009;1790:663-670. [PMID: 18848602 DOI: 10.1016/j.bbagen.2008.09.002] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.2] [Reference Citation Analysis]
77 Ratziu V, Poynard T. Assessing the outcome of nonalcoholic steatohepatitis? It’s time to get serious. Hepatology. 2006;44:802-805. [PMID: 17006914 DOI: 10.1002/hep.21391] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
78 Barros F, Setúbal S, Martinho JM, Ferraz L, Gaudêncio A. CORRELATION OF NON-ALCOHOLIC FATTY LIVER DISEASE AND FEATURES OF METABOLIC SYNDROME IN MORBIDLY OBESE PATIENTS IN THE PREOPERATIVE ASSESSMENT FOR BARIATRIC SURGERY. Arq Bras Cir Dig 2016;29:260-3. [PMID: 28076482 DOI: 10.1590/0102-6720201600040011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
79 Leeds JS, Forman EM, Morley S, Scott AR, Tesfaye S, Sanders DS. Abnormal liver function tests in patients with Type 1 diabetes mellitus: prevalence, clinical correlations and underlying pathologies. Diabet Med. 2009;26:1235-1241. [PMID: 20002475 DOI: 10.1111/j.1464-5491.2009.02839.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
80 Arizuka N, Murakami T, Suzuki K. The effect of β-caryophyllene on nonalcoholic steatohepatitis. J Toxicol Pathol 2017;30:263-73. [PMID: 29097836 DOI: 10.1293/tox.2017-0018] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
81 Demirag MD, Onen HI, Karaoguz MY, Dogan I, Karakan T, Ekmekci A, Guz G. Apolipoprotein E gene polymorphism in nonalcoholic fatty liver disease. Dig Dis Sci. 2007;52:3399-3403. [PMID: 17431774 DOI: 10.1007/s10620-007-9740-5] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 1.4] [Reference Citation Analysis]
82 Baratta F, Pastori D, Tozzi G, D'Erasmo L, Di Costanzo A, Arca M, Ettorre E, Ginanni Corradini S, Violi F, Angelico F, Del Ben M. Lysosomal acid lipase activity and liver fibrosis in the clinical continuum of non-alcoholic fatty liver disease. Liver Int. 2019;39:2301-2308. [PMID: 31392821 DOI: 10.1111/liv.14206] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
83 Ratziu V, Bellentani S, Cortez-Pinto H, Day C, Marchesini G. A position statement on NAFLD/NASH based on the EASL 2009 special conference. J Hepatol. 2010;53:372-384. [PMID: 20494470 DOI: 10.1016/j.jhep.2010.04.008] [Cited by in Crossref: 637] [Cited by in F6Publishing: 606] [Article Influence: 57.9] [Reference Citation Analysis]
84 Lirussi F, Mastropasqua E, Orando S, Orlando R, Lirussi F. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. The Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005165] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Shetty K, Chen J, Shin JH, Jogunoori W, Mishra L. Pathogenesis of hepatocellular carcinoma development in non alcoholic fatty liver disease. Curr Hepatol Rep. 2015;14:119-127. [PMID: 26114083 DOI: 10.1007/s11901-015-0260-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
86 Day CP. NASH-related liver failure: one hit too many? Am J Gastroenterol. 2002;97:1872-1874. [PMID: 12190148 DOI: 10.1111/j.1572-0241.2002.05952.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
87 Jain A, Mazer B, Deng Y, Ciarleglio M, Jain D, Taddei T, Zhang X. Hepatocellular Carcinoma: Does the Background Liver With or Without Cirrhosis Matter? Am J Clin Pathol 2021:aqab125. [PMID: 34542582 DOI: 10.1093/ajcp/aqab125] [Reference Citation Analysis]
88 Mirrakhimov AE, Polotsky VY. Obstructive sleep apnea and non-alcoholic Fatty liver disease: is the liver another target? Front Neurol. 2012;3:149. [PMID: 23087670 DOI: 10.3389/fneur.2012.00149] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 4.2] [Reference Citation Analysis]
89 Alfire ME, Treem WR. Nonalcoholic fatty liver disease. Pediatr Ann 2006;35:290-4, 297-9. [PMID: 16637558 DOI: 10.3928/0090-4481-20060401-14] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
90 Stepanova M, Henry L, Garg R, Kalwaney S, Saab S, Younossi Z. Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis. BMC Gastroenterol. 2015;15:175. [PMID: 26666336 DOI: 10.1186/s12876-015-0407-y] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
91 Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Keach JC, Lafferty HD, Stahler A, Haflidadottir S, Bendtsen F. Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology. 2015;149:389-97.e10. [PMID: 25935633 DOI: 10.1053/j.gastro.2015.04.043] [Cited by in Crossref: 1264] [Cited by in F6Publishing: 1171] [Article Influence: 210.7] [Reference Citation Analysis]
92 Duclos-vallee J, Yilmaz F, Johanet C, Roque-afonso A, Gigou M, Trichet C, Feray C, Ballot E, Dussaix E, Castaing D, Bismuth H, Samuel D, Guettier C. Could post-liver transplantation course be helpful for the diagnosis of so called cryptogenic cirrhosis? Clin Transplant 2005;19:591-9. [DOI: 10.1111/j.1399-0012.2004.00323.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.2] [Reference Citation Analysis]
93 Nair S, Cope K, Risby TH, Diehl AM. Obesity and female gender increase breath ethanol concentration: Potential implications for the pathogenesis of nonalcoholic steatohepatitis. Am J Gastroenterol. 2001;96:1200-1204. [PMID: 11316170 DOI: 10.1111/j.1572-0241.2001.03702.x] [Cited by in Crossref: 133] [Cited by in F6Publishing: 128] [Article Influence: 6.7] [Reference Citation Analysis]
94 Geier A, Tiniakos D, Denk H, Trauner M. From the origin of NASH to the future of metabolic fatty liver disease. Gut 2021:gutjnl-2020-323202. [PMID: 33632710 DOI: 10.1136/gutjnl-2020-323202] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
95 Ong JP, Younossi ZM. Approach to the Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease. Clinics in Liver Disease 2005;9:617-34. [DOI: 10.1016/j.cld.2005.07.002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
96 Merriman RB. Nonalcoholic fatty liver disease and HIV infection. Curr HIV/AIDS Rep 2006;3:113-7. [PMID: 16970837 DOI: 10.1007/BF02696654] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
97 Umetsu S, Mizukami H, Saito T, Uchida C, Igawa A, Kudo K, Itabashi C, Osonoi S, Danyang G, Sasaki T, Yagihashi S, Hakamada K. Diabetes, an independent poor prognostic factor of non-B non-C hepatocellular carcinoma, correlates with dihydropyrimidinase-like 3 promoter methylation. Sci Rep 2020;10:1156. [PMID: 31980687 DOI: 10.1038/s41598-020-57883-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
98 Havlioglu N, Brunt EM, Bacon BR. Budd-Chiari syndrome and hepatocellular carcinoma: a case report and review of the literature. Am J Gastroenterology 2003;98:201-4. [DOI: 10.1111/j.1572-0241.2003.07183.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
99 Nouri-Vaskeh M, Khalili N, Khalaji A, Behnam P, Alizadeh L, Ebrahimi S, Gilani N, Mohammadi M, Madinehzadeh SA, Zarei M. Circulating glucagon-like peptide-1 level in patients with liver cirrhosis. Arch Physiol Biochem 2020;:1-6. [PMID: 33043692 DOI: 10.1080/13813455.2020.1828479] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
100 Lemoine M. Stéatopathie métabolique: définition et histoire naturelle. Gastroentérologie Clinique et Biologique 2009;33:398-404. [DOI: 10.1016/j.gcb.2009.02.029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
101 Bedossa P, Paradis V. Hepatocellular Carcinoma. Practical Hepatic Pathology: A Diagnostic Approach. Elsevier; 2011. pp. 489-501. [DOI: 10.1016/b978-0-443-06803-4.00035-6] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
102 Jurczyk K, Laurans L, Karpińska E, Wawrzynowicz-Syczewska M, Parczewski M, Boroń-Kaczmarska A. Risk score based PEG Interferon alpha 2b and Ribavirin treatment response estimation model for genotype 1 chronic hepatitis C patients. Adv Med Sci 2011;56:165-71. [PMID: 22130295 DOI: 10.2478/v10039-011-0056-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
103 Evans CD, Oien KA, MacSween RN, Mills PR. Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury? J Clin Pathol 2002;55:689-92. [PMID: 12195000 DOI: 10.1136/jcp.55.9.689] [Cited by in Crossref: 69] [Cited by in F6Publishing: 62] [Article Influence: 3.6] [Reference Citation Analysis]
104 Ghobadloo SM, Yaghmaei B, Bakayev V, Goudarzi H, Noorinayer B, Rad FH, Samiy S, Aghabozorghi S, Zali MR. GSTP1, GSTM1, and GSTT1 genetic polymorphisms in patients with cryptogenic liver cirrhosis. J Gastrointest Surg. 2004;8:423-427. [PMID: 15120366 DOI: 10.1016/j.gassur.2004.02.005] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.3] [Reference Citation Analysis]
105 Akyüz F, Demir K, Özdil S, Aksoy N, Poturoğlu Ş, İbrişim D, Kaymakoğlu S, Beşışık F, Boztaş G, Çakaloğlu Y, Mungan Z, Çevikbaş U, Ökten A. The Effects of Rosiglitazone, Metformin, and Diet with Exercise in Nonalcoholic Fatty Liver Disease. Dig Dis Sci 2007;52:2359-67. [DOI: 10.1007/s10620-006-9145-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
106 Capanni M, Calella F, Biagini MR, Genise S, Raimondi L, Bedogni G, Svegliati-baroni G, Sofi F, Milani S, Abbate R, Surrenti C, Casini A. Prolonged n-3 polyunsaturated fatty acid supplementation ameliorates hepatic steatosis in patients with non-alcoholic fatty liver disease: a pilot study. Aliment Pharmacol Ther 2006;23:1143-51. [DOI: 10.1111/j.1365-2036.2006.02885.x] [Cited by in Crossref: 286] [Cited by in F6Publishing: 270] [Article Influence: 19.1] [Reference Citation Analysis]
107 Cope K, Risby T, Diehl AM. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology. 2000;119:1340-1347. [PMID: 11054393 DOI: 10.1053/gast.2000.19267] [Cited by in Crossref: 222] [Cited by in F6Publishing: 207] [Article Influence: 10.6] [Reference Citation Analysis]
108 Stebbing J, Wong N, Tan L, Scourfield A, Jiao LR, Shousha S, Grover D, Bower M, Nelson M. The relationship between prolonged antiretroviral therapy and cryptogenic liver disease. J Acquir Immune Defic Syndr. 2009;50:554-556. [PMID: 19300102 DOI: 10.1097/QAI.0b013e31819c338f] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
109 Hashimoto E, Taniai M, Kaneda H, Tokushige K, Hasegawa K, Okuda H, Shiratori K, Takasaki K. Comparison of Hepatocellular Carcinoma Patients With Alcoholic Liver Disease and Nonalcoholic Steatohepatitis. Alcoholism Clin Exp Res 2004;28:164S-8S. [DOI: 10.1111/j.1530-0277.2004.tb03237.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
110 García-compeán D, Jáquez-quintana JO, Lavalle-gonzález FJ, Reyes-cabello E, González-gonzález JA, Muñoz-espinosa LE, Vázquez-elizondo G, Villarreal-pérez JZ, Maldonado-garza HJ. The prevalence and clinical characteristics of glucose metabolism disorders in patients with liver cirrhosis. A prospective study. Annals of Hepatology 2012;11:240-8. [DOI: 10.1016/s1665-2681(19)31030-0] [Cited by in Crossref: 33] [Article Influence: 3.7] [Reference Citation Analysis]
111 Diehl AM, Choi SS. The Liver in Type 2 Diabetes Mellitus. In: Feinglos MN, Bethel MA, editors. Type 2 Diabetes Mellitus. Totowa: Humana Press; 2008. pp. 351-64. [DOI: 10.1007/978-1-60327-043-4_21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
112 Jesús Maldonado-garza H, Vázquez-elizondo G, Obed Gaytán-torres J, Ricardo Flores-rendón Á, Graciela Cárdenas-sandoval M, Javier Bosques-padilla F. Prevalence of minimal hepatic encephalopathy in cirrhotic patients. Annals of Hepatology 2011;10:S40-4. [DOI: 10.1016/s1665-2681(19)31605-9] [Cited by in Crossref: 19] [Article Influence: 1.9] [Reference Citation Analysis]
113 Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer. 2009;115:5651-5661. [PMID: 19834957 DOI: 10.1002/cncr.24687] [Cited by in Crossref: 257] [Cited by in F6Publishing: 239] [Article Influence: 23.4] [Reference Citation Analysis]
114 Lonardo A, Bagni A, Tarugi P, Loria P. The wide spectrum of steatohepatitis: a report of four cases and a review of the literature. Eur J Gastroenterol Hepatol. 2004;16:1043-1050. [PMID: 15371930 DOI: 10.1097/00042737-200410000-00015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
115 Eiszrich Á, Fehér J. Fatty Liver in Childhood. Hungarian Medical Journal 2008;2:519-31. [DOI: 10.1556/hmj.2.2008.28270] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
116 Ahmadieh H, Azar ST. Liver disease and diabetes: association, pathophysiology, and management. Diabetes Res Clin Pract. 2014;104:53-62. [PMID: 24485856 DOI: 10.1016/j.diabres.2014.01.003] [Cited by in Crossref: 43] [Cited by in F6Publishing: 42] [Article Influence: 6.1] [Reference Citation Analysis]
117 Adams LA, Angulo P. Vitamins E and C for the treatment of NASH: duplication of results but lack of demonstration of efficacy. Am J Gastroenterol. 2003;98:2348-2350. [PMID: 14638333 DOI: 10.1111/j.1572-0241.2003.08695.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.1] [Reference Citation Analysis]
118 Di Ciaula A, Calamita G, Shanmugam H, Khalil M, Bonfrate L, Wang DQ, Baffy G, Portincasa P. Mitochondria Matter: Systemic Aspects of Nonalcoholic Fatty Liver Disease (NAFLD) and Diagnostic Assessment of Liver Function by Stable Isotope Dynamic Breath Tests. Int J Mol Sci 2021;22:7702. [PMID: 34299321 DOI: 10.3390/ijms22147702] [Reference Citation Analysis]
119 Hayashi PH, Di Bisceglie AM. The progression of hepatitis B– and C–infections to chronic liver disease and hepatocellular carcinoma: epidemiology and pathogenesis. Medical Clinics of North America 2005;89:371-89. [DOI: 10.1016/j.mcna.2004.08.014] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
120 Prasad S, Dhiman RK, Duseja A, Chawla YK, Sharma A, Agarwal R. Lactulose improves cognitive functions and health-related quality of life in patients with cirrhosis who have minimal hepatic encephalopathy. Hepatology. 2007;45:549-559. [PMID: 17326150 DOI: 10.1002/hep.21533] [Cited by in Crossref: 385] [Cited by in F6Publishing: 325] [Article Influence: 27.5] [Reference Citation Analysis]
121 Hui JM, Farrell GC. Clear messages from sonographic shadows? Links between metabolic disorders and liver disease, and what to do about them. Journal of Gastroenterology and Hepatology 2003;18:1115-7. [DOI: 10.1046/j.1440-1746.2003.03170.x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 1.0] [Reference Citation Analysis]
122 Sanyal AJ, Banas C, Sargeant C, Luketic VA, Sterling RK, Stravitz RT, Shiffman ML, Heuman D, Coterrell A, Fisher RA, Contos MJ, Mills AS. Similarities and differences in outcomes of cirrhosis due to nonalcoholic steatohepatitis and hepatitis C. Hepatology 2006;43:682-9. [DOI: 10.1002/hep.21103] [Cited by in Crossref: 345] [Cited by in F6Publishing: 308] [Article Influence: 23.0] [Reference Citation Analysis]
123 Patel V, Sanyal AJ. Drug-induced steatohepatitis. Clin Liver Dis 2013;17:533-46, vii. [PMID: 24099016 DOI: 10.1016/j.cld.2013.07.012] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.1] [Reference Citation Analysis]
124 Cucchetti A, Cescon M, Ercolani G, Di Gioia P, Peri E, Pinna AD. Safety of hepatic resection in overweight and obese patients with cirrhosis. British Journal of Surgery 2011;98:1147-54. [DOI: 10.1002/bjs.7516] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 3.8] [Reference Citation Analysis]
125 Day CP. Non-alcoholic steatohepatitis (NASH): where are we now and where are we going? Gut. 2002;50:585-588. [PMID: 11950797 DOI: 10.1136/gut.50.5.585] [Cited by in Crossref: 123] [Cited by in F6Publishing: 116] [Article Influence: 6.5] [Reference Citation Analysis]
126 Bahrami A, Teymoori F, Eslamparast T, Sohrab G, Hejazi E, Poustchi H, Hekmatdoost A. Legume intake and risk of nonalcoholic fatty liver disease. Indian J Gastroenterol 2019;38:55-60. [DOI: 10.1007/s12664-019-00937-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
127 Silva CF, Nardelli MJ, Barbosa FA, Galizzi HO, Cal TCMF, Ferrari TCA, Faria LC, Couto CA. Liver stiffness is able to differentiate hepatosplenic Schistosomiasis mansoni from liver cirrhosis and spleen stiffness may be a predictor of variceal bleeding in hepatosplenic schistosomiasis. Trans R Soc Trop Med Hyg 2021:trab041. [PMID: 33728472 DOI: 10.1093/trstmh/trab041] [Reference Citation Analysis]
128 Senanayake SM, Niriella MA, Weerasinghe SK, Kasturiratne A, de Alwis JP, de Silva AP, Dassanayake AS, de Silva HJ. Survival of patients with alcoholic and cryptogenic cirrhosis without liver transplantation: a single center retrospective study. BMC Res Notes. 2012;5:663. [PMID: 23198995 DOI: 10.1186/1756-0500-5-663] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
129 de Barros F, Setúbal S, Martinho JM, Leite NC, Guaraná T, Monteiro ABS, Villela-nogueira CA. The Correlation Between Obesity-Related Diseases and Non-alcoholic Fatty Liver Disease in Women in the Pre-operative Evaluation for Bariatric Surgery Assessed by Transient Hepatic Elastography. OBES SURG 2016;26:2089-97. [DOI: 10.1007/s11695-016-2054-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
130 Björnsson E, Angulo P. Non-alcoholic fatty liver disease. Scandinavian Journal of Gastroenterology 2009;42:1023-30. [DOI: 10.1080/00365520701514529] [Cited by in Crossref: 32] [Cited by in F6Publishing: 34] [Article Influence: 2.7] [Reference Citation Analysis]
131 Marion AW, Baker AJ, Dhawan A. Fatty liver disease in children. Arch Dis Child 2004;89:648-52. [PMID: 15210498 DOI: 10.1136/adc.2003.029942] [Cited by in Crossref: 53] [Cited by in F6Publishing: 47] [Article Influence: 3.1] [Reference Citation Analysis]
132 Tweezer-zaks N, Doron-libner A, Weiss P, Ben-horin S, Barshack I, Lidar M, Livneh A. Familial Mediterranean Fever and Cryptogenic Cirrhosis. Medicine 2007;86:355-62. [DOI: 10.1097/md.0b013e31815be056] [Cited by in Crossref: 15] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
133 Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA; Nonalcoholic Steatohepatitis Clinical Research Network. Improvements in Histologic Features and Diagnosis Associated With Improvement in Fibrosis in Nonalcoholic Steatohepatitis: Results From the Nonalcoholic Steatohepatitis Clinical Research Network Treatment Trials. Hepatology 2019;70:522-31. [PMID: 30549292 DOI: 10.1002/hep.30418] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
134 Caldwell SH, Zaidman JS, Hespenheide EE. The liver and statin drug therapy: uncertain navigation in the sea of risk-benefit. Pharmacoepidem Drug Safe 2003;12:303-6. [DOI: 10.1002/pds.833] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
135 Ramesh S, Sanyal AJ. Evaluation and management of non-alcoholic steatohepatitis. J Hepatol. 2005;42 Suppl:S2-S12. [PMID: 15777569 DOI: 10.1016/j.jhep.2004.11.022] [Cited by in Crossref: 58] [Cited by in F6Publishing: 53] [Article Influence: 3.4] [Reference Citation Analysis]
136 Singh DK, Sakhuja P, Malhotra V, Gondal R, Sarin SK. Independent Predictors of Steatohepatitis and Fibrosis in Asian Indian Patients with Non-Alcoholic Steatohepatitis. Dig Dis Sci 2008;53:1967-76. [DOI: 10.1007/s10620-007-0074-0] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
137 Baffy G. Hepatocellular Carcinoma in Non-alcoholic Fatty Liver Disease: Epidemiology, Pathogenesis, and Prevention. J Clin Transl Hepatol 2013;1:131-7. [PMID: 26355775 DOI: 10.14218/JCTH.2013.00005] [Cited by in Crossref: 7] [Cited by in F6Publishing: 23] [Article Influence: 0.9] [Reference Citation Analysis]
138 Singh V, Ubaid S. Role of Silent Information Regulator 1 (SIRT1) in Regulating Oxidative Stress and Inflammation. Inflammation 2020;43:1589-98. [PMID: 32410071 DOI: 10.1007/s10753-020-01242-9] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 17.0] [Reference Citation Analysis]
139 Angelico F, Del Ben M, Francioso S, Hurtova M, Battista S, Palmieri GP, Tisone G, Angelico M. Recurrence of insulin resistant metabolic syndrome following liver transplantation: . European Journal of Gastroenterology & Hepatology 2003;15:99-102. [DOI: 10.1097/00042737-200301000-00018] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.7] [Reference Citation Analysis]
140 Zafrani ES. Non-alcoholic fatty liver disease: an emerging pathological spectrum. Virchows Arch. 2004;444:3-12. [PMID: 14685853 DOI: 10.1007/s00428-003-0943-7] [Cited by in Crossref: 71] [Cited by in F6Publishing: 58] [Article Influence: 3.9] [Reference Citation Analysis]
141 Longerich T, Schirmacher P. General aspects and pitfalls in liver transplant pathology. Clin Transplant 2006;20 Suppl 17:60-8. [PMID: 17100703 DOI: 10.1111/j.1399-0012.2006.00602.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
142 Sebastiani G, Walker AP. HFE gene in primary and secondary hepatic iron overload. World J Gastroenterol 2007; 13(35): 4673-4689 [PMID: 17729389 DOI: 10.3748/wjg.v13.i35.4673] [Cited by in CrossRef: 30] [Cited by in F6Publishing: 24] [Article Influence: 2.1] [Reference Citation Analysis]
143 Mccullough AJ. Update on Nonalcoholic Fatty Liver Disease: . Journal of Clinical Gastroenterology 2002;34:255-62. [DOI: 10.1097/00004836-200203000-00013] [Cited by in Crossref: 217] [Cited by in F6Publishing: 190] [Article Influence: 11.4] [Reference Citation Analysis]
144 Aranda-Michel J. Nutrition in hepatic failure and liver transplantation. Curr Gastroenterol Rep. 2001;3:362-370. [PMID: 11470007 DOI: 10.1007/s11894-001-0061-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 1.2] [Reference Citation Analysis]
145 Omar Jáquez Quintana J, García-compean D, Alberto González González J, Zacarías Villarreal Pérez J, Javier Lavalle González F, Elsa Muñoz Espinosa L, López Hernández P, Reyes Cabello E, Redondo Villarreal E, Flores Rendón R, Maldonado Garza H. The impact of diabetes mellitus in mortality of patients with compensated liver cirrhosis-a prospective study. Annals of Hepatology 2011;10:56-62. [DOI: 10.1016/s1665-2681(19)31588-1] [Cited by in Crossref: 36] [Article Influence: 3.6] [Reference Citation Analysis]
146 Yan E, Durazo F, Tong M, Hong K. Nonalcoholic Fatty Liver Disease: Pathogenesis, Identification, Progression, and Management. Nutrition Reviews 2007;65:376-84. [DOI: 10.1111/j.1753-4887.2007.tb00315.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
147 Lazo M, Solga SF, Horska A, Bonekamp S, Diehl AM, Brancati FL, Wagenknecht LE, Pi-Sunyer FX, Kahn SE, Clark JM;  Fatty Liver Subgroup of the Look AHEAD Research Group. Effect of a 12-month intensive lifestyle intervention on hepatic steatosis in adults with type 2 diabetes. Diabetes Care. 2010;33:2156-2163. [PMID: 20664019 DOI: 10.2337/dc10-0856] [Cited by in Crossref: 212] [Cited by in F6Publishing: 192] [Article Influence: 19.3] [Reference Citation Analysis]
148 Henao-Mejia J, Elinav E, Jin C, Hao L, Mehal WZ, Strowig T, Thaiss CA, Kau AL, Eisenbarth SC, Jurczak MJ, Camporez JP, Shulman GI, Gordon JI, Hoffman HM, Flavell RA. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature. 2012;482:179-185. [PMID: 22297845 DOI: 10.1038/nature10809] [Cited by in Crossref: 1446] [Cited by in F6Publishing: 1384] [Article Influence: 160.7] [Reference Citation Analysis]
149 O’Brien J, Powell LW. Non-alcoholic fatty liver disease: is iron relevant? Hepatol Int. 2012;6:332-341. [PMID: 22020821 DOI: 10.1007/s12072-011-9304-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 22] [Article Influence: 2.7] [Reference Citation Analysis]
150 Jonscher KR, Bruce KD. Current Models of Fatty Liver Disease; New Insights, Therapeutic Targets and Interventions. Adv Exp Med Biol 2019;1134:33-58. [PMID: 30919331 DOI: 10.1007/978-3-030-12668-1_3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
151 Sanal MG, Sarin SK. Association of nonalcoholic fatty liver disease with metabolic syndrome in Indian population. Diabetes Metab Syndr 2011;5:76-80. [PMID: 22813407 DOI: 10.1016/j.dsx.2012.02.015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
152 Pais R, Barritt AS 4th, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016;65:1245-1257. [PMID: 27486010 DOI: 10.1016/j.jhep.2016.07.033] [Cited by in Crossref: 190] [Cited by in F6Publishing: 172] [Article Influence: 38.0] [Reference Citation Analysis]
153 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 17.7] [Reference Citation Analysis]
154 Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. Clin Liver Dis 2016;20:293-312. [PMID: 27063270 DOI: 10.1016/j.cld.2015.10.011] [Cited by in Crossref: 111] [Cited by in F6Publishing: 90] [Article Influence: 18.5] [Reference Citation Analysis]
155 Georgescu EF, Ionescu R, Niculescu M, Mogoanta L, Vancica L. Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis. World J Gastroenterol 2009; 15(8): 942-954 [PMID: 19248193 DOI: 10.3748/wjg.15.942] [Cited by in CrossRef: 123] [Cited by in F6Publishing: 113] [Article Influence: 10.3] [Reference Citation Analysis]
156 Giannini EG, Marabotto E, Savarino V, Trevisani F, di Nolfo MA, Del Poggio P, Benvegnù L, Farinati F, Zoli M, Borzio F. Hepatocellular carcinoma in patients with cryptogenic cirrhosis. Clin Gastroenterol Hepatol. 2009;7:580-585. [PMID: 19418607 DOI: 10.1016/j.cgh.2009.01.001] [Cited by in Crossref: 35] [Cited by in F6Publishing: 30] [Article Influence: 2.9] [Reference Citation Analysis]
157 Bhagat V, Mindikoglu AL, Nudo CG, Schiff ER, Tzakis A, Regev A. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl. 2009;15:1814-1820. [PMID: 19938128 DOI: 10.1002/lt.21927] [Cited by in Crossref: 124] [Cited by in F6Publishing: 110] [Article Influence: 11.3] [Reference Citation Analysis]
158 Wobser H, Dorn C, Weiss TS, Amann T, Bollheimer C, Büttner R, Schölmerich J, Hellerbrand C. Lipid accumulation in hepatocytes induces fibrogenic activation of hepatic stellate cells. Cell Res. 2009;19:996-1005. [PMID: 19546889 DOI: 10.1038/cr.2009.73] [Cited by in Crossref: 130] [Cited by in F6Publishing: 135] [Article Influence: 10.8] [Reference Citation Analysis]
159 Lirussi F, Mastropasqua E, Orando S, Orlando R. Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;:CD005165. [PMID: 17253543 DOI: 10.1002/14651858.CD005165.pub2] [Cited by in Crossref: 31] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
160 窦爱霞, 宗蕾, 周琨, 陈婷, 潘浩, 张权, 李继强, 房静远, 陆伦根. DSG-Ⅰ型生物信息红外肝病治疗仪治疗大鼠非酒精性脂肪肝. 世界华人消化杂志 2008; 16(9): 935-940 [DOI: 10.11569/wcjd.v16.i9.935] [Reference Citation Analysis]
161 Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007;27:423-433. [PMID: 17403181 DOI: 10.1111/j.1478-3231.2007.01483.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 8.3] [Reference Citation Analysis]
162 Murray KF, Carithers RL Jr;  AASLD. AASLD practice guidelines: Evaluation of the patient for liver transplantation. Hepatology. 2005;41:1407-1432. [PMID: 15880505 DOI: 10.1002/hep.20704] [Cited by in Crossref: 519] [Cited by in F6Publishing: 410] [Article Influence: 32.4] [Reference Citation Analysis]
163 Angulo P. Current best treatment for non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2003;4:611-623. [PMID: 12739988 DOI: 10.1517/14656566.4.5.611] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.1] [Reference Citation Analysis]
164 Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, Mohan P, Schwimmer JB, Lavine JE, Torbenson MS. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012;95:892-900. [PMID: 22338037 DOI: 10.3945/ajcn.111.020156] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 7.7] [Reference Citation Analysis]
165 Kroh A, Uschner D, Lodewick T, Eickhoff RM, Schöning W, Ulmer FT, Neumann UP, Binnebösel M. Impact of body composition on survival and morbidity after liver resection in hepatocellular carcinoma patients. Hepatobiliary Pancreat Dis Int 2019;18:28-37. [PMID: 30115516 DOI: 10.1016/j.hbpd.2018.07.008] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
166 Gambarin–gelwan M, Kinkhabwala SV, Schiano TD, Bodian C, Yeh H, Futterweit W. Prevalence of Nonalcoholic Fatty Liver Disease in Women With Polycystic Ovary Syndrome. Clinical Gastroenterology and Hepatology 2007;5:496-501. [DOI: 10.1016/j.cgh.2006.10.010] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 7.5] [Reference Citation Analysis]
167 Lallukka S, Yki-Järvinen H. Non-alcoholic fatty liver disease and risk of type 2 diabetes. Best Pract Res Clin Endocrinol Metab 2016;30:385-95. [PMID: 27432073 DOI: 10.1016/j.beem.2016.06.006] [Cited by in Crossref: 75] [Cited by in F6Publishing: 69] [Article Influence: 15.0] [Reference Citation Analysis]
168 O’Leary JG, Lepe R, Davis GL. Indications for liver transplantation. Gastroenterology. 2008;134:1764-1776. [PMID: 18471553 DOI: 10.1053/j.gastro.2008.02.028] [Cited by in Crossref: 120] [Cited by in F6Publishing: 87] [Article Influence: 9.2] [Reference Citation Analysis]
169 Sasikala M, Surya P, Radhika G, Kumar PP, Rao MS, Mukherjee RM, Rao PN, Reddy DN. Identification of circulating CD90+ CD73+ cells in cirrhosis of liver. World J Stem Cells 2011; 3(7): 63-69 [PMID: 21860671 DOI: 10.4252/wjsc.v3.i7.63] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
170 Harrison SA, Kadakia S, Lang KA, Schenker S. Nonalcoholic steatohepatitis: what we know in the new millennium. Am J Gastroenterol. 2002;97:2714-2724. [PMID: 12425538 DOI: 10.1111/j.1572-0241.2002.07069.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 46] [Article Influence: 0.5] [Reference Citation Analysis]
171 Clouston AD, Powell EE. Interaction of non-alcoholic fatty liver disease with other liver diseases. Best Pract Res Clin Gastroenterol. 2002;16:767-781. [PMID: 12406444 DOI: 10.1053/bega.2002.0329] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 2.2] [Reference Citation Analysis]
172 Lin CF, Shiau TJ, Ko YC, Chen PH, Wang JD. Prevalence and determinants of biochemical dysfunction of the liver in Atayal Aboriginal community of Taiwan: is betel nut chewing a risk factor? BMC Gastroenterol 2008;8:13. [PMID: 18439308 DOI: 10.1186/1471-230X-8-13] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
173 Younossi ZM, Diehl AM, Ong JP. Nonalcoholic fatty liver disease: an agenda for clinical research. Hepatology. 2002;35:746-752. [PMID: 11915019 DOI: 10.1053/jhep.2002.32483] [Cited by in Crossref: 174] [Cited by in F6Publishing: 163] [Article Influence: 9.2] [Reference Citation Analysis]
174 Brunt EM. Alcoholic and nonalcoholic steatohepatitis. Clinics in Liver Disease 2002;6:399-420. [DOI: 10.1016/s1089-3261(02)00002-8] [Cited by in Crossref: 66] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
175 Caballería J, Rodés J. [Non-alcoholic steatohepatitis]. Med Clin (Barc) 2003;120:670-5. [PMID: 12747817 DOI: 10.1016/s0025-7753(03)73803-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
176 Moreno-Sánchez D. [Epidemiology and natural history of primary nonalcoholic fatty liver disease]. Gastroenterol Hepatol 2006;29:244-54. [PMID: 16584696 DOI: 10.1157/13085972] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
177 Rastogi A, Shasthry SM, Agarwal A, Bihari C, Jain P, Jindal A, Sarin S. Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study. APMIS. 2017;125:962-973. [PMID: 29076589 DOI: 10.1111/apm.12742] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
178 Zhang KY, Tung BY, Kowdley KV. Liver Transplantation for Metabolic Liver Diseases. Clinics in Liver Disease 2007;11:265-81. [DOI: 10.1016/j.cld.2007.04.002] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 1.8] [Reference Citation Analysis]
179 El Atrache MM, Abouljoud MS, Divine G, Yoshida A, Kim DY, Kazimi MM, Moonka D, Huang MA, Brown K. Recurrence of non-alcoholic steatohepatitis and cryptogenic cirrhosis following orthotopic liver transplantation in the context of the metabolic syndrome. Clin Transplant. 2012;26:E505-E512. [PMID: 23061759 DOI: 10.1111/ctr.12014] [Cited by in Crossref: 48] [Cited by in F6Publishing: 40] [Article Influence: 6.0] [Reference Citation Analysis]
180 Motamed N, Sohrabi M, Ajdarkosh H, Hemmasi G, Maadi M, Sayeedian FS, Pirzad R, Abedi K, Aghapour S, Fallahnezhad M, Zamani F. Fatty liver index vs waist circumference for predicting non-alcoholic fatty liver disease. World J Gastroenterol 2016; 22(10): 3023-3030 [PMID: 26973398 DOI: 10.3748/wjg.v22.i10.3023] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 34] [Article Influence: 9.2] [Reference Citation Analysis]
181 Davila JA, Petersena NJ, Nelson HA, El-Serag HB. Geographic variation within the United States in the incidence of hepatocellular carcinoma. J Clin Epidemiol. 2003;56:487-493. [PMID: 12812824 DOI: 10.1016/s0895-4356(02)00605-4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
182 Adams LA, Lindor KD. Nonalcoholic fatty liver disease. Ann Epidemiol. 2007;17:863-869. [PMID: 17728149 DOI: 10.1016/j.annepidem.2007.05.013] [Cited by in Crossref: 197] [Cited by in F6Publishing: 191] [Article Influence: 14.1] [Reference Citation Analysis]
183 Atamni HJA, Botzman M, Mott R, Gat-viks I, Iraqi FA. Mapping liver fat female-dependent quantitative trait loci in collaborative cross mice. Mamm Genome 2016;27:565-73. [DOI: 10.1007/s00335-016-9658-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
184 Angulo P, Lindor KD. Non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2002;17 Suppl:S186-S190. [PMID: 12000605 DOI: 10.1046/j.1440-1746.17.s1.10.x] [Cited by in Crossref: 283] [Cited by in F6Publishing: 266] [Article Influence: 14.9] [Reference Citation Analysis]
185 Fracanzani AL, Valenti L, Bugianesi E, Andreoletti M, Colli A, Vanni E, Bertelli C, Fatta E, Bignamini D, Marchesini G, Fargion S. Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes. Hepatology. 2008;48:792-798. [PMID: 18752331 DOI: 10.1002/hep.22429] [Cited by in Crossref: 392] [Cited by in F6Publishing: 367] [Article Influence: 30.2] [Reference Citation Analysis]
186 Fehér J, Lengyel G. A new approach to drug therapy in non-alcoholic steatohepatitis (NASH). J Int Med Res. 2003;31:537-551. [PMID: 14708419 DOI: 10.1177/147323000303100610] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
187 Chande N, Laidlaw M, Adams P, Marotta P. Yo Jyo Hen Shi Ko (YHK) improves transaminases in nonalcoholic steatohepatitis (NASH): a randomized pilot study. Dig Dis Sci 2006;51:1183-9. [PMID: 16944007 DOI: 10.1007/s10620-006-8030-y] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
188 Duseja A, Singh SP, Saraswat VA, Acharya SK, Chawla YK, Chowdhury S, Dhiman RK, Jayakumar RV, Madan K, Misra SP, Mishra H, Modi SK, Muruganathan A, Saboo B, Sahay R, Upadhyay R. Non-alcoholic Fatty Liver Disease and Metabolic Syndrome-Position Paper of the Indian National Association for the Study of the Liver, Endocrine Society of India, Indian College of Cardiology and Indian Society of Gastroenterology. J ClinExpHepatol. 2015;5:51-68. [PMID: 25941433 DOI: 10.1016/j.jceh.2015.02.006] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 11.5] [Reference Citation Analysis]
189 Kallwitz ER, Guzman G, TenCate V, Vitello J, Layden-Almer J, Berkes J, Patel R, Layden TJ, Cotler SJ. The histologic spectrum of liver disease in African-American, non-Hispanic white, and Hispanic obesity surgery patients. Am J Gastroenterol. 2009;104:64-69. [PMID: 19098851 DOI: 10.1038/ajg.2008.12] [Cited by in Crossref: 49] [Cited by in F6Publishing: 43] [Article Influence: 4.1] [Reference Citation Analysis]
190 Pagano G, Pacini G, Musso G, Gambino R, Mecca F, Depetris N, Cassader M, David E, Cavallo-Perin P, Rizzetto M. Nonalcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association. Hepatology. 2002;35:367-372. [PMID: 11826410 DOI: 10.1053/jhep.2002.30690] [Cited by in Crossref: 524] [Cited by in F6Publishing: 480] [Article Influence: 27.6] [Reference Citation Analysis]
191 Mendes FD, Lindor KD. Recent advances in the treatment of non-alcoholic fatty liver disease. Expert Opinion on Investigational Drugs 2005;14:29-35. [DOI: 10.1517/13543784.14.1.29] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
192 Kojima H, Sakurai S, Matsumura M, Umemoto N, Uemura M, Morimoto H, Tamagawa Y, Fukui H. Cryptogenic cirrhosis in the region where obesity is not prevalent. World J Gastroenterol 2006; 12(13): 2080-2085 [PMID: 16610061 DOI: 10.3748/wjg.v12.i13.2080] [Cited by in CrossRef: 23] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
193 Marmur J, Bergquist A, Stål P. Liver transplantation of patients with cryptogenic cirrhosis: clinical characteristics and outcome. Scand J Gastroenterol 2010;45:60-9. [PMID: 20030578 DOI: 10.3109/00365520903384742] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
194 Phipps M, Livanos A, Guo A, Pomenti S, Yeh J, Dakhoul L, Burney H, Kettler C, Liu H, Miller E, Gawrieh S, deLemos A, Scanga A, Chalasani N, Wattacheril J. Gender Matters: Characteristics of Hepatocellular Carcinoma in Women From a Large, Multicenter Study in the United States. Am J Gastroenterol 2020;115:1486-95. [PMID: 32453046 DOI: 10.14309/ajg.0000000000000643] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
195 Zezos P, Renner EL. Liver transplantation and non-alcoholic fatty liver disease. World J Gastroenterol 2014; 20(42): 15532-15538 [PMID: 25400437 DOI: 10.3748/wjg.v20.i42.15532] [Cited by in CrossRef: 99] [Cited by in F6Publishing: 84] [Article Influence: 14.1] [Reference Citation Analysis]
196 Brunt EM, Neuschwander-tetri BA, Burt AD. Fatty liver disease. MacSween's Pathology of the Liver. Elsevier; 2012. pp. 293-359. [DOI: 10.1016/b978-0-7020-3398-8.00006-4] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
197 Rosmorduc O. Relationship between hepatocellular carcinoma, metabolic syndrome and non-alcoholic fatty liver disease: which clinical arguments? Ann Endocrinol (Paris). 2013;74:115-120. [PMID: 23597944 DOI: 10.1016/j.ando.2013.02.008] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
198 Rangnekar AS, Lammert F, Igolnikov A, Green RM. Quantitative trait loci analysis of mice administered the methionine-choline deficient dietary model of experimental steatohepatitis. Liver Int 2006;26:1000-5. [PMID: 16953841 DOI: 10.1111/j.1478-3231.2006.01314.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.0] [Reference Citation Analysis]
199 Chitturi S, Farrell GC, Hashimoto E, Saibara T, Lau GK, Sollano JD; Asia-Pacific Working Party on NAFLD. Non-alcoholic fatty liver disease in the Asia-Pacific region: definitions and overview of proposed guidelines. J Gastroenterol Hepatol. 2007;22:778-787. [PMID: 17565630 DOI: 10.1111/j.1440-1746.2007.05001.x] [Cited by in Crossref: 208] [Cited by in F6Publishing: 202] [Article Influence: 14.9] [Reference Citation Analysis]
200 Tilg H, Kaser A. Treatment strategies in nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol. 2005;2:148-155. [PMID: 16265156 DOI: 10.1038/ncpgasthep0116] [Cited by in Crossref: 46] [Cited by in F6Publishing: 47] [Article Influence: 2.9] [Reference Citation Analysis]
201 Fassio E, Alvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology. 2004;40:820-826. [PMID: 15382171 DOI: 10.1002/hep.20410] [Cited by in Crossref: 45] [Cited by in F6Publishing: 128] [Article Influence: 2.6] [Reference Citation Analysis]
202 Kolly P, Dufour JF. Surveillance for Hepatocellular Carcinoma in Patients with NASH. Diagnostics (Basel). 2016;6. pii:E22. [PMID: 27338480 DOI: 10.3390/diagnostics6020022] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 3.8] [Reference Citation Analysis]
203 Valery PC, McPhail S, Stuart KA, Hartel G, Clark PJ, O'Beirne J, Skoien R, Rahman T, Moser C, Powell EE. Changing prevalence of aetiological factors and comorbidities among Australians hospitalised for cirrhosis. Intern Med J 2021;51:691-8. [PMID: 32096890 DOI: 10.1111/imj.14809] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
204 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010;4:439-74. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
205 Tan HK, Teng MLP, Soh AYS, Cheo SHY, Fook-Chong S, Goh GBB, Tan CK, Wong GW, Lee GH, Chang JPE. Poor Outcomes of Cirrhosis due to Nonalcoholic Steatohepatitis Compared With Hepatitis B After Decompensation With Ascites. Am J Gastroenterol 2021;116:1437-46. [PMID: 33834737 DOI: 10.14309/ajg.0000000000001176] [Reference Citation Analysis]
206 Polyzos SA, Kountouras J, Mantzoros CS. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics. Metabolism 2019;92:82-97. [DOI: 10.1016/j.metabol.2018.11.014] [Cited by in Crossref: 165] [Cited by in F6Publishing: 168] [Article Influence: 82.5] [Reference Citation Analysis]
207 Sasaki M, Itatsu K, Minato H, Takamura H, Ohta T, Nakanuma Y. Flare-up of Nonalcoholic Steatohepatitis After Hepatectomy Resulted in Hepatic Failure in a Patient with Type 2 Diabetes Mellitus. Dig Dis Sci 2007;52:3473-6. [DOI: 10.1007/s10620-006-9662-7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
208 El-Serag HB. Hepatocellular carcinoma: an epidemiologic view. J Clin Gastroenterol. 2002;35:S72-S78. [PMID: 12394209 DOI: 10.1097/00004836-200211002-00002] [Cited by in Crossref: 440] [Cited by in F6Publishing: 422] [Article Influence: 24.4] [Reference Citation Analysis]
209 Massoud O, Charlton M. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma. Clinics in Liver Disease 2018;22:201-11. [DOI: 10.1016/j.cld.2017.08.014] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
210 Syn WK, Jung Y, Omenetti A, Abdelmalek M, Guy CD, Yang L, Wang J, Witek RP, Fearing CM, Pereira TA, Teaberry V, Choi SS, Conde-Vancells J, Karaca GF, Diehl AM. Hedgehog-mediated epithelial-to-mesenchymal transition and fibrogenic repair in nonalcoholic fatty liver disease. Gastroenterology 2009;137:1478-1488.e8. [PMID: 19577569 DOI: 10.1053/j.gastro.2009.06.051] [Cited by in Crossref: 179] [Cited by in F6Publishing: 173] [Article Influence: 14.9] [Reference Citation Analysis]
211 Chen QK, Chen HY, Huang KH, Zhong YQ, Han JA, Zhu ZH, Zhou XD. Clinical features and risk factors of patients with fatty liver in Guangzhou area. World J Gastroenterol 2004; 10(6): 899-902 [PMID: 15040041 DOI: 10.3748/wjg.v10.i6.899] [Cited by in CrossRef: 14] [Cited by in F6Publishing: 15] [Article Influence: 0.8] [Reference Citation Analysis]
212 Edgren G, Hjalgrim H, Rostgaard K, Dahl V, Titlestad K, Erikstrup C, Wikman A, Norda R, Majeed A; NHLBI Recipient Epidemiology and Donor Evaluation Study-III (REDS-III). Searching for unknown transfusion-transmitted hepatitis viruses: a binational cohort study of 1.5 million transfused patients. J Intern Med 2018;284:92-103. [PMID: 29624755 DOI: 10.1111/joim.12762] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
213 Rezaee-Zavareh MS, Hesamizadeh K, Behnava B, Alavian SM, Gholami-Fesharaki M, Sharafi H. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. Ann Hepatol. 2017;16:188-197. [PMID: 28233739 DOI: 10.5604/16652681.1231562] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 8.0] [Reference Citation Analysis]
214 Kazemi-Shirazi L, Veloso MP, Frommlet F, Steindl-Munda P, Wrba F, Zehetmayer S, Marsik C, Ferenci P. Differentiation of nonalcoholic from alcoholic steatohepatitis: are routine laboratory markers useful? Wien Klin Wochenschr. 2008;120:25-30. [PMID: 18239988 DOI: 10.1007/s00508-007-0921-1] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
215 Brunt EM, Neuschwander-Tetri BA, Oliver D, Wehmeier KR, Bacon BR. Nonalcoholic steatohepatitis: histologic features and clinical correlations with 30 blinded biopsy specimens. Hum Pathol 2004;35:1070-82. [PMID: 15343508 DOI: 10.1016/j.humpath.2004.04.017] [Cited by in Crossref: 112] [Cited by in F6Publishing: 104] [Article Influence: 6.6] [Reference Citation Analysis]
216 Park SH. [Nonalcoholic steatohepatitis: pathogenesis and treatment]. Korean J Hepatol 2008;14:12-27. [PMID: 18367854 DOI: 10.3350/kjhep.2008.14.1.12] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
217 Jacobsen MC, Thrower SL, Ger RB, Leng S, Court LE, Brock KK, Tamm EP, Cressman ENK, Cody DD, Layman RR. Multi-energy computed tomography and material quantification: Current barriers and opportunities for advancement. Med Phys 2020;47:3752-71. [PMID: 32453879 DOI: 10.1002/mp.14241] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Nakanishi Y, Tsuneyama K, Fujimoto M, Salunga TL, Nomoto K, An J, Takano Y, Iizuka S, Nagata M, Suzuki W, Shimada T, Aburada M, Nakano M, Selmi C, Gershwin ME. Monosodium glutamate (MSG): A villain and promoter of liver inflammation and dysplasia. Journal of Autoimmunity 2008;30:42-50. [DOI: 10.1016/j.jaut.2007.11.016] [Cited by in Crossref: 88] [Cited by in F6Publishing: 82] [Article Influence: 6.8] [Reference Citation Analysis]
219 Caldwell SH, Hespenheide EE, Redick JA, Iezzoni JC, Battle EH, Sheppard BL. A Pilot Study of A Thiazolidinedione, Troglitazone, in Nonalcoholic Steatohepatitis. American Journal of Gastroenterology 2001;96:519-25. [DOI: 10.1111/j.1572-0241.2001.03553.x] [Cited by in Crossref: 289] [Cited by in F6Publishing: 258] [Article Influence: 14.5] [Reference Citation Analysis]
220 Alexander J, Torbenson M, Wu TT, Yeh MM. Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: a clinical and pathological study. J Gastroenterol Hepatol. 2013;28:848-854. [PMID: 23302015 DOI: 10.1111/jgh.12116] [Cited by in Crossref: 77] [Cited by in F6Publishing: 77] [Article Influence: 9.6] [Reference Citation Analysis]
221 Islam SMT, Won J, Khan M, Chavin KD, Singh I. Peroxisomal footprint in the pathogenesis of nonalcoholic steatohepatitis. Ann Hepatol 2020;19:466-71. [PMID: 31870746 DOI: 10.1016/j.aohep.2019.11.007] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
222 de Oliveira CP, Stefano JT, de Siqueira ER, Silva LS, de Campos Mazo DF, Lima VM, Furuya CK, Mello ES, Souza FG, Rabello F. Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis. Hepatol Res. 2008;38:159-165. [PMID: 18197877 DOI: 10.1111/j.1872-034x.2007.00215.x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 32] [Article Influence: 1.1] [Reference Citation Analysis]
223 Niaz A, Ali Z, Nayyar S, Fatima N. Prevalence of NAFLD in Healthy and Young Male Individuals. ISRN Gastroenterol 2011;2011:363546. [PMID: 21991504 DOI: 10.5402/2011/363546] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
224 Lin TY, Yeh ML, Huang CF, Huang CI, Dai CY, Hsieh MH, Chen SC, Huang JF, Yu ML, Chuang WL. Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. Eur J Gastroenterol Hepatol 2019;31:224-9. [PMID: 30308578 DOI: 10.1097/MEG.0000000000001285] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
225 Della Corte C, Aghemo A, Colombo M. Individualized hepatocellular carcinoma risk: The challenges for designing successful chemoprevention strategies. World J Gastroenterol 2013; 19(9): 1359-1371 [PMID: 23538741 DOI: 10.3748/wjg.v19.i9.1359] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
226 Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S, Nonaka K, Sogawa K, Satoh M, Sawai S, Matsushita K, Imazeki F, Yokosuka O, Nomura F. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol 2013;13:120. [PMID: 23875831 DOI: 10.1186/1471-230X-13-120] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 3.1] [Reference Citation Analysis]
227 Contos MJ, Cales W, Sterling RK, Luketic VA, Shiffman ML, Mills AS, Fisher RA, Ham J, Sanyal AJ. Development of nonalcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis. Liver Transpl. 2001;7:363-373. [PMID: 11303298 DOI: 10.1053/jlts.2001.23011] [Cited by in Crossref: 281] [Cited by in F6Publishing: 232] [Article Influence: 14.1] [Reference Citation Analysis]
228 Baranova A, Younossi ZM. Adipokines in Non-Alcoholic Fatty Liver Disease. In: Fantuzzi G, Mazzone T, editors. Adipose Tissue and Adipokines in Health and Disease. Totowa: Humana Press; 2007. pp. 291-305. [DOI: 10.1007/978-1-59745-370-7_22] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
229 Marrero JA. Hepatocellular carcinoma: . Current Opinion in Gastroenterology 2003;19:243-9. [DOI: 10.1097/00001574-200305000-00007] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
230 Diehl AM. Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clinics in Liver Disease 2004;8:619-38. [DOI: 10.1016/j.cld.2004.04.012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 73] [Article Influence: 4.4] [Reference Citation Analysis]
231 Kang BK, Yu ES, Lee SS, Lee Y, Kim N, Sirlin CB, Cho EY, Yeom SK, Byun JH, Park SH, Lee MG. Hepatic fat quantification: a prospective comparison of magnetic resonance spectroscopy and analysis methods for chemical-shift gradient echo magnetic resonance imaging with histologic assessment as the reference standard. Invest Radiol. 2012;47:368-375. [PMID: 22543969 DOI: 10.1097/rli.0b013e31824baff3] [Cited by in Crossref: 88] [Cited by in F6Publishing: 40] [Article Influence: 9.8] [Reference Citation Analysis]
232 Ko JS, Yoon JM, Yang HR, Myung JK, Kim H, Kang GH, Cheon JE, Seo JK. Clinical and histological features of nonalcoholic fatty liver disease in children. Dig Dis Sci. 2009;54:2225-2230. [PMID: 19697129 DOI: 10.1007/s10620-009-0949-3] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 3.5] [Reference Citation Analysis]
233 Bath NM, Leverson G, Al-Adra DP, D'Alessandro AM, Mezrich JD, Foley DP. Microsteatosis in Livers From Donation After Circulatory Death Donors Is Associated With Inferior Outcomes Following Liver Transplantation. Liver Transpl 2020;26:1127-37. [PMID: 32453905 DOI: 10.1002/lt.25803] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
234 Marcolin É, Forgiarini LF, Tieppo J, Dias AS, Freitas LARD, Marroni NP. Methionine- and choline-deficient diet induces hepatic changes characteristic of non-alcoholic steatohepatitis. Arq Gastroenterol 2011;48:72-9. [DOI: 10.1590/s0004-28032011000100015] [Cited by in Crossref: 29] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
235 Wang X, Li J, Riaz DR, Shi G, Liu C, Dai Y. Outcomes of liver transplantation for nonalcoholic steatohepatitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2014;12:394-402.e1. [PMID: 24076414 DOI: 10.1016/j.cgh.2013.09.023] [Cited by in Crossref: 102] [Cited by in F6Publishing: 89] [Article Influence: 12.8] [Reference Citation Analysis]
236 Quaglia A, Alves VA, Balabaud C, Bhathal PS, Bioulac-sage P, Crawford JM, Dhillon AP, Ferrell L, Guido M, Hytiroglou P, Nakanuma Y, Paradis V, Snover DC, Theise ND, Thung SN, Tsui WMS, van Leeuwen DJ; The International Liver Pathology Study Group. Role of aetiology in the progression, regression, and parenchymal remodelling of liver disease: implications for liver biopsy interpretation. Histopathology 2016;68:953-67. [DOI: 10.1111/his.12957] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 3.6] [Reference Citation Analysis]
237 Le TH, Caldwell SH, Redick JA, Sheppard BL, Davis CA, Arseneau KO, Iezzoni JC, Hespenheide EE, Al-Osaimi A, Peterson TC. The zonal distribution of megamitochondria with crystalline inclusions in nonalcoholic steatohepatitis. Hepatology. 2004;39:1423-1429. [PMID: 15122772 DOI: 10.1002/hep.20202] [Cited by in Crossref: 69] [Cited by in F6Publishing: 66] [Article Influence: 4.1] [Reference Citation Analysis]
238 Nalbantoglu I, Jain D. Cryptogenic cirrhosis: Old and new perspectives in the era of molecular and genomic medicine. Semin Diagn Pathol 2019;36:389-94. [PMID: 31395291 DOI: 10.1053/j.semdp.2019.07.003] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
239 Lin M, Kao S, Chung P, Chan K, Yang M, Wang C. Improvement for High Fat Diet-Induced Hepatic Injuries and Oxidative Stress by Flavonoid-Enriched Extract from Nelumbo nucifera Leaf. J Agric Food Chem 2009;57:5925-32. [DOI: 10.1021/jf901058a] [Cited by in Crossref: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
240 Rosmorduc O, Fartoux L. HCC and NASH: how strong is the clinical demonstration? Clin Res Hepatol Gastroenterol 2012;36:202-8. [PMID: 22326764 DOI: 10.1016/j.clinre.2011.12.011] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 3.1] [Reference Citation Analysis]
241 Lazo M, Hernaez R, Eberhardt MS, Bonekamp S, Kamel I, Guallar E, Koteish A, Brancati FL, Clark JM. Prevalence of nonalcoholic fatty liver disease in the United States: the Third National Health and Nutrition Examination Survey, 1988-1994. Am J Epidemiol 2013;178:38-45. [PMID: 23703888 DOI: 10.1093/aje/kws448] [Cited by in Crossref: 506] [Cited by in F6Publishing: 472] [Article Influence: 63.3] [Reference Citation Analysis]
242 Henao-Mejia J, Elinav E, Thaiss CA, Flavell RA. The intestinal microbiota in chronic liver disease. Adv Immunol. 2013;117:73-97. [PMID: 23611286 DOI: 10.1016/b978-0-12-410524-9.00003-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 24] [Article Influence: 4.5] [Reference Citation Analysis]
243 Rinella ME, Elias MS, Smolak RR, Fu T, Borensztajn J, Green RM. Mechanisms of hepatic steatosis in mice fed a lipogenic methionine choline-deficient diet. J Lipid Res. 2008;49:1068-1076. [PMID: 18227531 DOI: 10.1194/jlr.m800042-jlr200] [Cited by in Crossref: 273] [Cited by in F6Publishing: 169] [Article Influence: 21.0] [Reference Citation Analysis]
244 Boursier J, Guillaume M, Bouzbib C, Lannes A, Pais R, Smatti S, Cariou B, Bureau C, Ganne-Carrié N, Bourlière M, de Lédinghen V. NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF NON-ALCOHOLIC FATTY LIVER DISEASE. Clin Res Hepatol Gastroenterol 2021;:101769. [PMID: 34332133 DOI: 10.1016/j.clinre.2021.101769] [Reference Citation Analysis]
245 Promrat K, Lutchman G, Uwaifo GI, Freedman RJ, Soza A, Heller T, Doo E, Ghany M, Premkumar A, Park Y, Liang TJ, Yanovski JA, Kleiner DE, Hoofnagle JH. A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 2004;39:188-96. [PMID: 14752837 DOI: 10.1002/hep.20012] [Cited by in Crossref: 543] [Cited by in F6Publishing: 472] [Article Influence: 31.9] [Reference Citation Analysis]
246 Zamin JI, de Mattos AA, Perin C, Ramos GZ. [The importance of AST / ALT rate in nonalcoholic steatohepatitis diagnosis]. Arq Gastroenterol 2002;39:22-6. [PMID: 12184161 DOI: 10.1590/s0004-28032002000100005] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 0.5] [Reference Citation Analysis]
247 Koniaris LG, McKillop IH, Schwartz SI, Zimmers TA. Liver regeneration. J Am Coll Surg. 2003;197:634-659. [PMID: 14522336 DOI: 10.1016/S1072-7515(03)00374-0] [Cited by in Crossref: 187] [Cited by in F6Publishing: 78] [Article Influence: 10.4] [Reference Citation Analysis]
248 Mulhall BP, Ong JP, Younossi ZM. Non-alcoholic fatty liver disease: an overview. J Gastroenterol Hepatol. 2002;17:1136-1143. [PMID: 12453271 DOI: 10.1046/j.1440-1746.2002.02881.x] [Cited by in Crossref: 135] [Cited by in F6Publishing: 119] [Article Influence: 7.5] [Reference Citation Analysis]
249 Miller JP. Serum triglycerides, the liver and the pancreas: . Current Opinion in Lipidology 2000;11:377-82. [DOI: 10.1097/00041433-200008000-00006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
250 Zamin I Jr, Mattos AA, Mattos AZ, Migon E, Bica C, Alexandre CO. Prevalence of the hemochromatosis gene mutation in patients with nonalcoholic steatohepatitis and correlation with degree of liver fibrosis. Arq Gastroenterol 2006;43:224-8. [PMID: 17160239 DOI: 10.1590/s0004-28032006000300013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
251 Kallwitz ER, Kumar M, Aggarwal R, Berger R, Layden-Almer J, Gupta N, Cotler SJ. Ethnicity and nonalcoholic fatty liver disease in an obesity clinic: the impact of triglycerides. Dig Dis Sci. 2008;53:1358-1363. [PMID: 18347982 DOI: 10.1007/s10620-008-0234-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.3] [Reference Citation Analysis]
252 Wiegand J, Mössner J, Tillmann HL. [Non-alcoholic fatty liver disease and non-alcoholic steatohepatitis]. Internist (Berl) 2007;48:154-63. [PMID: 17226007 DOI: 10.1007/s00108-006-1796-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
253 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695-708. [PMID: 20955971 DOI: 10.1016/j.bpg.2010.08.005] [Cited by in Crossref: 128] [Cited by in F6Publishing: 115] [Article Influence: 12.8] [Reference Citation Analysis]
254 Vuppalanchi R, Gould RJ, Wilson LA, Unalp-Arida A, Cummings OW, Chalasani N, Kowdley KV; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network. Hepatol Int 2012;6:379-85. [PMID: 21557024 DOI: 10.1007/s12072-011-9277-8] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 7.1] [Reference Citation Analysis]
255 Clouston AD, Powell EE. Nonalcoholic fatty liver disease: is all the fat bad? Intern Med J. 2004;34:187-191. [PMID: 15086699 DOI: 10.1111/j.1444-0903.2004.00574.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 1.5] [Reference Citation Analysis]
256 Miyaoka H, Michitaka K, Tokumoto Y, Miyake T, Shigematsu S, Soga Y, Abe M, Hiasa Y, Matsuura B, Horiike N, Onji M. LAPAROSCOPIC FEATURES AND INTEROBSERVER VARIATION OF HISTOLOGICAL DIAGNOSIS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE: LAPAROSCOPY AND HISTOLOGY OF NAFLD. Digestive Endoscopy 2008;20:22-8. [DOI: 10.1111/j.1443-1661.2007.00771.x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
257 Chang E, Park CY, Park SW. Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig 2013;4:517-24. [PMID: 24843703 DOI: 10.1111/jdi.12107] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
258 Malnick SD, Beergabel M, Knobler H. Non-alcoholic fatty liver: a common manifestation of a metabolic disorder. QJM. 2003;96:699-709. [PMID: 14500857 DOI: 10.1093/qjmed/hcg120] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 1.9] [Reference Citation Analysis]
259 Kwon SY, Kim SS, Kwon OS, Kwon KA, Chung MG, Park DK, Kim YS, Koo YS, Kim YK, Choi DJ, Kim JH. Prognostic significance of glycaemic control in patients with HBV and HCV-related cirrhosis and diabetes mellitus. Diabet Med 2005;22:1530-5. [PMID: 16241918 DOI: 10.1111/j.1464-5491.2005.01687.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
260 Lonardo A, Adinolfi LE, Loria P, Carulli N, Ruggiero G, Day CP. Steatosis and hepatitis C virus: mechanisms and significance for hepatic and extrahepatic disease. Gastroenterology. 2004;126:586-597. [PMID: 14762795 DOI: 10.1053/j.gastro.2003.11.020] [Cited by in Crossref: 318] [Cited by in F6Publishing: 298] [Article Influence: 18.7] [Reference Citation Analysis]
261 Wang X, Lin SX, Tao J, Wei XQ, Liu YT, Chen YM, Wu B. Study of liver cirrhosis over ten consecutive years in Southern China. World J Gastroenterol 2014; 20(37): 13546-13555 [PMID: 25309085 DOI: 10.3748/wjg.v20.i37.13546] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 28] [Article Influence: 4.1] [Reference Citation Analysis]
262 Mercado-Irizarry A, Torres EA. Cryptogenic cirrhosis: Current knowledge and future directions. Clin Liver Dis (Hoboken) 2016;7:69-72. [PMID: 31041033 DOI: 10.1002/cld.539] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 2.2] [Reference Citation Analysis]
263 Brunt EM, Tiniakos DG. Pathology of steatohepatitis. Best Practice & Research Clinical Gastroenterology 2002;16:691-707. [DOI: 10.1053/bega.2002.0326] [Cited by in Crossref: 43] [Cited by in F6Publishing: 40] [Article Influence: 2.3] [Reference Citation Analysis]
264 Liu CM, Tung TH, Liu JH, Chen VTK, Lin CH, Hsu CT, Chou P. A community-based epidemiological study of elevated serum alanine aminotransferase levels in Kinmen, Taiwan. World J Gastroenterol 2005; 11(11): 1616-1622 [PMID: 15786537 DOI: 10.3748/wjg.v11.i11.1616] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
265 Solga SF, Clark JM, Alkhuraishi AR, Torbenson M, Tabesh A, Schweitzer M, Diehl AM, Magnuson TH. Race and comorbid factors predict nonalcoholic fatty liver disease histopathology in severely obese patients. Surg Obes Relat Dis 2005;1:6-11. [PMID: 16925194 DOI: 10.1016/j.soard.2004.12.006] [Cited by in Crossref: 37] [Cited by in F6Publishing: 35] [Article Influence: 2.5] [Reference Citation Analysis]
266 Halpin LE, Gunning WT, Yamamoto BK. Methamphetamine causes acute hyperthermia-dependent liver damage. Pharmacol Res Perspect 2013;1:e00008. [PMID: 25505562 DOI: 10.1002/prp2.8] [Cited by in Crossref: 26] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
267 Baumgardner JN, Shankar K, Hennings L, Badger TM, Ronis MJ. A new model for nonalcoholic steatohepatitis in the rat utilizing total enteral nutrition to overfeed a high-polyunsaturated fat diet. Am J Physiol Gastrointest Liver Physiol. 2008;294:G27-G38. [PMID: 17947452 DOI: 10.1152/ajpgi.00296.2007] [Cited by in Crossref: 90] [Cited by in F6Publishing: 88] [Article Influence: 6.4] [Reference Citation Analysis]
268 Thomas V, Harish K. Are we overestimating the risks of NASH? Gastroenterology. 2006;130:1015-106; author reply 1016-1017. [PMID: 16530550 DOI: 10.1053/j.gastro.2006.01.078] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
269 García-Sesma A, Calvo J, Manrique A, Cambra F, Justo I, Caso O, Marcacuzco A, Loinaz C, Jiménez C. Morbidly Obese Patients Awaiting Liver Transplantation-Sleeve Gastrectomy: Safety and Efficacy From a Liver Transplant Unit Experience. Transplant Proc 2019;51:33-7. [PMID: 30598229 DOI: 10.1016/j.transproceed.2018.01.060] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
270 Basaranoglu M, Basaranoglu G. Pathophysiology of insulin resistance and steatosis in patients with chronic viral hepatitis. World J Gastroenterol 2011; 17(36): 4055-4062 [PMID: 22039318 DOI: 10.3748/wjg.v17.i36.4055] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
271 Ricardo de Andrade A, Cotrim HP, Alves E, Soares D, Rocha R, Almeida A, Almeida CG, Antonio de Freitas L. Nonalcoholic fatty liver disease in severely obese individuals: The influence of bariatric surgery. Annals of Hepatology 2008;7:364-8. [DOI: 10.1016/s1665-2681(19)31838-1] [Cited by in Crossref: 22] [Article Influence: 1.7] [Reference Citation Analysis]
272 Machicao VI, Krishna M, Bonatti H, Aqel BA, Nguyen JH, Weigand SD, Rosser BG, Hughes C, Dickson RC. Hepatitis C recurrence is not associated with allograft steatosis within the first year after liver transplantation: Hepatitis C Recurrence after Liver Transplantation. Liver Transpl 2004;10:599-606. [DOI: 10.1002/lt.20107] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 1.5] [Reference Citation Analysis]
273 Siciliano M, Parlati L, Maldarelli F, Rossi M, Ginanni Corradini S. Liver transplantation in adults: Choosing the appropriate timing. World J Gastrointest Pharmacol Ther 2012; 3(4): 49-61 [PMID: 22966483 DOI: 10.4292/wjgpt.v3.i4.49] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
274 Angelico F, Burattin M, Alessandri C, Del Ben M, Lirussi F, Angelico F. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd005166.pub2] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
275 Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: Effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol 2006; 12(3): 345-353 [PMID: 16489632 DOI: 10.3748/wjg.v12.i3.345] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
276 Lazo M, Rubin J, Clark JM, Coresh J, Schneider AL, Ndumele C, Hoogeveen RC, Ballantyne CM, Selvin E. The association of liver enzymes with biomarkers of subclinical myocardial damage and structural heart disease. J Hepatol. 2015;62:841-847. [PMID: 25433159 DOI: 10.1016/j.jhep.2014.11.024] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 2.9] [Reference Citation Analysis]
277 Perlemuter G, Bigorgne A, Cassard-Doulcier AM, Naveau S. Nonalcoholic fatty liver disease: from pathogenesis to patient care. Nat Clin Pract Endocrinol Metab 2007;3:458-69. [PMID: 17515890 DOI: 10.1038/ncpendmet0505] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 5.1] [Reference Citation Analysis]
278 Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology. 2014;59:2188-2195. [PMID: 24375711 DOI: 10.1002/hep.26986] [Cited by in Crossref: 437] [Cited by in F6Publishing: 394] [Article Influence: 62.4] [Reference Citation Analysis]
279 Aravinthan A, Scarpini C, Tachtatzis P, Verma S, Penrhyn-lowe S, Harvey R, Davies SE, Allison M, Coleman N, Alexander G. Hepatocyte senescence predicts progression in non-alcohol-related fatty liver disease. Journal of Hepatology 2013;58:549-56. [DOI: 10.1016/j.jhep.2012.10.031] [Cited by in Crossref: 131] [Cited by in F6Publishing: 131] [Article Influence: 16.4] [Reference Citation Analysis]
280 Suraweera D, Dutson E, Saab S. Liver Transplantation and Bariatric Surgery: Best Approach. Clin Liver Dis. 2017;21:215-230. [PMID: 28364810 DOI: 10.1016/j.cld.2016.12.001] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 4.7] [Reference Citation Analysis]
281 Nayak NC, Vasdev N, Saigal S, Soin AS. End-stage nonalcoholic fatty liver disease: evaluation of pathomorphologic features and relationship to cryptogenic cirrhosis from study of explant livers in a living donor liver transplant program. Hum Pathol 2010;41:425-30. [PMID: 19954815 DOI: 10.1016/j.humpath.2009.06.021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 32] [Article Influence: 3.2] [Reference Citation Analysis]
282 Liu KY, Wang LT, Hsu SH, Wang SN. Homeobox Genes and Hepatocellular Carcinoma. Cancers (Basel) 2019;11:E621. [PMID: 31058850 DOI: 10.3390/cancers11050621] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
283 Chitturi S, George J. Interaction of iron, insulin resistance, and nonalcoholic steatohepatitis. Curr Gastroenterol Rep 2003;5:18-25. [DOI: 10.1007/s11894-003-0005-y] [Cited by in Crossref: 61] [Cited by in F6Publishing: 57] [Article Influence: 3.4] [Reference Citation Analysis]
284 Lonardo A, Loria P, Carulli N. Concurrent non-alcoholic steatohepatitis and psoriasis. Report of three cases from the POLI.ST.E.N.A. study. Digestive and Liver Disease 2001;33:86-7. [DOI: 10.1016/s1590-8658(01)80144-4] [Cited by in Crossref: 26] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
285 Henao-Mejia J, Elinav E, Thaiss CA, Licona-Limon P, Flavell RA. Role of the intestinal microbiome in liver disease. J Autoimmun. 2013;46:66-73. [PMID: 24075647 DOI: 10.1016/j.jaut.2013.07.001] [Cited by in Crossref: 106] [Cited by in F6Publishing: 96] [Article Influence: 13.3] [Reference Citation Analysis]
286 Argo CK, Northup PG, Al-Osaimi AM, Caldwell SH. Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis. J Hepatol 2009;51:371-9. [PMID: 19501928 DOI: 10.1016/j.jhep.2009.03.019] [Cited by in Crossref: 353] [Cited by in F6Publishing: 335] [Article Influence: 29.4] [Reference Citation Analysis]
287 Zang S, Ma X, Zhuang Z, Liu J, Bian D, Xun Y, Zhang Q, Zhao F, Yang W, Liu J, Luo Y, Liu Y, Ye B, Ye D, Shi J. Increased ratio of neutrophil elastase to α 1-antitrypsin is closely associated with liver inflammation in patients with nonalcoholic steatohepatitis. Clin Exp Pharmacol Physiol 2016;43:13-21. [DOI: 10.1111/1440-1681.12499] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
288 Garcia-Monzon C, Martin-Perez E, Iacono OL, Fernandez-Bermejo M, Majano PL, Apolinario A, Larraiaga E, Moreno-Otero R. Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity. J Hepatol. 2000;33:716-724. [PMID: 11097478 DOI: 10.1016/s0168-8278(00)80301-3] [Cited by in Crossref: 182] [Cited by in F6Publishing: 43] [Article Influence: 9.1] [Reference Citation Analysis]
289 Barritt AS 4th, Dellon ES, Kozlowski T, Gerber DA, Hayashi PH. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. J Clin Gastroenterol. 2011;45:372-378. [PMID: 20733515 DOI: 10.1097/mcg.0b013e3181eeaff0] [Cited by in Crossref: 30] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
290 Chan TT, Chan WK, Wong GL, Chan AW, Nik Mustapha NR, Chan SL, Chong CC, Mahadeva S, Shu SS, Lai PB, Chan HL, Wong VW. Positive Hepatitis B Core Antibody Is Associated With Cirrhosis and Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease. Am J Gastroenterol. 2020;115:867-875. [PMID: 32149781 DOI: 10.14309/ajg.0000000000000588] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 9.0] [Reference Citation Analysis]
291 Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular Carcinoma in the United States: NAFLD May Be a Common Underlying Liver Disease in Patients With Hepatocellular Carcinoma in the United States. Hepatology 2002;36:1349-54. [DOI: 10.1002/hep.1840360609] [Cited by in Crossref: 255] [Cited by in F6Publishing: 123] [Article Influence: 18.2] [Reference Citation Analysis]
292 Caldwell SH, Lee VD, Kleiner DE, Al-osaimi AM, Argo CK, Northup PG, Berg CL. NASH and cryptogenic cirrhosis: A histological analysis. Annals of Hepatology 2009;8:346-52. [DOI: 10.1016/s1665-2681(19)31748-x] [Cited by in Crossref: 81] [Article Influence: 6.8] [Reference Citation Analysis]
293 Noureddin M, Chan JL, Barradas K, Dimick-Santos L, Schabel E, Omokaro SO, Anania FA, Myers RP, Miller V, Sanyal AJ, Chalasani N; Liver Forum NASH Cirrhosis Working Group. Attribution of Nonalcoholic Steatohepatitis as an Etiology of Cirrhosis for Clinical Trials Eligibility: Recommendations From the Multi-stakeholder Liver Forum. Gastroenterology 2020;159:422-427.e1. [PMID: 32353369 DOI: 10.1053/j.gastro.2020.04.039] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
294 Hashimoto E, Tokushige K, Ludwig J. Diagnosis and classification of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis: Current concepts and remaining challenges. Hepatol Res. 2015;45:20-28. [PMID: 24661406 DOI: 10.1111/hepr.12333] [Cited by in Crossref: 57] [Cited by in F6Publishing: 50] [Article Influence: 8.1] [Reference Citation Analysis]
295 Wlazlo N, van Greevenbroek MM, Curvers J, Schoon EJ, Friederich P, Twisk JW, Bravenboer B, Stehouwer CD. Diabetes mellitus at the time of diagnosis of cirrhosis is associated with higher incidence of spontaneous bacterial peritonitis, but not with increased mortality. Clin Sci (Lond). 2013;125:341-348. [PMID: 23566037 DOI: 10.1042/cs20120596] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
296 El-serag HB, Richardson PA, Everhart JE. The role of diabetes in hepatocellular carcinoma: a case-control study among United States veterans. Am J Gastroenterol 2001;96:2462-7. [DOI: 10.1111/j.1572-0241.2001.04054.x] [Cited by in Crossref: 185] [Cited by in F6Publishing: 166] [Article Influence: 9.3] [Reference Citation Analysis]
297 Cadranel JF, Jouannaud V, Loison S. [Improving insulin resistance: certain progress in the management of patients with non-alcoholic steatohepatitis...but the story continues]. Gastroenterol Clin Biol 2004;28:265-7. [PMID: 15094675 DOI: 10.1016/s0399-8320(04)94916-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
298 Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. J Gastroenterol 2006;41:725-32. [PMID: 16988759 DOI: 10.1007/s00535-006-1876-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
299 Valtuena S, Numeroso F, Ardigo D, Pedrazzoni M, Franzini L, Piatti PM, Monti L, Zavaroni I. Relation-ship between leptin, insulin, body composition and liver steatosis in non-diabetic moderate drinkers with normal transaminase levels. Eur J Endocrinol. 2005;153:283-290. [PMID: 16061835 DOI: 10.1530/eje.1.01960] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
300 Omata M, Lesmana LA, Tateishi R, Chen PJ, Lin SM, Yoshida H, Kudo M, Lee JM, Choi BI, Poon RT, Shiina S, Cheng AL, Jia JD, Obi S, Han KH, Jafri W, Chow P, Lim SG, Chawla YK, Budihusodo U, Gani RA, Lesmana CR, Putranto TA, Liaw YF, Sarin SK. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439-474. [PMID: 20827404 DOI: 10.1007/s12072-010-9165-7] [Cited by in Crossref: 684] [Cited by in F6Publishing: 686] [Article Influence: 62.2] [Reference Citation Analysis]
301 Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-8. [PMID: 15352910 DOI: 10.1111/j.1365-2036.2004.02153.x] [Cited by in Crossref: 123] [Cited by in F6Publishing: 107] [Article Influence: 7.2] [Reference Citation Analysis]
302 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol 2013; 5(6): 311-322 [PMID: 23805355 DOI: 10.4254/wjh.v5.i6.311] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 4.3] [Reference Citation Analysis]
303 Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, May SB, Kramer JR, Richardson PA, Davila JA. Temporal trends of nonalcoholic fatty liver disease-related hepatocellular carcinoma in the veteran affairs population. Clin Gastroenterol Hepatol 2015;13:594-601.e1. [PMID: 25148760 DOI: 10.1016/j.cgh.2014.08.013] [Cited by in Crossref: 143] [Cited by in F6Publishing: 138] [Article Influence: 20.4] [Reference Citation Analysis]
304 Marchesini G, Moscatiello S, Di Domizio S, Forlani G. Obesity-associated liver disease. J Clin Endocrinol Metab. 2008;93:S74-S80. [PMID: 18987273 DOI: 10.1210/jc.2008-1399] [Cited by in Crossref: 176] [Cited by in F6Publishing: 168] [Article Influence: 14.7] [Reference Citation Analysis]
305 Miyasato M, Murase-mishiba Y, Bessho M, Miyawaki M, Imbe H, Tsutsumi C, Tanimoto K, Imagawa A, Terasaki J, Hanafusa T. The cytokeratin-18 fragment level as a biomarker of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. Clinica Chimica Acta 2014;433:184-9. [DOI: 10.1016/j.cca.2014.03.018] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.1] [Reference Citation Analysis]
306 Harrison SA, Neuschwander-tetri BA. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Clinics in Liver Disease 2004;8:861-79. [DOI: 10.1016/j.cld.2004.06.008] [Cited by in Crossref: 81] [Cited by in F6Publishing: 74] [Article Influence: 4.8] [Reference Citation Analysis]
307 Afzali A, Berry K, Ioannou GN. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl. 2012;18:29-37. [PMID: 21932374 DOI: 10.1002/lt.22435] [Cited by in Crossref: 100] [Cited by in F6Publishing: 88] [Article Influence: 11.1] [Reference Citation Analysis]
308 Merchante N, Mira JA, Pineda JA. [Non alcoholic steatosis in HIV infection]. Med Clin (Barc) 2009;133:112-6. [PMID: 19515391 DOI: 10.1016/j.medcli.2008.10.033] [Reference Citation Analysis]
309 Hübscher SG. Histological assessment of non-alcoholic fatty liver disease. Histopathology. 2006;49:450-465. [PMID: 17064291 DOI: 10.1111/j.1365-2559.2006.02416.x] [Cited by in Crossref: 180] [Cited by in F6Publishing: 168] [Article Influence: 12.0] [Reference Citation Analysis]
310 Zois CD, Baltayiannis GH, Bekiari A, Goussia A, Karayiannis P, Doukas M, Demopoulos D, Mitsellou A, Vougiouklakis T, Mitsi V, Tsianos EV. Steatosis and steatohepatitis in postmortem material from Northwestern Greece. World J Gastroenterol 2010; 16(31): 3944-3949 [PMID: 20712056 DOI: 10.3748/wjg.v16.i31.3944] [Cited by in CrossRef: 34] [Cited by in F6Publishing: 32] [Article Influence: 3.1] [Reference Citation Analysis]
311 Maheshwari A, Thuluvath PJ. Cryptogenic Cirrhosis and NAFLD: Are They Related? Am J Gastroenterology 2006;101:664-8. [DOI: 10.1111/j.1572-0241.2006.00478.x] [Cited by in Crossref: 61] [Cited by in F6Publishing: 49] [Article Influence: 4.1] [Reference Citation Analysis]
312 Contos MJ, Choudhury J, Mills AS, Sanyal AJ. The histologic spectrum of nonalcoholic fatty liver disease. Clin Liver Dis 2004;8:481-500, vii. [PMID: 15331059 DOI: 10.1016/j.cld.2004.04.013] [Cited by in Crossref: 46] [Cited by in F6Publishing: 42] [Article Influence: 2.7] [Reference Citation Analysis]
313 Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. Journal of Hepatology 2004;41:592-8. [DOI: 10.1016/j.jhep.2004.06.030] [Cited by in Crossref: 91] [Cited by in F6Publishing: 93] [Article Influence: 5.4] [Reference Citation Analysis]
314 Alchera E, Rolla S, Imarisio C, Bardina V, Valente G, Novelli F, Carini R. Adenosine A2a receptor stimulation blocks development of nonalcoholic steatohepatitis in mice by multilevel inhibition of signals that cause immunolipotoxicity. Transl Res 2017;182:75-87. [PMID: 28011152 DOI: 10.1016/j.trsl.2016.11.009] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 2.6] [Reference Citation Analysis]
315 Loria P, Carulli N, Lonardo A. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1200-1; author reply 1201-2. [PMID: 15842599 DOI: 10.1111/j.1572-0241.2005.41837_3.x] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
316 Tateishi R, Uchino K, Fujiwara N, Takehara T, Okanoue T, Seike M, Yoshiji H, Yatsuhashi H, Shimizu M, Torimura T, Moriyama M, Sakaida I, Okada H, Chiba T, Chuma M, Nakao K, Isomoto H, Sasaki Y, Kaneko S, Masaki T, Chayama K, Koike K. A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011-2015 update. J Gastroenterol 2019;54:367-76. [PMID: 30498904 DOI: 10.1007/s00535-018-1532-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 58] [Article Influence: 19.3] [Reference Citation Analysis]
317 Jiang Y, Zhang H, Dong LY, Wang D, An W. Increased hepatic UCP2 expression in rats with nonalcoholic steatohepatitis is associated with upregulation of Sp1 binding to its motif within the proximal promoter region. J Cell Biochem. 2008;105:277-289. [PMID: 18543254 DOI: 10.1002/jcb.21827] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
318 Wells SA. Quantification of Hepatic Fat and Iron with Magnetic Resonance Imaging. Magnetic Resonance Imaging Clinics of North America 2014;22:397-416. [DOI: 10.1016/j.mric.2014.04.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
319 Nelson Hayes C, Zhang P, Chayama K; Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan, Department of Gastroenterology and Metabolism, Graduate School of Biomedical & Health Sciences, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Minami-ku, Hiroshima, Japan. The Role of Lipids in Hepatocellular Carcinoma. In: Tirnitz-parker JE, editor. Hepatocellular Carcinoma. Codon Publications; 2019. pp. 95-110. [DOI: 10.15586/hepatocellularcarcinoma.2019.ch5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
320 Koh YM, Jang SW, Ahn TW. Anti-obesity effect of Yangkyuksanwha-tang in high-fat diet-induced obese mice. BMC Complement Altern Med 2019;19:246. [PMID: 31488172 DOI: 10.1186/s12906-019-2669-3] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
321 Lefkowitch JH. Steatosis, Steatohepatitis and Related Conditions. Scheuer's Liver Biopsy Interpretation. Elsevier; 2010. pp. 93-114. [DOI: 10.1016/b978-0-7020-3410-7.00013-7] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
322 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458:511-523. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1] [Cited by in Crossref: 69] [Cited by in F6Publishing: 70] [Article Influence: 6.9] [Reference Citation Analysis]
323 Dooghaie Moghadam A, Eslami P, Razavi-Khorasani N, Moazzami B, Zahedi-Tajrishi F, Farokhi E, Makhdoomi Sharabiani K, Mansour-Ghanaei A, Mehrvar A, Aghajanpoor Pasha M, Saeedi S, Iravani S. Recurrence of fatty liver disease following liver transplantation for NAFLD-related cirrhosis: Current status and challenges. Caspian J Intern Med 2020;11:346-54. [PMID: 33680375 DOI: 10.22088/cjim.11.4.346] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
324 Niwa H, Sasaki M, Haratake J, Kasai T, Katayanagi K, Kurumaya H, Masuda S, Minato H, Zen Y, Uchiyama A, Miwa A, Saito K, Sudo Y, Nakanuma Y. Clinicopathological significance of antinuclear antibodies in non-alcoholic steatohepatitis. Hepatol Res 2007;37:923-31. [PMID: 17610500 DOI: 10.1111/j.1872-034X.2007.00150.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
325 Ahn SB, Powell EE, Russell A, Hartel G, Irvine KM, Moser C, Valery PC. Type 2 Diabetes: A Risk Factor for Hospital Readmissions and Mortality in Australian Patients With Cirrhosis. Hepatol Commun. 2020;4:1279-1292. [PMID: 32923832 DOI: 10.1002/hep4.1536] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
326 Willner IR, Waters B, Patil SR, Reuben A, Morelli J, Riely CA. Ninety patients with nonalcoholic steatohepatitis: insulin resistance, familial tendency, and severity of disease. Am J Gastroenterol 2001;96:2957-61. [PMID: 11693332 DOI: 10.1111/j.1572-0241.2001.04667.x] [Cited by in Crossref: 262] [Cited by in F6Publishing: 254] [Article Influence: 13.1] [Reference Citation Analysis]
327 Machado M, Cortez-Pinto H. Non-alcoholic fatty liver disease and insulin resistance. Eur J Gastroenterol Hepatol. 2005;17:823-826. [PMID: 16003131 DOI: 10.1097/00042737-200508000-00008] [Cited by in Crossref: 41] [Cited by in F6Publishing: 41] [Article Influence: 2.6] [Reference Citation Analysis]
328 Georgescu EF. Angiotensin receptor blockers in the treatment of NASH/NAFLD: could they be a first-class option? Adv Ther. 2008;25:1141-1174. [PMID: 18972077 DOI: 10.1007/s12325-008-0110-2] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.4] [Reference Citation Analysis]
329 Anstee QM, Targher G, Day CP. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol. 2013;10:330-344. [PMID: 23507799 DOI: 10.1038/nrgastro.2013.41] [Cited by in Crossref: 861] [Cited by in F6Publishing: 807] [Article Influence: 107.6] [Reference Citation Analysis]
330 Luo X, Song X, Zhu A, Si Y, Ji L, Ma Z, Jiao Z, Wu J. Development of poly(vinyl acetate-methylacrylic acid)/chitosan/Fe3O4 nanoparticles for the diagnosis of non-alcoholic steatohepatitis with magnetic resonance imaging. J Mater Sci: Mater Med 2012;23:3075-82. [DOI: 10.1007/s10856-012-4763-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
331 Marrero JA, Lok AS. Occult hepatitis B virus infection in patients with hepatocellular carcinoma: Innocent bystander, cofactor, or culprit. Gastroenterology. 2004;126:347-350. [PMID: 14699513 DOI: 10.1053/j.gastro.2003.11.021] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 1.5] [Reference Citation Analysis]
332 Kumar S, Verma AK, Rani R, Sharma A, Wang J, Shah SA, Behari J, Salazar Gonzalez R, Kohli R, Gandhi CR. Hepatic Deficiency of Augmenter of Liver Regeneration Predisposes to Nonalcoholic Steatohepatitis and Fibrosis. Hepatology 2020;72:1586-604. [PMID: 32031683 DOI: 10.1002/hep.31167] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
333 Yu AS, Keeffe EB. Elevated AST or ALT to nonalcoholic fatty liver disease: accurate predictor of disease prevalence? Am J Gastroenterol 2003;98:955-6. [PMID: 12809814 DOI: 10.1111/j.1572-0241.2003.07485.x] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 3.1] [Reference Citation Analysis]
334 Wang CC, Lin SK, Tseng YF, Hsu CS, Tseng TC, Lin HH, Wang LY, Kao JH. Elevation of serum aminotransferase activity increases risk of carotid atherosclerosis in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2009;24:1411-1416. [PMID: 19702910 DOI: 10.1111/j.1440-1746.2009.05872.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.8] [Reference Citation Analysis]
335 Pang G, Xie J, Chen Q, Hu Z. Energy intake, metabolic homeostasis, and human health. Food Science and Human Wellness 2014;3:89-103. [DOI: 10.1016/j.fshw.2015.01.001] [Cited by in Crossref: 12] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
336 Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol. 2009;50:511-517. [PMID: 19155082 DOI: 10.1016/j.jhep.2008.10.021] [Cited by in Crossref: 97] [Cited by in F6Publishing: 85] [Article Influence: 7.5] [Reference Citation Analysis]
337 González-gonzález JA, García-compean D, Vázquez-elizondo G, Garza-galindo A, Jáquez-quintana JO, Maldonado-garza H. Nonvariceal upper gastrointestinal bleeding in patients with liver cirrhosis. Clinical features, outcomes and predictors of in-hospital mortality. A prospective study. Annals of Hepatology 2011;10:287-95. [DOI: 10.1016/s1665-2681(19)31540-6] [Cited by in Crossref: 33] [Article Influence: 3.3] [Reference Citation Analysis]
338 Mathur SK, Jain P, Mathur P. Microarray evidences the role of pathologic adipose tissue in insulin resistance and their clinical implications. J Obes 2011;2011:587495. [PMID: 21603273 DOI: 10.1155/2011/587495] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 0.6] [Reference Citation Analysis]
339 Blonski W, Kotlyar DS, Forde KA. Non-viral causes of hepatocellular carcinoma. World J Gastroenterol 2010; 16(29): 3603-3615 [PMID: 20677332 DOI: 10.3748/wjg.v16.i29.3603] [Cited by in CrossRef: 107] [Cited by in F6Publishing: 97] [Article Influence: 9.7] [Reference Citation Analysis]
340 Younossi ZM, Gorreta F, Ong JP, Schlauch K, Del Giacco L, Elariny H, Van Meter A, Younoszai A, Goodman Z, Baranova A. Hepatic gene expression in patients with obesity-related non-alcoholic steatohepatitis. Liver Int. 2005;25:760-771. [PMID: 15998427 DOI: 10.1111/j.1478-3231.2005.01117.x] [Cited by in Crossref: 76] [Cited by in F6Publishing: 68] [Article Influence: 4.8] [Reference Citation Analysis]
341 Alexopoulos AS, Crowley MJ, Wang Y, Moylan CA, Guy CD, Henao R, Piercy DL, Seymour KA, Sudan R, Portenier DD, Diehl AM, Coviello AD, Abdelmalek MF. Glycemic Control Predicts Severity of Hepatocyte Ballooning and Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease. Hepatology 2021. [PMID: 33724511 DOI: 10.1002/hep.31806] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
342 Albano E, Mottaran E, Vidali M, Reale E, Saksena S, Occhino G, Burt AD, Day CP. Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut. 2005;54:987-993. [PMID: 15951547 DOI: 10.1136/gut.2004.057968] [Cited by in Crossref: 135] [Cited by in F6Publishing: 133] [Article Influence: 8.4] [Reference Citation Analysis]
343 Li YH, Choi DH, Lee EH, Seo SR, Lee S, Cho EH. Sirtuin 3 (SIRT3) Regulates α-Smooth Muscle Actin (α-SMA) Production through the Succinate Dehydrogenase-G Protein-coupled Receptor 91 (GPR91) Pathway in Hepatic Stellate Cells. J Biol Chem 2016;291:10277-92. [PMID: 26912655 DOI: 10.1074/jbc.M115.692244] [Cited by in Crossref: 28] [Cited by in F6Publishing: 12] [Article Influence: 5.6] [Reference Citation Analysis]
344 Rolla S, Alchera E, Imarisio C, Bardina V, Valente G, Cappello P, Mombello C, Follenzi A, Novelli F, Carini R. The balance between IL-17 and IL-22 produced by liver-infiltrating T-helper cells critically controls NASH development in mice. Clinical Science 2016;130:193-203. [DOI: 10.1042/cs20150405] [Cited by in Crossref: 56] [Cited by in F6Publishing: 37] [Article Influence: 9.3] [Reference Citation Analysis]
345 Ikeda H, Suzuki M, Takahashi H, Kobayashi M, Okuse N, Moriya H, Koike J, Maeyama S, Yotsuyanagi H, Itoh F. Hepatocellular carcinoma with silent and cirrhotic non-alcoholic steatohepatitis, accompanying ectopic liver tissue attached to gallbladder. Pathol Int. 2006;56:40-45. [PMID: 16398679 DOI: 10.1111/j.1440-1827.2006.01916.x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
346 Kumar R, Goh BG, Kam JW, Chang PE, Tan CK. Comparisons between non-alcoholic steatohepatitis and alcohol-related hepatocellular carcinoma. Clin Mol Hepatol 2020;26:196-208. [PMID: 31914720 DOI: 10.3350/cmh.2019.0012] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
347 Angelico F, Corradini SG, Pastori D, Fargion S, Fracanzani AL, Angelico M, Bolondi L, Tozzi G, Pujatti PL, Labbadia G, Corazza GR, Averna M, Perticone F, Croce G, Persico M, Bucci T, Baratta F, Polimeni L, Del Ben M, Violi F, Violi F, Angelico F, Pastori D, Baratta F, Del Ben M, Polimeni L, Labbadia G, Basili S, Raparelli V, Napoleone L, Corradini SG, Ferri F, Monica P, Mischitelli M, Lucia P, Tozzi G, D'amico J, Colzi M, Andreozzi P, Perticone F, Caroleo B, Corazza GR, Michela M, Gaetano B, Sacerdoti D, Brocco S, Angelico M, Santopaolo F, Francioso S, Pujatti PL, Faedo A, Andriulli A, Ippolito AM, Bolondi L, Tovoli F, Fargion S, Fracanzani AL, Davì G, Di Michele D, Croce G, Averna M, Giammanco A, Persico M, Bucci T, Iuliano L, Ciacciarelli M. Severe reduction of blood lysosomal acid lipase activity in cryptogenic cirrhosis: A nationwide multicentre cohort study. Atherosclerosis 2017;262:179-84. [DOI: 10.1016/j.atherosclerosis.2017.03.038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
348 Lahmek P, Nahon S. Stéatopathies hépatiques non alcooliques. EMC - Hépato-Gastroenterologie 2005;2:269-83. [DOI: 10.1016/j.emchg.2005.01.011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
349 Devries MC, Samjoo IA, Hamadeh MJ, Tarnopolsky MA. Effect of Endurance Exercise on Hepatic Lipid Content, Enzymes, and Adiposity in Men and Women. Obesity 2008;16:2281-8. [DOI: 10.1038/oby.2008.358] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 7.2] [Reference Citation Analysis]
350 Zolfaghari H, Askari G, Siassi F, Feizi A, Sotoudeh G. Intake of Nutrients, Fiber, and Sugar in Patients with Nonalcoholic Fatty Liver Disease in Comparison to Healthy Individuals. Int J Prev Med. 2016;7:98. [PMID: 27625763 DOI: 10.4103/2008-7802.188083] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 4.4] [Reference Citation Analysis]
351 Carmiel-Haggai M, Cederbaum AI, Nieto N. Binge ethanol exposure increases liver injury in obese rats. Gastroenterology 2003;125:1818-33. [PMID: 14724834 DOI: 10.1053/j.gastro.2003.09.019] [Cited by in Crossref: 62] [Cited by in F6Publishing: 59] [Article Influence: 3.6] [Reference Citation Analysis]
352 Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Is cryptogenic cirrhosis different from NASH cirrhosis? Journal of Hepatology 2018;68:519-25. [DOI: 10.1016/j.jhep.2017.11.018] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 10.3] [Reference Citation Analysis]
353 Vespasiani-Gentilucci U, Gallo P, Piemonte F, Riva E, Porcari A, Vorini F, Tozzi G, Piccioni L, Galati G, De Vincentis A, Carotti S, Morini S, D'Amico J, Angeletti S, Pedone C, Picardi A. Lysosomal Acid Lipase Activity Is Reduced Both in Cryptogenic Cirrhosis and in Cirrhosis of Known Etiology. PLoS One. 2016;11:e0156113. [PMID: 27219619 DOI: 10.1371/journal.pone.0156113] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
354 Zhang H, Chen L, Xin Y, Lou Y, Liu Y, Xuan S. Apolipoprotein c3 gene polymorphisms are not a risk factor for developing non-alcoholic Fatty liver disease: a meta-analysis. Hepat Mon. 2014;14:e23100. [PMID: 25477977 DOI: 10.5812/hepatmon.23100] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
355 Sorom AJ, Nyberg SL, Gores GJ. Keratin, fas, and cryptogenic liver failure. Liver Transpl. 2002;8:1195-1197. [PMID: 12474161 DOI: 10.1053/jlts.2002.0081195] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
356 Saadeh S. Nonalcoholic Fatty liver disease and obesity. Nutr Clin Pract. 2007;22:1-10. [PMID: 17242448 DOI: 10.1177/011542650702200101] [Cited by in Crossref: 47] [Cited by in F6Publishing: 43] [Article Influence: 3.4] [Reference Citation Analysis]
357 Kumagai H, Yokoyama K, Katsuyama K, Hara S, Yamamoto H, Yamagata T, Taniguchi N, Hirota N, Itoh K. A New Method for Measuring the Speed of Sound in Rat Liver ex Vivo Using an Ultrasound System: Correlation of Sound Speed with Fat Deposition. Ultrasound in Medicine & Biology 2014;40:2499-507. [DOI: 10.1016/j.ultrasmedbio.2014.03.019] [Cited by in Crossref: 14] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
358 Agrawal S, Duseja AK. Non-alcoholic Fatty Liver Disease: East Versus West. J Clin Exp Hepatol 2012;2:122-34. [PMID: 25755421 DOI: 10.1016/S0973-6883(12)60101-7] [Cited by in Crossref: 25] [Cited by in F6Publishing: 16] [Article Influence: 2.8] [Reference Citation Analysis]
359 Iannaccone R, Piacentini F, Murakami T, Paradis V, Belghiti J, Hori M, Kim T, Durand F, Wakasa K, Monden M. Hepatocellular carcinoma in patients with nonalcoholic fatty liver disease: helical CT and MR imaging findings with clinical-pathologic comparison. Radiology. 2007;243:422-430. [PMID: 17356175 DOI: 10.1148/radiol.2432051244] [Cited by in Crossref: 54] [Cited by in F6Publishing: 44] [Article Influence: 3.9] [Reference Citation Analysis]
360 Brunt EM, Kleiner DE, Carpenter DH, Rinella M, Harrison SA, Loomba R, Younossi Z, Neuschwander-Tetri BA, Sanyal AJ; American Association for the Study of Liver Diseases NASH Task Force. NAFLD: Reporting Histologic Findings in Clinical Practice. Hepatology 2021;73:2028-38. [PMID: 33111374 DOI: 10.1002/hep.31599] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 11.0] [Reference Citation Analysis]
361 Buyse S, Valla D. [Carbohydrate metabolism dysregulation in cirrhosis: pathophysiology, prognostic impact and therapeutic implications]. Gastroenterol Clin Biol 2007;31:266-73. [PMID: 17396083 DOI: 10.1016/s0399-8320(07)89371-7] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
362 Pacifico L, Poggiogalle E, Cantisani V, Menichini G, Ricci P, Ferraro F, Chiesa C. Pediatric nonalcoholic fatty liver disease: A clinical and laboratory challenge. World J Hepatol 2010; 2(7): 275-288 [PMID: 21161009 DOI: 10.4254/wjh.v2.i7.275] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.7] [Reference Citation Analysis]
363 Stefan N, Kantartzis K, Häring H. Causes and Metabolic Consequences of Fatty Liver. Endocrine Reviews 2008;29:939-60. [DOI: 10.1210/er.2008-0009] [Cited by in Crossref: 338] [Cited by in F6Publishing: 318] [Article Influence: 26.0] [Reference Citation Analysis]
364 Pariente A. [Diagnosis and management of non alcoholic fatty liver disease]. Gastroenterol Clin Biol 2009;33:413-24. [PMID: 19375255 DOI: 10.1016/j.gcb.2009.02.028] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
365 Karrar A, Stepanova M, Alaparthi L, Lingam S, Younoszai Z, Zheng L, Malik KS, Younossi E, Monge F, Hunt SL. Anti-adipocyte antibody response in patients with non-alcoholic fatty liver disease. J Gastroenterol Hepatol. 2015;30:900-908. [PMID: 25469790 DOI: 10.1111/jgh.12856] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
366 Harrison SA, Torgerson S, Hayashi PH. The natural history of nonalcoholic fatty liver disease: a clinical histopathological study. Am J Gastroenterol. 2003;98:2042-2047. [PMID: 14499785 DOI: 10.1111/j.1572-0241.2003.07659.x] [Cited by in Crossref: 320] [Cited by in F6Publishing: 296] [Article Influence: 17.8] [Reference Citation Analysis]
367 Iijima H, Moriyasu F, Tsuchiya K, Suzuki S, Yoshida M, Shimizu M, Sasaki S, Nishiguchi S, Maeyama S. Decrease in accumulation of ultrasound contrast microbubbles in non-alcoholic steatohepatitis. Hepatol Res. 2007;37:722-730. [PMID: 17559420 DOI: 10.1111/j.1872-034x.2007.00130.x] [Cited by in Crossref: 62] [Cited by in F6Publishing: 36] [Article Influence: 4.4] [Reference Citation Analysis]
368 Basaranoglu M, Basaranoglu G, Sabuncu T, Sentürk H. Fructose as a key player in the development of fatty liver disease. World J Gastroenterol 2013; 19(8): 1166-1172 [PMID: 23482247 DOI: 10.3748/wjg.v19.i8.1166] [Cited by in CrossRef: 135] [Cited by in F6Publishing: 119] [Article Influence: 16.9] [Reference Citation Analysis]
369 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Virchows Arch. 2011;458:511-523. [PMID: 21442288 DOI: 10.1007/s00428-011-1066-1].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
370 Caldwell S. Cryptogenic Cirrhosis: What Are We Missing? Curr Gastroenterol Rep 2010;12:40-8. [DOI: 10.1007/s11894-009-0082-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
371 Ratziu V, Tahiri M, Bonyhay L. La stéatohépatite non alcoolique. Annales d'Endocrinologie 2005;66:71-80. [DOI: 10.1016/s0003-4266(05)81735-4] [Cited by in Crossref: 4] [Article Influence: 0.3] [Reference Citation Analysis]
372 Wong CR, Njei B, Nguyen MH, Nguyen A, Lim JK. Survival after treatment with curative intent for hepatocellular carcinoma among patients with vs without non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2017;46:1061-9. [PMID: 28960360 DOI: 10.1111/apt.14342] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 4.3] [Reference Citation Analysis]
373 Nair S, Diehl AM, Wiseman M, Farr GH, Perrillo RP. Metformin in the treatment of non-alcoholic steatohepatitis: a pilot open label trial: METFORMIN IN NASH. Alimentary Pharmacology & Therapeutics 2004;20:23-8. [DOI: 10.1111/j.1365-2036.2004.02025.x] [Cited by in Crossref: 254] [Cited by in F6Publishing: 226] [Article Influence: 14.9] [Reference Citation Analysis]
374 Caldwell SH, Crespo DM. The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease. J Hepatol. 2004;40:578-584. [PMID: 15030972 DOI: 10.1016/j.jhep.2004.02.013] [Cited by in Crossref: 187] [Cited by in F6Publishing: 161] [Article Influence: 11.0] [Reference Citation Analysis]
375 Qureshi K, Abrams GA. Metabolic liver disease of obesity and role of adipose tissue in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2007; 13(26): 3540-3553 [PMID: 17659704 DOI: 10.3748/wjg.v13.i26.3540] [Cited by in CrossRef: 160] [Cited by in F6Publishing: 148] [Article Influence: 11.4] [Reference Citation Analysis]
376 Loria P, Lonardo A, Carulli N. Should nonalcoholic fatty liver disease be renamed? Dig Dis. 2005;23:72-82. [PMID: 15920328 DOI: 10.1159/000084728] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
377 Marchesini G, Forlani G. NASH: from liver diseases to metabolic disorders and back to clinical hepatology. Hepatology. 2002;35:497-499. [PMID: 11826428 DOI: 10.1053/jhep.2002.31551] [Cited by in Crossref: 94] [Cited by in F6Publishing: 89] [Article Influence: 4.9] [Reference Citation Analysis]
378 Angulo P, Hui JM, Marchesini G, Bugianesi E, George J, Farrell GC, Enders F, Saksena S, Burt AD, Bida JP, Lindor K, Sanderson SO, Lenzi M, Adams LA, Kench J, Therneau TM, Day CP. The NAFLD fibrosis score: a noninvasive system that identifies liver fibrosis in patients with NAFLD. Hepatology. 2007;45:846-854. [PMID: 17393509 DOI: 10.1002/hep.21496] [Cited by in Crossref: 1507] [Cited by in F6Publishing: 1363] [Article Influence: 107.6] [Reference Citation Analysis]
379 Koehler EM, Schouten JN, Hansen BE, van Rooij FJ, Hofman A, Stricker BH, Janssen HL. Prevalence and risk factors of non-alcoholic fatty liver disease in the elderly: results from the Rotterdam study. J Hepatol. 2012;57:1305-1311. [PMID: 22871499 DOI: 10.1016/j.jhep.2012.07.028] [Cited by in Crossref: 135] [Cited by in F6Publishing: 115] [Article Influence: 15.0] [Reference Citation Analysis]
380 Wong VW, Chan HL, Hui AY, Chan KF, Liew CT, Chan FK, Sung JJ. Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther 2004;20:45-9. [PMID: 15225170 DOI: 10.1111/j.1365-2036.2004.02012.x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 38] [Article Influence: 2.2] [Reference Citation Analysis]
381 Aby ES, Lee E, Saggi SS, Viramontes MR, Grotts JF, Agopian VG, Busuttil RW, Saab S. Pretransplant Sarcopenia in Patients With NASH Cirrhosis Does Not Impact Rehospitalization or Mortality. Journal of Clinical Gastroenterology 2019;53:680-5. [DOI: 10.1097/mcg.0000000000001109] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
382 Schwenzer NF, Springer F, Schraml C, Stefan N, Machann J, Schick F. Non-invasive assessment and quantification of liver steatosis by ultrasound, computed tomography and magnetic resonance. J Hepatol. 2009;51:433-445. [PMID: 19604596 DOI: 10.1016/j.jhep.2009.05.023] [Cited by in Crossref: 472] [Cited by in F6Publishing: 436] [Article Influence: 39.3] [Reference Citation Analysis]
383 Browning JD, Kumar KS, Saboorian MH, Thiele DL. Ethnic differences in the prevalence of cryptogenic cirrhosis. Am J Gastroenterol. 2004;99:292-298. [PMID: 15046220 DOI: 10.1111/j.1572-0241.2004.04059.x] [Cited by in Crossref: 150] [Cited by in F6Publishing: 136] [Article Influence: 8.8] [Reference Citation Analysis]
384 Verdi H, Sare Koytak E, Önder O, Arslan Ergül A, Cinar K, Idilman R, Erden E, Mithat Bozdayi A, Yurdaydin C, Uzunalimoglu Ö, Bozkaya H. Peroxisome Proliferator-Activated Receptor α L162V Polymorphism in Nonalcoholic Steatohepatitis and Genotype 1 Hepatitis C Virus-Related Liver Steatosis: . Journal of Investigative Medicine 2005;53:353-9. [DOI: 10.2310/6650.2005.53706] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
385 Gwack J, Hwang S, Ko K, Jun JK, Park SK, Chang S, Shin H, Yoo K. Fasting Serum Glucose and Subsequent Liver Cancer Risk in a Korean Prospective Cohort. J Prev Med Public Health 2007;40:23. [DOI: 10.3961/jpmph.2007.40.1.23] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
386 Murag S, Ahmed A, Kim D. Recent Epidemiology of Nonalcoholic Fatty Liver Disease. Gut Liver 2021;15:206-16. [PMID: 32921636 DOI: 10.5009/gnl20127] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
387 Green RM. NASH--hepatic metabolism and not simply the metabolic syndrome. Hepatology. 2003;38:14-17. [PMID: 12829980 DOI: 10.1053/jhep.2003.50325] [Cited by in Crossref: 56] [Cited by in F6Publishing: 55] [Article Influence: 3.1] [Reference Citation Analysis]
388 Masuoka HC, Chalasani N. Nonalcoholic fatty liver disease: an emerging threat to obese and diabetic individuals. Ann N Y Acad Sci. 2013;1281:106-122. [PMID: 23363012 DOI: 10.1111/nyas.12016] [Cited by in Crossref: 159] [Cited by in F6Publishing: 148] [Article Influence: 19.9] [Reference Citation Analysis]
389 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol. 2008;14:4300-4308. [PMID: 18666317 DOI: 10.3748/wjg.v14.i27.4300] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
390 Chiappini F, Barrier A, Saffroy R, Domart MC, Dagues N, Azoulay D, Sebagh M, Franc B, Chevalier S, Debuire B. Exploration of global gene expression in human liver steatosis by high-density oligonucleotide microarray. Lab Invest. 2006;86:154-165. [PMID: 16344856 DOI: 10.1038/labinvest.3700374] [Cited by in Crossref: 69] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
391 Ong JP, Younossi ZM. Is hepatocellular carcinoma part of the natural history of nonalcoholic steatohepatitis? Gastroenterology 2002;123:375-8. [DOI: 10.1053/gast.2002.34453] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 1.5] [Reference Citation Analysis]
392 Safwan M, Collins KM, Abouljoud MS, Salgia R. Outcome of liver transplantation in patients with prior bariatric surgery. Liver Transpl. 2017;23:1415-1421. [PMID: 28752920 DOI: 10.1002/lt.24832] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 11.0] [Reference Citation Analysis]
393 Wang CC, Tseng TC, Hsieh TC, Hsu CS, Wang PC, Lin HH, Kao JH. Severity of fatty liver on ultrasound correlates with metabolic and cardiovascular risk. Kaohsiung J Med Sci. 2012;28:151-160. [PMID: 22385608 DOI: 10.1016/j.kjms.2011.10.005] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
394 Day CP, Saksena S. Non-alcoholic steatohepatitis: definitions and pathogenesis. J Gastroenterol Hepatol. 2002;17 Suppl 3:S377-S384. [PMID: 12472967 DOI: 10.1046/j.1440-1746.17.s3.31.x] [Cited by in Crossref: 103] [Cited by in F6Publishing: 109] [Article Influence: 7.9] [Reference Citation Analysis]
395 Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202-1219. [PMID: 12717402 DOI: 10.1053/jhep.2003.50193] [Cited by in Crossref: 1410] [Cited by in F6Publishing: 1315] [Article Influence: 78.3] [Reference Citation Analysis]
396 Yalamanchili K, Saadeh S, Klintmalm GB, Jennings LW, Davis GL. Nonalcoholic fatty liver disease after liver transplantation for cryptogenic cirrhosis or nonalcoholic fatty liver disease. Liver Transpl. 2010;16:431-439. [PMID: 20373454 DOI: 10.1002/lt.22004] [Cited by in Crossref: 145] [Cited by in F6Publishing: 116] [Article Influence: 13.2] [Reference Citation Analysis]
397 Vernon G, Baranova A, Younossi ZM. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther. 2011;34:274-285. [PMID: 21623852 DOI: 10.1111/j.1365-2036.2011.04724.x] [Cited by in Crossref: 1806] [Cited by in F6Publishing: 1700] [Article Influence: 180.6] [Reference Citation Analysis]
398 Yu Z, Wong VW. Commentary: new tools to assess hepatic steatosis--what do we want to measure? Aliment Pharmacol Ther 2012;36:293; discussion 294. [PMID: 22747453 DOI: 10.1111/j.1365-2036.2012.05168.x] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
399 van Hoek B. Non-alcoholic fatty liver disease: a brief review. Scand J Gastroenterol Suppl. 2004;56-59. [PMID: 15696851 DOI: 10.1080/00855920410011013] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
400 Day CP. Pathogenesis of steatohepatitis. Best Pract Res Clin Gastroenterol. 2002;16:663-678. [PMID: 12406438 DOI: 10.1053/bega.2002.0333] [Cited by in Crossref: 283] [Cited by in F6Publishing: 273] [Article Influence: 15.7] [Reference Citation Analysis]
401 Ong JP, Younossi ZM. Nonalcoholic fatty liver disease (NAFLD)--two decades later: are we smarter about its natural history? Am J Gastroenterol. 2003;98:1915-1917. [PMID: 14499766 DOI: 10.1111/j.1572-0241.2003.07667.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 1.2] [Reference Citation Analysis]
402 Judi L, Toukan A, Khader Y, Ajlouni K, Khatib MA. Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus. Ann Saudi Med 2010;30:25-32. [PMID: 20103955 DOI: 10.4103/0256-4947.59369] [Cited by in F6Publishing: 10] [Reference Citation Analysis]
403 Raman M, Allard J. Non alcoholic fatty liver disease: a clinical approach and review. Can J Gastroenterol 2006;20:345-9. [PMID: 16691301 DOI: 10.1155/2006/918262] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
404 Toriguchi K, Hatano E, Tanabe K, Takemoto K, Nakamura K, Koyama Y, Seo S, Taura K, Uemoto S. Attenuation of steatohepatitis, fibrosis, and carcinogenesis in mice fed a methionine-choline deficient diet by CCAAT/enhancer-binding protein homologous protein deficiency. J Gastroenterol Hepatol. 2014;29:1109-1118. [PMID: 24329600 DOI: 10.1111/jgh.12481] [Cited by in Crossref: 28] [Cited by in F6Publishing: 29] [Article Influence: 4.0] [Reference Citation Analysis]
405 Vassilatou E. Nonalcoholic fatty liver disease and polycystic ovary syndrome. World J Gastroenterol 2014; 20(26): 8351-8363 [PMID: 25024594 DOI: 10.3748/wjg.v20.i26.8351] [Cited by in CrossRef: 65] [Cited by in F6Publishing: 57] [Article Influence: 9.3] [Reference Citation Analysis]
406 Chou YT, Cheng HJ, Wu JS, Yang YC, Chou CY, Chang CJ, Lu FH. The association of sleep duration and sleep quality with non-alcoholic fatty liver disease in a Taiwanese population. Obes Res Clin Pract 2018;12:500-5. [PMID: 29929928 DOI: 10.1016/j.orcp.2018.05.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
407 Thuluvath PJ, Kantsevoy S, Thuluvath AJ, Savva Y. Reply to: “NASH-related and cryptogenic cirrhosis similarities extend beyond cirrhosis”. Journal of Hepatology 2018;69:973-5. [DOI: 10.1016/j.jhep.2018.06.015] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
408 Kim WR, Brown RS Jr, Terrault NA, El-Serag H. Burden of liver disease in the United States: summary of a workshop. Hepatology. 2002;36:227-242. [PMID: 12085369 DOI: 10.1053/jhep.2002.34734] [Cited by in Crossref: 406] [Cited by in F6Publishing: 370] [Article Influence: 21.4] [Reference Citation Analysis]
409 Quaglia A, Roberts EA, Torbenson M. Developmental and Inherited Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 111-274. [DOI: 10.1016/b978-0-7020-6697-9.00003-0] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
410 Omer Z, Cetinkalp S, Akyildiz M, Yilmaz F, Batur Y, Yilmaz C, Akarca U. Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease: . European Journal of Gastroenterology & Hepatology 2010;22:18-23. [DOI: 10.1097/meg.0b013e32832e2baf] [Cited by in Crossref: 75] [Cited by in F6Publishing: 45] [Article Influence: 6.8] [Reference Citation Analysis]
411 Hernandez BY, Zhu X, Kwee S, Chan OT, Tsai N, Okimoto G, Horio D, McGlynn KA, Altekruse S, Wong LL. Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev 2013;22:2016-23. [PMID: 23983238 DOI: 10.1158/1055-9965.EPI-13-0397] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
412 Vespasiani-Gentilucci U, Gallo P, Porcari A, Carotti S, Galati G, Piccioni L, De Vincentis A, Dell'Unto C, Vorini F, Morini S, Riva E, Picardi A. The PNPLA3 rs738409 C > G polymorphism is associated with the risk of progression to cirrhosis in NAFLD patients. Scand J Gastroenterol 2016;51:967-73. [PMID: 27150500 DOI: 10.3109/00365521.2016.1161066] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
413 Montano-Loza AJ, Sultan A, Falanga D, Loss G, Mason AL. Immunogenetic susceptibility to diabetes mellitus in patients with liver disease. Liver Int 2009;29:1543-51. [PMID: 19663932 DOI: 10.1111/j.1478-3231.2009.02095.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
414 Liu K, Mccaughan GW. Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. In: Yu J, editor. Obesity, Fatty Liver and Liver Cancer. Singapore: Springer; 2018. pp. 3-18. [DOI: 10.1007/978-981-10-8684-7_2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
415 Cholankeril G, Wong RJ, Hu M, Perumpail RB, Yoo ER, Puri P, Younossi ZM, Harrison SA, Ahmed A. Liver Transplantation for Nonalcoholic Steatohepatitis in the US: Temporal Trends and Outcomes. Dig Dis Sci. 2017;62:2915-2922. [PMID: 28744836 DOI: 10.1007/s10620-017-4684-x] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 28.3] [Reference Citation Analysis]
416 García-Compeán D, Jáquez-Quintana JO, Lavalle-González FJ, González-González JA, Muñoz-Espinosa LE, Villarreal-Pérez JZ, Maldonado-Garza HJ. Subclinical abnormal glucose tolerance is a predictor of death in liver cirrhosis. World J Gastroenterol 2014; 20(22): 7011-7018 [PMID: 24944496 DOI: 10.3748/wjg.v20.i22.7011] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.9] [Reference Citation Analysis]
417 Rocha R, Cotrim HP, Carvalho FM, Siqueira AC, Braga H, Freitas LA. Body mass index and waist circumference in non-alcoholic fatty liver disease. J Hum Nutr Diet. 2005;18:365-370. [PMID: 16150132 DOI: 10.1111/j.1365-277x.2005.00634.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 27] [Article Influence: 3.4] [Reference Citation Analysis]
418 Kadayifci A, Merriman RB, Bass NM. Medical Treatment of Non-alcoholic Steatohepatitis. Clinics in Liver Disease 2007;11:119-40. [DOI: 10.1016/j.cld.2007.02.001] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 1.9] [Reference Citation Analysis]
419 Maor-kendler Y, Batts KP, Burgart LJ, Wiesner RH, Krom RA, Rosen CB, Charlton MR. COMPARATIVE ALLOGRAFT HISTOLOGY AFTER LIVER TRANSPLANTATION FOR CRYPTOGENIC CIRRHOSIS, ALCOHOL, HEPATITIS C, AND CHOLESTATIC LIVER DISEASES1: . Transplantation 2000;70:292-7. [DOI: 10.1097/00007890-200007270-00009] [Cited by in Crossref: 58] [Cited by in F6Publishing: 49] [Article Influence: 2.8] [Reference Citation Analysis]
420 Rosso C, Mezzabotta L, Gaggini M, Salomone F, Gambino R, Marengo A, Saba F, Vanni E, Jouness RI, Saponaro C. Peripheral insulin resistance predicts liver damage in nondiabetic subjects with nonalcoholic fatty liver disease. Hepatology. 2016;63:107-116. [PMID: 26473614 DOI: 10.1002/hep.28287] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 6.0] [Reference Citation Analysis]
421 Kadayifci A, Tan V, Ursell PC, Merriman RB, Bass NM. Clinical and pathologic risk factors for atherosclerosis in cirrhosis: a comparison between NASH-related cirrhosis and cirrhosis due to other aetiologies. J Hepatol. 2008;49:595-599. [PMID: 18662837 DOI: 10.1016/j.jhep.2008.05.024] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 5.5] [Reference Citation Analysis]
422 Grattagliano I, Di Ciaula A, Baj J, Molina-Molina E, Shanmugam H, Garruti G, Wang DQ, Portincasa P. Protocols for Mitochondria as the Target of Pharmacological Therapy in the Context of Nonalcoholic Fatty Liver Disease (NAFLD). Methods Mol Biol 2021;2310:201-46. [PMID: 34096005 DOI: 10.1007/978-1-0716-1433-4_12] [Reference Citation Analysis]
423 Brun P, Castagliuolo I, Leo VD, Buda A, Pinzani M, Palù G, Martines D. Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis. American Journal of Physiology-Gastrointestinal and Liver Physiology 2007;292:G518-25. [DOI: 10.1152/ajpgi.00024.2006] [Cited by in Crossref: 534] [Cited by in F6Publishing: 531] [Article Influence: 38.1] [Reference Citation Analysis]
424 Della Corte C, Colombo M. Surveillance for hepatocellular carcinoma. Semin Oncol. 2012;39:384-398. [PMID: 22846857 DOI: 10.1053/j.seminoncol.2012.05.002] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
425 Clark JM, Brancati FL, Diehl AM. Nonalcoholic fatty liver disease. Gastroenterology. 2002;122:1649-1657. [PMID: 12016429 DOI: 10.1053/gast.2002.33573] [Cited by in Crossref: 598] [Cited by in F6Publishing: 571] [Article Influence: 31.5] [Reference Citation Analysis]
426 Garcia RFL, Morales E, Garcia CE, Saksena S, Hübscher SG, Elias E. Recurrent and de novo non-alcoholic steatohepatitis following orthotopic liver transplantation. Arq Gastroenterol 2001;38:247-53. [DOI: 10.1590/s0004-28032001000400007] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
427 Yatsuji S, Hashimoto E, Kaneda H, Taniai M, Tokushige K, Shiratori K. Diagnosing autoimmune hepatitis in nonalcoholic fatty liver disease: is the International Autoimmune Hepatitis Group scoring system useful? J Gastroenterol. 2005;40:1130-1138. [PMID: 16378177 DOI: 10.1007/s00535-005-1711-z] [Cited by in Crossref: 49] [Cited by in F6Publishing: 49] [Article Influence: 3.3] [Reference Citation Analysis]
428 Khullar V, Dolganiuc A, Firpi RJ. Pre-and-post transplant considerations in patients with nonalcoholic fatty liver disease. World J Transplant 2014; 4(2): 81-92 [PMID: 25032097 DOI: 10.5500/wjt.v4.i2.81] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
429 Pourshams A, Malekzadeh R, Monavvari A, Akbari MR, Mohamadkhani A, Yarahmadi S, Seddighi N, Mohamadnejad M, Sotoudeh M, Madjlessi A. Prevalence and etiology of persistently elevated alanine aminotransferase levels in healthy Iranian blood donors. J Gastroenterol Hepatol. 2005;20:229-233. [PMID: 15683425 DOI: 10.1111/j.1440-1746.2004.03511.x] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 1.8] [Reference Citation Analysis]
430 Chan R, Wong VW, Chu WC, Wong GL, Li LS, Leung J, Chim AM, Yeung DK, Sea MM, Woo J. Diet-Quality Scores and Prevalence of Nonalcoholic Fatty Liver Disease: A Population Study Using Proton-Magnetic Resonance Spectroscopy. PLoS One. 2015;10:e0139310. [PMID: 26418083 DOI: 10.1371/journal.pone.0139310] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
431 Chitturi S, Farrell GC, George J. Non-alcoholic steatohepatitis in the Asia-Pacific region: future shock? J Gastroenterol Hepatol. 2004;19:368-374. [PMID: 15012772 DOI: 10.1111/j.1440-1746.2003.03252.x] [Cited by in Crossref: 101] [Cited by in F6Publishing: 96] [Article Influence: 5.9] [Reference Citation Analysis]
432 Konerman MA, Loomba R. Editorial: the burden and aetiology of liver cirrhosis, and the risk of death. Aliment Pharmacol Ther 2016;44:202-3. [PMID: 27296684 DOI: 10.1111/apt.13658] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
433 Philip G, Djerboua M, Carlone D, Flemming JA. Validation of a hierarchical algorithm to define chronic liver disease and cirrhosis etiology in administrative healthcare data. PLoS One 2020;15:e0229218. [PMID: 32069337 DOI: 10.1371/journal.pone.0229218] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
434 Mazzolini G, Sowa JP, Atorrasagasti C, Kücükoglu Ö, Syn WK, Canbay A. Significance of Simple Steatosis: An Update on the Clinical and Molecular Evidence. Cells 2020;9:E2458. [PMID: 33187255 DOI: 10.3390/cells9112458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
435 Jang BK. Does obesity increase the risk of hepatocellular carcinoma in chronic hepatitis B patients? Clin Mol Hepatol 2016;22:336-8. [PMID: 27729635 DOI: 10.3350/cmh.2016.0104] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
436 Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: Epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008; 14(27): 4300-4308 [PMID: 18666317 DOI: 10.3748/wjg.14.4300] [Cited by in CrossRef: 408] [Cited by in F6Publishing: 377] [Article Influence: 31.4] [Reference Citation Analysis]
437 Davis GL, Dempster J, Meler JD, Orr DW, Walberg MW, Brown B, Berger BD, O'Connor JK, Goldstein RM. Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent). 2008;21:266-280. [PMID: 18628926 DOI: 10.1080/08998280.2008.11928410] [Cited by in Crossref: 105] [Cited by in F6Publishing: 102] [Article Influence: 10.5] [Reference Citation Analysis]
438 Rinaldi L, Nascimbeni F, Giordano M, Masetti C, Guerrera B, Amelia A, Fascione MC, Ballestri S, Romagnoli D, Zampino R, Nevola R, Baldelli E, Iuliano N, Rosato V, Lonardo A, Adinolfi LE. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis. World J Gastroenterol 2017; 23(8): 1458-1468 [PMID: 28293093 DOI: 10.3748/wjg.v23.i8.1458] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 17] [Article Influence: 6.0] [Reference Citation Analysis]
439 Dufour JF, Oneta CM, Gonvers JJ, Bihl F, Cerny A, Cereda JM, Zala JF, Helbling B, Steuerwald M, Zimmermann A; Swiss Association for the Study of the Liver. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4:1537-1543. [PMID: 17162245 DOI: 10.1016/j.cgh.2006.09.025] [Cited by in Crossref: 234] [Cited by in F6Publishing: 216] [Article Influence: 16.7] [Reference Citation Analysis]
440 Nderitu P, Bosco C, Garmo H, Holmberg L, Malmström H, Hammar N, Walldius G, Jungner I, Ross P, Van Hemelrijck M. The association between individual metabolic syndrome components, primary liver cancer and cirrhosis: A study in the Swedish AMORIS cohort. Int J Cancer 2017;141:1148-60. [PMID: 28577304 DOI: 10.1002/ijc.30818] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 7.3] [Reference Citation Analysis]
441 Abdel-Razik A, Eldars W, Elhelaly R, Elzehery R. C-reactive protein and insulin-like growth factor-1 in differential diagnosis of ascites. J Gastroenterol Hepatol. 2016;31:1868-1873. [PMID: 27010362 DOI: 10.1111/jgh.13386] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
442 Janovsky CCPS, Cesena FH, Valente VAT, Conceição RDO, Santos RD, Bittencourt MS. Association between Thyroid-Stimulating Hormone Levels and Non-Alcoholic Fatty Liver Disease Is Not Independent from Metabolic Syndrome Criteria. Eur Thyroid J 2018;7:302-7. [PMID: 30574460 DOI: 10.1159/000492324] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
443 Lirussi F, Azzalini L, Orando S, Orlando R, Angelico F. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst Rev 2007;:CD004996. [PMID: 17253535 DOI: 10.1002/14651858.CD004996.pub3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 30] [Article Influence: 1.4] [Reference Citation Analysis]
444 Veena J, Muragundla A, Sidgiddi S, Subramaniam S. Non-alcoholic fatty liver disease: need for a balanced nutritional source. Br J Nutr. 2014;112:1858-1872. [PMID: 25274101 DOI: 10.1017/s0007114514002591] [Cited by in Crossref: 21] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
445 Tardu A, Karagul S, Yagci MA, Ertugrul I, Sumer F, Kirmizi S, Yaylak F, Koc C, Hatipoglu S, Kayaalp C, Yilmaz S. Histopathological Examination of Explanted Liver After Transplantation in Patients With Cryptogenic Cirrhosis. Transplant Proc 2015;47:1450-2. [PMID: 26093740 DOI: 10.1016/j.transproceed.2015.04.020] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
446 Bruguera M. [Liver diseases in the elderly]. Gastroenterol Hepatol. 2014;37:535-543. [PMID: 24951302 DOI: 10.1016/j.gastrohep.2014.04.005] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
447 Lonardo A, Loria P. Of liver, whisky and plants: a requiem for colchicine in alcoholic cirrhosis? Eur J Gastroenterol Hepatol 2002;14:355-8. [PMID: 11943945 DOI: 10.1097/00042737-200204000-00003] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
448 Leite AB, Mattos AA, Mattos AZ, Coral GP, Evaldt S. Risk factors for nonalcoholic steatohepatitis in cryptogenic cirrhosis. Arq Gastroenterol 2012;49:245-9. [PMID: 23329217 DOI: 10.1590/s0004-28032012000400003] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
449 Della Corte C, Triolo M, Iavarone M, Sangiovanni A. Early diagnosis of liver cancer: an appraisal of international recommendations and future perspectives. Liver Int 2016;36:166-76. [PMID: 26386254 DOI: 10.1111/liv.12965] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
450 Kallwitz ER, McLachlan A, Cotler SJ. Role of peroxisome proliferators-activated receptors in the pathogenesis and treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2008; 14(1): 22-28 [PMID: 18176957 DOI: 10.3748/wjg.14.22] [Cited by in CrossRef: 101] [Cited by in F6Publishing: 99] [Article Influence: 7.8] [Reference Citation Analysis]
451 Milić S, Lulić D, Štimac D. Non-alcoholic fatty liver disease and obesity: Biochemical, metabolic and clinical presentations. World J Gastroenterol 2014; 20(28): 9330-9337 [PMID: 25071327 DOI: 10.3748/wjg.v20.i28.9330] [Cited by in F6Publishing: 123] [Reference Citation Analysis]
452 Ganesh S, Rustgi VK. Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clin Liver Dis 2016;20:351-64. [PMID: 27063274 DOI: 10.1016/j.cld.2015.10.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
453 Perez NE, Siddiqui FA, Mutchnick MG, Dhar R, Tobi M, Ullah N, Saksouk FA, Wheeler DE, Ehrinpreis MN. Ultrasound diagnosis of fatty liver in patients with chronic liver disease: a retrospective observational study. J Clin Gastroenterol. 2007;41:624-629. [PMID: 17577120 DOI: 10.1097/01.mcg.0000225680.45088.01] [Cited by in Crossref: 34] [Cited by in F6Publishing: 33] [Article Influence: 2.4] [Reference Citation Analysis]
454 Than NN, Ghazanfar A, Hodson J, Tehami N, Coldham C, Mergental H, Manas D, Shah T, Newsome PN, Reeves H, Shetty S. Comparing clinical presentations, treatments and outcomes of hepatocellular carcinoma due to hepatitis C and non-alcoholic fatty liver disease. QJM 2017;110:73-81. [PMID: 27634970 DOI: 10.1093/qjmed/hcw151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
455 Manna P, Sil PC. Arjunolic acid: beneficial role in type 1 diabetes and its associated organ pathophysiology. Free Radic Res 2012;46:815-30. [PMID: 22486656 DOI: 10.3109/10715762.2012.683431] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
456 Caldwell S, Marchesini G. Cryptogenic vs. NASH-cirrhosis: The rose exists well before its name.... Journal of Hepatology 2018;68:391-2. [DOI: 10.1016/j.jhep.2017.12.006] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
457 Miquilena Colina ME, García Monzón C. [Obesity and liver disease]. Gastroenterol Hepatol 2010;33:591-604. [PMID: 20206411 DOI: 10.1016/j.gastrohep.2009.12.009] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
458 Parekh S, Anania FA. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease. Gastroenterology. 2007;132:2191-2207. [PMID: 17498512 DOI: 10.1053/j.gastro.2007.03.055] [Cited by in Crossref: 217] [Cited by in F6Publishing: 208] [Article Influence: 15.5] [Reference Citation Analysis]
459 Ong JP, Younossi ZM. Epidemiology and Natural History of NAFLD and NASH. Clinics in Liver Disease 2007;11:1-16. [DOI: 10.1016/j.cld.2007.02.009] [Cited by in Crossref: 292] [Cited by in F6Publishing: 273] [Article Influence: 20.9] [Reference Citation Analysis]
460 Chagas AL, Kikuchi LO, Oliveira CP, Vezozzo DC, Mello ES, Oliveira AC, Cella LC, Herman P, Bachella T, Caldwell SH, Alves VA, Carrilho FJ. Does hepatocellular carcinoma in non-alcoholic steatohepatitis exist in cirrhotic and non-cirrhotic patients? Braz J Med Biol Res 2009;42:958-62. [PMID: 19787150 DOI: 10.1590/s0100-879x2009005000019] [Cited by in Crossref: 40] [Cited by in F6Publishing: 26] [Article Influence: 3.3] [Reference Citation Analysis]
461 Motola-kuba D, Zamora-valdés D, Uribe M, Méndez-sánchez N. Hepatocellular carcinoma. An overview. Annals of Hepatology 2006;5:16-24. [DOI: 10.1016/s1665-2681(19)32034-4] [Cited by in Crossref: 88] [Article Influence: 5.9] [Reference Citation Analysis]
462 Poordad F, Gish R, Wakil A, Garcia-Kennedy R, Martin P, Yao FY. De novo non-alcoholic fatty liver disease following orthotopic liver transplantation. Am J Transplant. 2003;3:1413-1417. [PMID: 14525603 DOI: 10.1046/j.1600-6143.2003.00203.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 1.4] [Reference Citation Analysis]
463 Lonardo A. Renaming NAFLD to MAFLD: Could the LDE System Assist in This Transition? J Clin Med 2021;10:492. [PMID: 33572544 DOI: 10.3390/jcm10030492] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
464 Gomez-dominguez E, Gisbert JP, Moreno-monteagudo JA, Garcia-buey L, Moreno-otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther 2006;23:1643-7. [DOI: 10.1111/j.1365-2036.2006.02926.x] [Cited by in Crossref: 138] [Cited by in F6Publishing: 128] [Article Influence: 9.2] [Reference Citation Analysis]
465 Brown AJ, Tendler DA, McMurray RG, Setji TL. Polycystic ovary syndrome and severe nonalcoholic steatohepatitis: beneficial effect of modest weight loss and exercise on liver biopsy findings. Endocr Pract. 2005;11:319-324. [PMID: 16191492 DOI: 10.4158/ep.11.5.319] [Cited by in Crossref: 31] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
466 Tellez-Avila FI, Sanchez-Avila F, García-Saenz-de-Sicilia M, Chavez-Tapia NC, Franco-Guzman AM, Lopez-Arce G, Cerda-Contreras E, Uribe M. Prevalence of metabolic syndrome, obesity and diabetes type 2 in cryptogenic cirrhosis. World J Gastroenterol 2008; 14(30): 4771-4775 [PMID: 18720537 DOI: 10.3748/wjg.14.4771] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 40] [Article Influence: 3.9] [Reference Citation Analysis]
467 Anagnostopoulos GK, Arvanitidis D, Tsiakos S, Margantinis G, Grigoriadis K, Kostopoulos P. Is Hepatocellular Carcinoma Part of the Natural History of Nonalcoholic Steatohepatitis?: . Journal of Clinical Gastroenterology 2003;37:88-9. [DOI: 10.1097/00004836-200307000-00025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
468 Hui J. Long-Term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C. Hepatology 2003;38:420-7. [DOI: 10.1053/jhep.2003.50320] [Cited by in Crossref: 301] [Cited by in F6Publishing: 267] [Article Influence: 16.7] [Reference Citation Analysis]
469 van Greevenbroek MM, Vermeulen VMM, de Bruin TW. Identification of novel molecular candidates for fatty liver in the hyperlipidemic mouse model, HcB19. Journal of Lipid Research 2004;45:1148-54. [DOI: 10.1194/jlr.m400062-jlr200] [Cited by in Crossref: 22] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
470 Guebre-Xabier M, Yang S, Lin HZ, Schwenk R, Krzych U, Diehl AM. Altered hepatic lymphocyte subpopulations in obesity-related murine fatty livers: potential mechanism for sensitization to liver damage. Hepatology. 2000;31:633-640. [PMID: 10706553 DOI: 10.1002/hep.510310313] [Cited by in Crossref: 134] [Cited by in F6Publishing: 139] [Article Influence: 6.4] [Reference Citation Analysis]
471 Younossi Z, Stepanova M, Sanyal AJ, Harrison SA, Ratziu V, Abdelmalek MF, Diehl AM, Caldwell S, Shiffman ML, Schall RA, McColgan B, Subramanian GM, Myers RP, Muir A, Afdhal NH, Bosch J, Goodman Z. The conundrum of cryptogenic cirrhosis: Adverse outcomes without treatment options. J Hepatol 2018;69:1365-70. [PMID: 30144554 DOI: 10.1016/j.jhep.2018.08.013] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 8.7] [Reference Citation Analysis]
472 Wong RJ, Ahmed A. Obesity and non-alcoholic fatty liver disease: Disparate associations among Asian populations. World J Hepatol 2014; 6(5): 263-273 [PMID: 24868320 DOI: 10.4254/wjh.v6.i5.263] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 11.0] [Reference Citation Analysis]
473 Di Ciaula A, Baj J, Garruti G, Celano G, De Angelis M, Wang HH, Di Palo DM, Bonfrate L, Wang DQ, Portincasa P. Liver Steatosis, Gut-Liver Axis, Microbiome and Environmental Factors. A Never-Ending Bidirectional Cross-Talk. J Clin Med 2020;9:E2648. [PMID: 32823983 DOI: 10.3390/jcm9082648] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 17.0] [Reference Citation Analysis]
474 Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol. 2003;18:124-138. [PMID: 12542595 DOI: 10.1046/j.1440-1746.2003.02989.x] [Cited by in Crossref: 159] [Cited by in F6Publishing: 146] [Article Influence: 8.8] [Reference Citation Analysis]
475 Patil DT, Yerian LM. Evolution of nonalcoholic fatty liver disease recurrence after liver transplantation. Liver Transpl. 2012;18:1147-1153. [PMID: 22740341 DOI: 10.1002/lt.23499] [Cited by in Crossref: 47] [Cited by in F6Publishing: 39] [Article Influence: 5.9] [Reference Citation Analysis]
476 Stine JG, Wentworth BJ, Zimmet A, Rinella ME, Loomba R, Caldwell SH, Argo CK. Systematic review with meta-analysis: risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Aliment Pharmacol Ther 2018;48:696-703. [PMID: 30136293 DOI: 10.1111/apt.14937] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 23.7] [Reference Citation Analysis]
477 Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ben Ari Z. Metabolic syndrome in liver transplant recipients: prevalence, risk factors, and association with cardiovascular events. Liver Transpl. 2011;17:15-22. [PMID: 21254340 DOI: 10.1002/lt.22198] [Cited by in Crossref: 153] [Cited by in F6Publishing: 135] [Article Influence: 15.3] [Reference Citation Analysis]
478 Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ;  Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313-1321. [PMID: 15915461 DOI: 10.1002/hep.20701] [Cited by in Crossref: 5693] [Cited by in F6Publishing: 5496] [Article Influence: 355.8] [Reference Citation Analysis]
479 Serfaty L, Lemoine M. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis. Diabetes Metab. 2008;34:634-637. [PMID: 19195623 DOI: 10.1016/s1262-3636(08)74597-x] [Cited by in Crossref: 83] [Cited by in F6Publishing: 39] [Article Influence: 6.9] [Reference Citation Analysis]
480 Diehl AM. Hepatic complications of obesity. Gastroenterol Clin North Am. 2010;39:57-68. [PMID: 20202579 DOI: 10.1016/j.gtc.2004.12.012] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
481 Maurantonio M, Ballestri S, Odoardi MR, Lonardo A, Loria P. Treatment of atherogenic liver based on the pathogenesis of nonalcoholic fatty liver disease: a novel approach to reduce cardiovascular risk? Arch Med Res. 2011;42:337-353. [PMID: 21843565 DOI: 10.1016/j.arcmed.2011.08.004] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 2.5] [Reference Citation Analysis]
482 Anstee QM, Goldin RD. Mouse models in non-alcoholic fatty liver disease and steatohepatitis research. Int J Exp Pathol. 2006;87:1-16. [PMID: 16436109 DOI: 10.1111/j.0959-9673.2006.00465.x] [Cited by in Crossref: 487] [Cited by in F6Publishing: 483] [Article Influence: 32.5] [Reference Citation Analysis]
483 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. J Gastroenterol 2015;50:364-77. [DOI: 10.1007/s00535-015-1050-7] [Cited by in Crossref: 122] [Cited by in F6Publishing: 62] [Article Influence: 20.3] [Reference Citation Analysis]
484 Mitsuyoshi H, Yasui K, Harano Y, Endo M, Tsuji K, Minami M, Itoh Y, Okanoue T, Yoshikawa T. Analysis of hepatic genes involved in the metabolism of fatty acids and iron in nonalcoholic fatty liver disease. Hepatol Res. 2009;39:366-373. [PMID: 19054139 DOI: 10.1111/j.1872-034X.2008.00464.x] [Cited by in Crossref: 97] [Cited by in F6Publishing: 47] [Article Influence: 7.5] [Reference Citation Analysis]
485 Benedict M, Zhang X. Non-alcoholic fatty liver disease: An expanded review. World J Hepatol 2017; 9(16): 715-732 [PMID: 28652891 DOI: 10.4254/wjh.v9.i16.715] [Cited by in Crossref: 304] [Cited by in F6Publishing: 267] [Article Influence: 76.0] [Reference Citation Analysis]
486 Gill RM, Kakar S. Nonalcoholic Steatohepatitis. Surgical Pathology Clinics 2013;6:227-57. [DOI: 10.1016/j.path.2013.03.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
487 Xu P, Zhang Y, Wang W, Yuan Q, Liu Z, Rasoul LM, Wu Q, Liu M, Ye X, Li D, Ren G. Long-Term Administration of Fibroblast Growth Factor 21 Prevents Chemically-Induced Hepatocarcinogenesis in Mice. Dig Dis Sci 2015;60:3032-43. [PMID: 26003555 DOI: 10.1007/s10620-015-3711-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
488 Contos MJ, Sanyal AJ. The clinicopathologic spectrum and management of nonalcoholic fatty liver disease. Adv Anat Pathol. 2002;9:37-51. [PMID: 11756758 DOI: 10.1097/00125480-200201000-00005] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 2.4] [Reference Citation Analysis]
489 Tiniakos DG, Anstee QM, Burt AD. Fatty Liver Disease. Macsween's Pathology of the Liver. Elsevier; 2018. pp. 308-71. [DOI: 10.1016/b978-0-7020-6697-9.00005-4] [Cited by in Crossref: 7] [Article Influence: 2.3] [Reference Citation Analysis]
490 Wang SN, Wang ST, Lee KT. The potential interplay of adipokines with toll-like receptors in the development of hepatocellular carcinoma. Gastroenterol Res Pract 2011;2011:215986. [PMID: 21960997 DOI: 10.1155/2011/215986] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
491 El-Serag HB. Hepatocellular carcinoma and hepatitis C in the United States. Hepatology. 2002;36:S74-S83. [PMID: 12407579 DOI: 10.1053/jhep.2002.36807] [Cited by in Crossref: 34] [Cited by in F6Publishing: 135] [Article Influence: 1.8] [Reference Citation Analysis]
492 Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J 2020;50:1038-47. [PMID: 31760676 DOI: 10.1111/imj.14709] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 27.0] [Reference Citation Analysis]
493 Di Ciaula A, Passarella S, Shanmugam H, Noviello M, Bonfrate L, Wang DQ, Portincasa P. Nonalcoholic Fatty Liver Disease (NAFLD). Mitochondria as Players and Targets of Therapies? Int J Mol Sci 2021;22:5375. [PMID: 34065331 DOI: 10.3390/ijms22105375] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
494 Calzadilla Bertot L, Adams LA. The Natural Course of Non-Alcoholic Fatty Liver Disease. Int J Mol Sci. 2016;17. [PMID: 27213358 DOI: 10.3390/ijms17050774] [Cited by in Crossref: 248] [Cited by in F6Publishing: 244] [Article Influence: 49.6] [Reference Citation Analysis]
495 Bernal-Reyes R, Castro-Narro G, Malé-Velázquez R, Carmona-Sánchez R, González-Huezo MS, García-Juárez I, Chávez-Tapia N, Aguilar-Salinas C, Aiza-Haddad I, Ballesteros-Amozurrutia MA, Bosques-Padilla F, Castillo-Barradas M, Chávez-Barrera JA, Cisneros-Garza L, Flores-Calderón J, García-Compeán D, Gutiérrez-Grobe Y, Higuera de la Tijera MF, Kershenobich-Stalnikowitz D, Ladrón de Guevara-Cetina L, Lizardi-Cervera J, López-Cossio JA, Martínez-Vázquez S, Márquez-Guillén E, Méndez-Sánchez N, Moreno-Alcantar R, Poo-Ramírez JL, Ramos-Martínez P, Rodríguez-Hernández H, Sánchez-Ávila JF, Stoopen-Rometti M, Torre-Delgadillo A, Torres-Villalobos G, Trejo-Estrada R, Uribe-Esquivel M, Velarde-Ruiz Velasco JA. The Mexican consensus on nonalcoholic fatty liver disease.Rev Gastroenterol Mex (Engl Ed). 2019;84:69-99. [PMID: 30711302 DOI: 10.1016/j.rgmx.2018.11.007] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
496 Yoo HY, Thuluvath PJ. The effect of insulin-dependent diabetes mellitus on outcome of liver transplantation. Transplantation. 2002;74:1007-1012. [PMID: 12394846 DOI: 10.1097/00007890-200210150-00019] [Cited by in Crossref: 94] [Cited by in F6Publishing: 78] [Article Influence: 4.9] [Reference Citation Analysis]
497 Younossi ZM. Interactions between non-alcoholic fatty liver disease and hepatitis C viral infection. J Gastroenterol Hepatol 2004;19:S253-7. [DOI: 10.1111/j.1440-1746.2004.03682.x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
498 Clark JM, Alkhuraishi AR, Solga SF, Alli P, Diehl AM, Magnuson TH. Roux-en-Y gastric bypass improves liver histology in patients with non-alcoholic fatty liver disease. Obes Res. 2005;13:1180-1186. [PMID: 16076987 DOI: 10.1038/oby.2005.140] [Cited by in Crossref: 131] [Cited by in F6Publishing: 118] [Article Influence: 8.7] [Reference Citation Analysis]
499 Castelló B, Aguilera V, Blázquez MT, Rubín Á, García M, Vinaixa C, Benlloch S, Sanjuan F, Montalva E, López R, Berenguer M. Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis. Annals of Hepatology 2019;18:855-61. [DOI: 10.1016/j.aohep.2019.06.014] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
500 James O, Day C. Non-alcoholic steatohepatitis: another disease of affluence. Lancet. 1999;353:1634-1636. [PMID: 10335777 DOI: 10.1016/s0140-6736(99)00163-4] [Cited by in Crossref: 186] [Cited by in F6Publishing: 46] [Article Influence: 8.5] [Reference Citation Analysis]
501 Tannapfel A, Denk H, Dienes HP, Langner C, Schirmacher P, Trauner M, Flott-Rahmel B. [Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. Grade 2 consensus-based guidelines]. Pathologe. 2010;31:225-237. [PMID: 20221762 DOI: 10.1007/s00292-010-1298-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 0.1] [Reference Citation Analysis]
502 El-Zayadi AR. Hepatitis C comorbidities affecting the course and response to therapy. World J Gastroenterol 2009; 15(40): 4993-4999 [PMID: 19859990 DOI: 10.3748/wjg.15.4993] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 25] [Article Influence: 2.0] [Reference Citation Analysis]
503 Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-tainturier M, Giral P, Grimaldi A, Opolon P, Poynard T. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis: Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93. [DOI: 10.1053/jhep.2002.33324] [Cited by in Crossref: 329] [Cited by in F6Publishing: 302] [Article Influence: 18.3] [Reference Citation Analysis]
504 Younossi ZM, Baranova A, Ziegler K, Del Giacco L, Schlauch K, Born TL, Elariny H, Gorreta F, VanMeter A, Younoszai A. A genomic and proteomic study of the spectrum of nonalcoholic fatty liver disease. Hepatology. 2005;42:665-674. [PMID: 16116632 DOI: 10.1002/hep.20838] [Cited by in Crossref: 147] [Cited by in F6Publishing: 134] [Article Influence: 9.2] [Reference Citation Analysis]
505 Li X, Jiao Y, Xing Y, Gao P. Diabetes Mellitus and Risk of Hepatic Fibrosis/Cirrhosis. Biomed Res Int. 2019;2019:5308308. [PMID: 31080822 DOI: 10.1155/2019/5308308] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 2.5] [Reference Citation Analysis]
506 Chitturi S, Le V, Kench J, Loh C, George J. Gliclazide-induced acute hepatitis with hypersensitivity features. Dig Dis Sci 2002;47:1107-10. [PMID: 12018908 DOI: 10.1023/a:1015002526879] [Cited by in Crossref: 18] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
507 Youssef WI, McCullough AJ. Steatohepatitis in obese individuals. Best Pract Res Clin Gastroenterol. 2002;16:733-747. [PMID: 12406442 DOI: 10.1053/bega.2002.0334] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 2.8] [Reference Citation Analysis]
508 Wang SN, Lee KT, Ker CG. Leptin in hepatocellular carcinoma. World J Gastroenterol 2010; 16(46): 5801-5809 [PMID: 21155000 DOI: 10.3748/wjg.v16.i46.5801] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 35] [Article Influence: 3.6] [Reference Citation Analysis]
509 Peng L, Wang J, Li F. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database Syst Rev. 2011;6:CD003619. [PMID: 21678341 DOI: 10.1002/14651858.cd003619.pub3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
510 Ayata G, Gordon FD, Lewis WD, Pomfret E, Pomposelli JJ, Jenkins RL, Khettry U. Cryptogenic cirrhosis: clinicopathologic findings at and after liver transplantation. Hum Pathol. 2002;33:1098-1104. [PMID: 12454814 DOI: 10.1053/hupa.2002.129419] [Cited by in Crossref: 116] [Cited by in F6Publishing: 90] [Article Influence: 6.1] [Reference Citation Analysis]
511 Guidorizzi de Siqueira AC, Cotrim HP, Rocha R, Carvalho FM, de Freitas LA, Barreto D, Gouveia L, Landeiro L. Non-alcoholic fatty liver disease and insulin resistance: importance of risk factors and histological spectrum. Eur J Gastroenterol Hepatol. 2005;17:837-841. [PMID: 16003133 DOI: 10.1097/00042737-200508000-00010] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 1.8] [Reference Citation Analysis]
512 Rinella ME, Green RM. The methionine-choline deficient dietary model of steatohepatitis does not exhibit insulin resistance. J Hepatol. 2004;40:47-51. [PMID: 14672613 DOI: 10.1016/j.jhep.2003.09.020] [Cited by in Crossref: 288] [Cited by in F6Publishing: 276] [Article Influence: 16.9] [Reference Citation Analysis]
513 Hsiao TJ, Chen JC, Wang JD. Insulin resistance and ferritin as major determinants of nonalcoholic fatty liver disease in apparently healthy obese patients. Int J Obes Relat Metab Disord. 2004;28:167-172. [PMID: 14610526 DOI: 10.1038/sj.ijo.0802519] [Cited by in Crossref: 72] [Cited by in F6Publishing: 63] [Article Influence: 4.2] [Reference Citation Analysis]
514 Scheen AJ, Luyckx FH. Obesity and liver disease. Best Pract Res Clin Endocrinol Metab. 2002;16:703-716. [PMID: 12468416 DOI: 10.1053/beem.2002.0225] [Cited by in Crossref: 82] [Cited by in F6Publishing: 81] [Article Influence: 4.6] [Reference Citation Analysis]
515 McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis 2011;15:223-43, vii-x. [PMID: 21689610 DOI: 10.1016/j.cld.2011.03.006] [Cited by in Crossref: 286] [Cited by in F6Publishing: 288] [Article Influence: 28.6] [Reference Citation Analysis]
516 Hussain HK, Chenevert TL, Londy FJ, Gulani V, Swanson SD, McKenna BJ, Appelman HD, Adusumilli S, Greenson JK, Conjeevaram HS. Hepatic fat fraction: MR imaging for quantitative measurement and display--early experience. Radiology. 2005;237:1048-1055. [PMID: 16237138 DOI: 10.1148/radiol.2373041639] [Cited by in Crossref: 221] [Cited by in F6Publishing: 197] [Article Influence: 13.8] [Reference Citation Analysis]
517 Cieślak B, Lewandowski Z, Urban M, Ziarkiewicz-Wróblewska B, Krawczyk M. Microvesicular liver graft steatosis as a risk factor of initial poor function in relation to suboptimal donor parameters. Transplant Proc 2009;41:2985-8. [PMID: 19857657 DOI: 10.1016/j.transproceed.2009.08.019] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.5] [Reference Citation Analysis]
518 Ramrakhiani S, Bacon BR. Hepatology in the new millennium. Advances in viral hepatitis, hepatic disorders, and liver transplantation. Med Clin North Am. 2000;84:1085-1105. [PMID: 11026919 DOI: 10.1016/S0025-7125(05)70277-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
519 Golabi P, Bush H, Stepanova M, Locklear CT, Jacobson IM, Mishra A, Trimble G, Erario M, Venkatesan C, Younossi I, Goodman Z, Younossi ZM. Liver Transplantation (LT) for Cryptogenic Cirrhosis (CC) and Nonalcoholic Steatohepatitis (NASH) Cirrhosis: Data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016. Medicine (Baltimore). 2018;97:e11518. [PMID: 30075518 DOI: 10.1097/md.0000000000011518] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 8.3] [Reference Citation Analysis]
520 Saeed N, Glass L, Sharma P, Shannon C, Sonnenday CJ, Tincopa MA. Incidence and Risks for Nonalcoholic Fatty Liver Disease and Steatohepatitis Post-liver Transplant: Systematic Review and Meta-analysis. Transplantation. 2019;103:e345-e354. [PMID: 31415032 DOI: 10.1097/tp.0000000000002916] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 19.0] [Reference Citation Analysis]
521 Mohammed OK, Mahadeva S. Clinical outcomes of cryptogenic compared with non-cryptogenic cirrhosis: A retrospective cohort study. J Gastroenterol Hepatol. 2015;30:1423-1428. [PMID: 25867030 DOI: 10.1111/jgh.12978] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
522 Morita Y, Ueno T, Sasaki N, Kuhara K, Yoshioka S, Tateishi Y, Nagata E, Kage M, Sata M. Comparison of Liver Histology Between Patients with Non-Alcoholic Steatohepatitis and Patients with Alcoholic Steatohepatitis in Japan. Alcoholism: Clinical and Experimental Research 2005;29:277S-81S. [DOI: 10.1097/01.alc.0000191777.36629.33] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
523 Evelson P, Llesuy S, Filinger E, Rodriguez RR, Lemberg A, Scorticati C, Susemihl M, Villareal I, Polo JM, Peredo H. Decreased oxidative stress in prehepatic portal hypertensive rat livers following the induction of diabetes. Clin Exp Pharmacol Physiol. 2004;31:169-173. [PMID: 15008960 DOI: 10.1111/j.1440-1681.2004.03963.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
524 Abe H, Yoshizawa K, Kitahara T, Aizawa R, Matsuoka M, Aizawa Y. Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo. J Gastroenterol. 2008;43:967-974. [PMID: 19107341 DOI: 10.1007/s00535-008-2264-8] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 3.4] [Reference Citation Analysis]
525 Cortez-Pinto H, Jesus L, Barros H, Lopes C, Moura MC, Camilo ME. How different is the dietary pattern in non-alcoholic steatohepatitis patients? Clin Nutr. 2006;25:816-823. [PMID: 16677739 DOI: 10.1016/j.clnu.2006.01.027] [Cited by in Crossref: 162] [Cited by in F6Publishing: 155] [Article Influence: 10.8] [Reference Citation Analysis]
526 Wlazlo N, Beijers HJBH, Schoon EJ, Sauerwein HP, Stehouwer CDA, Bravenboer B. High prevalence of diabetes mellitus in patients with liver cirrhosis: Diabetes in liver cirrhosis. Diabetic Medicine 2010;27:1308-11. [DOI: 10.1111/j.1464-5491.2010.03093.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 2.5] [Reference Citation Analysis]
527 Siebler J, Galle PR. Treatment of nonalcoholic fatty liver disease. World J Gastroenterol 2006; 12(14): 2161-2167 [PMID: 16610015 DOI: 10.3748/wjg.v12.i14.2161] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.1] [Reference Citation Analysis]
528 Tada T, Kumada T, Toyoda H, Mizuno K, Sone Y, Akita T, Tanaka J. Progression of liver fibrosis is associated with non-liver-related mortality in patients with nonalcoholic fatty liver disease. Hepatol Commun. 2017;1:899-910. [PMID: 29404500 DOI: 10.1002/hep4.1105] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
529 O'Leary JG, Landaverde C, Jennings L, Goldstein RM, Davis GL. Patients with NASH and cryptogenic cirrhosis are less likely than those with hepatitis C to receive liver transplants. Clin Gastroenterol Hepatol 2011;9:700-704.e1. [PMID: 21570483 DOI: 10.1016/j.cgh.2011.04.007] [Cited by in Crossref: 68] [Cited by in F6Publishing: 60] [Article Influence: 6.8] [Reference Citation Analysis]
530 Delic D, Mitrovic N, Radovanovic-spurnic A, Stojkovic-svirtlih N, Simonovic-babic J. Epidemiological characteristics and clinical manifestations of acute non-A-E hepatitis. VSP 2010;67:903-9. [DOI: 10.2298/vsp1011903d] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
531 Zamora-valdés D, Ponciano-rodríguez G, Chávez-tapia NC, Méndez-sánchez N. The endocannabinoid system in chronic liver disease. Annals of Hepatology 2005;4:248-54. [DOI: 10.1016/s1665-2681(19)32047-2] [Cited by in Crossref: 10] [Article Influence: 0.6] [Reference Citation Analysis]
532 Salvi P, Ruffini R, Agnoletti D, Magnani E, Pagliarani G, Comandini G, Praticò A, Borghi C, Benetos A, Pazzi P. Increased arterial stiffness in nonalcoholic fatty liver disease: the Cardio-GOOSE study. J Hypertens. 2010;28:1699-1707. [PMID: 20467324 DOI: 10.1097/hjh.0b013e32833a7de6] [Cited by in Crossref: 75] [Cited by in F6Publishing: 27] [Article Influence: 6.8] [Reference Citation Analysis]
533 Wang K, Tang Z, Wang J, Cao P, Li Q, Shui W, Wang H, Zheng Z, Zhang Y. RETRACTED: Polysaccharide from Angelica sinensis ameliorates high-fat diet and STZ-induced hepatic oxidative stress and inflammation in diabetic mice by activating the Sirt1–AMPK pathway. The Journal of Nutritional Biochemistry 2017;43:88-97. [DOI: 10.1016/j.jnutbio.2017.02.001] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 3.3] [Reference Citation Analysis]
534 Finotti M, Romano M, Auricchio P, Scopelliti M, Brizzolari M, Grossi U, Piccino M, Benvenuti S, Morana G, Cillo U, Zanus G. Target Therapies for NASH/NAFLD: From the Molecular Aspect to the Pharmacological and Surgical Alternatives. J Pers Med 2021;11:499. [PMID: 34199535 DOI: 10.3390/jpm11060499] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
535 Koteish A, Diehl AM. Obesity and liver disease. Curr Treat Options Gastro 2001;4:101-5. [DOI: 10.1007/s11938-001-0020-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
536 Kurita S, Takamura T, Ota T, Matsuzawa-nagata N, Kita Y, Uno M, Nabemoto S, Ishikura K, Misu H, Ando H, Zen Y, Nakanuma Y, Kaneko S. Olmesartan ameliorates a dietary rat model of non-alcoholic steatohepatitis through its pleiotropic effects. European Journal of Pharmacology 2008;588:316-24. [DOI: 10.1016/j.ejphar.2008.04.028] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.1] [Reference Citation Analysis]
537 Nagaya T, Tanaka N, Suzuki T, Sano K, Horiuchi A, Komatsu M, Nakajima T, Nishizawa T, Joshita S, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Nakayama J, Tanaka E, Aoyama T. Down-regulation of SREBP-1c is associated with the development of burned-out NASH. J Hepatol. 2010;53:724-731. [PMID: 20655124 DOI: 10.1016/j.jhep.2010.04.033] [Cited by in Crossref: 70] [Cited by in F6Publishing: 71] [Article Influence: 6.4] [Reference Citation Analysis]
538 Ghoghaei M, Taghdiri F, Khajeh E, Azmoudeh Ardalan F, Sedaghat M, Hosseini Shirvani S, Zarei S, Toolabi K. Parathyroid Hormone Levels May Predict Nonalcoholic Steatohepatitis in Morbidly Obese Patients. Hepat Mon 2015;15:e29697. [PMID: 26300934 DOI: 10.5812/hepatmon.29697v2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
539 Ratziu V, Munteanu M, Charlotte F, Bonyhay L, Poynard T; LIDO Study Group. Fibrogenic impact of high serum glucose in chronic hepatitis C. J Hepatol. 2003;39:1049-1055. [PMID: 14642625 DOI: 10.1016/s0168-8278(03)00456-2] [Cited by in Crossref: 116] [Cited by in F6Publishing: 39] [Article Influence: 6.8] [Reference Citation Analysis]
540 Le D, Marks D, Lyle E, Corless CL, Diggs BS, Jobe BA, Kay T, Deveney CW, Wolfe BM, Roberts CT. Serum leptin levels, hepatic leptin receptor transcription, and clinical predictors of non-alcoholic steatohepatitis in obese bariatric surgery patients. Surg Endosc. 2007;21:1593-1599. [PMID: 17294310 DOI: 10.1007/s00464-006-9185-5] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
541 Salgado Júnior W, Santos JSD, Sankarankutty AK, Castro e Silva OD. Nonalcoholic fatty liver disease and obesity. Acta Cir Bras 2006;21:72-8. [DOI: 10.1590/s0102-86502006000700017] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
542 Alam S, Fahim SM. Transition of an acronym from nonalcoholic fatty liver disease to metabolic dysfunction-associated fatty liver disease. World J Hepatol 2021; 13(10): 1203-1207 [DOI: 10.4254/wjh.v13.i10.1203] [Reference Citation Analysis]
543 Poonawala A, Nair SP, Thuluvath PJ. Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study. Hepatology. 2000;32:689-692. [PMID: 11003611 DOI: 10.1053/jhep.2000.17894] [Cited by in Crossref: 358] [Cited by in F6Publishing: 309] [Article Influence: 17.0] [Reference Citation Analysis]
544 Schwimmer JB, Deutsch R, Rauch JB, Behling C, Newbury R, Lavine JE. Obesity, insulin resistance, and other clinicopathological correlates of pediatric nonalcoholic fatty liver disease. J Pediatr. 2003;143:500-505. [PMID: 14571229 DOI: 10.1067/s0022-3476(03)00325-1] [Cited by in Crossref: 327] [Cited by in F6Publishing: 115] [Article Influence: 18.2] [Reference Citation Analysis]
545 Zamin Jr. I, Mattos AAD, Mattos ÂZD, Migon E, Soares E, Perry MLS. Modelo experimental de esteatohepatite não-alcoólica com dieta deficiente em metionina e colina. Arq Gastroenterol 2009;46:69-74. [DOI: 10.1590/s0004-28032009000100017] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
546 Lonardo A, Loria P, Leonardi F, Borsatti A, Neri P, Pulvirenti M, Verrone A, Bagni A, Bertolotti M, Ganazzi D, Carulli N. Fasting insulin and uric acid levels but not indices of iron metabolism are independent predictors of non-alcoholic fatty liver disease. A case-control study. Digestive and Liver Disease 2002;34:204-11. [DOI: 10.1016/s1590-8658(02)80194-3] [Cited by in Crossref: 78] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
547 Lai MS, Hsieh MS, Chiu YH, Chen TH. Type 2 diabetes and hepatocellular carcinoma: A cohort study in high prevalence area of hepatitis virus infection. Hepatology. 2006;43:1295-1302. [PMID: 16729295 DOI: 10.1002/hep.21208] [Cited by in Crossref: 129] [Cited by in F6Publishing: 131] [Article Influence: 8.6] [Reference Citation Analysis]
548 Völzke H. Multicausality in fatty liver disease: Is there a rationale to distinguish between alcoholic and non-alcoholic origin? World J Gastroenterol 2012; 18(27): 3492-3501 [PMID: 22826613 DOI: 10.3748/wjg.v18.i27.3492] [Cited by in CrossRef: 44] [Cited by in F6Publishing: 38] [Article Influence: 4.9] [Reference Citation Analysis]
549 Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study. Gut 2005;54:533-9. [PMID: 15753540 DOI: 10.1136/gut.2004.052167] [Cited by in Crossref: 441] [Cited by in F6Publishing: 405] [Article Influence: 27.6] [Reference Citation Analysis]
550 Newsome PN. Recurrence of nonalcoholic fatty liver disease after liver transplantation: it is common, but does it affect outcome? Liver Transpl 2010;16:420-2. [PMID: 20373452 DOI: 10.1002/lt.22038] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
551 Amarapurkar D, Amarapurkar A. Indications of Liver Biopsy in the Era of Noninvasive Assessment of Liver Fibrosis. J Clin Exp Hepatol 2015;5:314-9. [PMID: 26900273 DOI: 10.1016/j.jceh.2015.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
552 Chan R, Wong VW, Chu WC, Wong GL, Li LS, Leung J, Chim AM, Yeung DK, Sea MM, Woo J, Chan FK, Chan HL. Higher estimated net endogenous Acid production may be associated with increased prevalence of nonalcoholic Fatty liver disease in chinese adults in Hong Kong. PLoS One 2015;10:e0122406. [PMID: 25905490 DOI: 10.1371/journal.pone.0122406] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 2.7] [Reference Citation Analysis]
553 Dhiman RK, Kurmi R, Thumburu KK, Venkataramarao SH, Agarwal R, Duseja A, Chawla Y. Diagnosis and prognostic significance of minimal hepatic encephalopathy in patients with cirrhosis of liver. Dig Dis Sci. 2010;55:2381-2390. [PMID: 20508990 DOI: 10.1007/s10620-010-1249-7] [Cited by in Crossref: 128] [Cited by in F6Publishing: 119] [Article Influence: 11.6] [Reference Citation Analysis]
554 Ratziu V, Giral P, Charlotte F, Bruckert E, Thibault V, Theodorou I, Khalil L, Turpin G, Opolon P, Poynard T. Liver fibrosis in overweight patients. Gastroenterology. 2000;118:1117-1123. [PMID: 10833486 DOI: 10.1016/s0016-5085(00)70364-7] [Cited by in Crossref: 628] [Cited by in F6Publishing: 195] [Article Influence: 29.9] [Reference Citation Analysis]
555 Sutedja DS, Gow PJ, Hubscher SG, Elias E. Revealing the cause of cryptogenic cirrhosis by posttransplant liver biopsy. Transplant Proc. 2004;36:2334-2337. [PMID: 15561241 DOI: 10.1016/j.transproceed.2004.07.003] [Cited by in Crossref: 31] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
556 Adams LA, Sanderson S, Lindor KD, Angulo P. The histological course of nonalcoholic fatty liver disease: a longitudinal study of 103 patients with sequential liver biopsies. J Hepatol. 2005;42:132-138. [PMID: 15629518 DOI: 10.1016/j.jhep.2004.09.012] [Cited by in Crossref: 596] [Cited by in F6Publishing: 555] [Article Influence: 37.3] [Reference Citation Analysis]
557 Sanjeevi A, Lyden E, Sunderman B, Weseman R, Ashwathnarayan R, Mukherjee S. Outcomes of liver transplantation for cryptogenic cirrhosis: a single-center study of 71 patients. Transplant Proc 2003;35:2977-80. [PMID: 14697954 DOI: 10.1016/j.transproceed.2003.10.059] [Cited by in F6Publishing: 29] [Reference Citation Analysis]
558 Watanabe S, Hashimoto E, Ikejima K, Uto H, Ono M, Sumida Y, Seike M, Takei Y, Takehara T, Tokushige K, Nakajima A, Yoneda M, Saibara T, Shiota G, Sakaida I, Nakamuta M, Mizuta T, Tsubouchi H, Sugano K, Shimosegawa T. Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatol Res. 2015;45:363-377. [PMID: 25832328 DOI: 10.1111/hepr.12511] [Cited by in Crossref: 59] [Cited by in F6Publishing: 110] [Article Influence: 9.8] [Reference Citation Analysis]
559 Alshammari GM, Balakrishnan A, Chinnasamy T. Butein protects the nonalcoholic fatty liver through mitochondrial reactive oxygen species attenuation in rats. Biofactors 2018;44:289-98. [PMID: 29672963 DOI: 10.1002/biof.1428] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
560 Sass DA, Chang P, Chopra KB. Nonalcoholic fatty liver disease: a clinical review. Dig Dis Sci. 2005;50:171-180. [PMID: 15712657 DOI: 10.1007/s10620-005-1267-z] [Cited by in Crossref: 166] [Cited by in F6Publishing: 162] [Article Influence: 10.4] [Reference Citation Analysis]
561 Pedrosa de Oliveira C, Sobroza de Mello E, Af Alves V, Mahmud Saviero S, Strauss E. Changes in histological criteria lead to different prevalences of nonalcoholic steatohepatitis in severe obesity. Annals of Hepatology 2007;6:255-61. [DOI: 10.1016/s1665-2681(19)31907-6] [Cited by in Crossref: 8] [Article Influence: 0.6] [Reference Citation Analysis]
562 Wu TC, Chen LK, Tsai SH, Liaw YH, Hwang B. Hepatic steatosis: an experimental model for quantification. Arch Gerontol Geriatr 2011;52:164-6. [PMID: 20398952 DOI: 10.1016/j.archger.2010.03.009] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
563 Wang C, Tseng T, Kao J. Hepatitis B virus infection and metabolic syndrome: Fact or fiction?: Hepatitis B virus and metabolic syndrome. J Gastroenterol Hepatol 2015;30:14-20. [DOI: 10.1111/jgh.12700] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 7.3] [Reference Citation Analysis]
564 Ascha MS, Hanouneh IA, Lopez R, Tamimi TA, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology. 2010;51:1972-1978. [PMID: 20209604 DOI: 10.1002/hep.23527] [Cited by in Crossref: 759] [Cited by in F6Publishing: 706] [Article Influence: 69.0] [Reference Citation Analysis]
565 Abdel-Razik A, Mousa N, Elalfy H, Sheta TF, Awad M, Abdelsalam M, Elhelaly R, Elzehery R, Gouda NS, Eldars W. A Novel Combination of C-Reactive Protein and Vascular Endothelial Growth Factor in Differential Diagnosis of Ascites. J Gastrointest Cancer 2017;48:50-7. [PMID: 27614744 DOI: 10.1007/s12029-016-9873-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
566 Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127:S97-103. [PMID: 15508109 DOI: 10.1053/j.gastro.2004.09.021] [Cited by in Crossref: 269] [Cited by in F6Publishing: 253] [Article Influence: 15.8] [Reference Citation Analysis]
567 Adams LA, Angulo P. Recent concepts in non-alcoholic fatty liver disease. Diabet Med 2005;22:1129-33. [DOI: 10.1111/j.1464-5491.2005.01748.x] [Cited by in Crossref: 193] [Cited by in F6Publishing: 190] [Article Influence: 12.1] [Reference Citation Analysis]
568 Peng L, Wang J, Li F, Wang J. Weight reduction for non-alcoholic fatty liver disease. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd003619.pub2] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
569 Bae JS, Lee JY, Lee DH, Kim H, Lee Y, Han JK. Quantitative Evaluation of Hepatic Steatosis Using Normalized Local Variance in a Rat Model: Comparison with Histopathology as the Reference Standard. Korean J Radiol 2019;20:1399-407. [PMID: 31464118 DOI: 10.3348/kjr.2019.0068] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
570 Lindenmeyer CC, McCullough AJ. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View. Clin Liver Dis. 2018;22:11-21. [PMID: 29128051 DOI: 10.1016/j.cld.2017.08.003] [Cited by in Crossref: 79] [Cited by in F6Publishing: 75] [Article Influence: 26.3] [Reference Citation Analysis]
571 Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2005;128:1752-1764. [PMID: 15887162 DOI: 10.1053/j.gastro.2005.03.033] [Cited by in Crossref: 93] [Cited by in F6Publishing: 86] [Article Influence: 5.8] [Reference Citation Analysis]
572 Rawla P, Sunkara T, Muralidharan P, Raj JP. Update in global trends and aetiology of hepatocellular carcinoma. Contemp Oncol (Pozn). 2018;22:141-150. [PMID: 30455585 DOI: 10.5114/wo.2018.78941] [Cited by in Crossref: 63] [Cited by in F6Publishing: 71] [Article Influence: 21.0] [Reference Citation Analysis]
573 Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM, Borsatti A, Bertolotti M, Cassani F, Bagni A. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 2003;48:2173-2181. [PMID: 14705824 DOI: 10.1023/b:ddas.0000004522.36120.08] [Cited by in Crossref: 91] [Cited by in F6Publishing: 41] [Article Influence: 5.4] [Reference Citation Analysis]
574 Sevastianos VA, Hadziyannis SJ. Nonalcoholic fatty liver disease: from clinical recognition to treatment. Expert Rev Gastroenterol Hepatol. 2008;2:59-79. [PMID: 19072371 DOI: 10.1586/17474124.2.1.59] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
575 Nanda K. Non-alcoholic steatohepatitis in children. Pediatric Transplantation 2004;8:613-8. [DOI: 10.1111/j.1399-3046.2004.00241.x] [Cited by in Crossref: 47] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
576 Pierce AA, Duwaerts CC, Siao K, Mattis AN, Goodsell A, Baron JL, Maher JJ. CD18 deficiency improves liver injury in the MCD model of steatohepatitis. PLoS One 2017;12:e0183912. [PMID: 28873429 DOI: 10.1371/journal.pone.0183912] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
577 Czaja AJ. Cryptogenic chronic hepatitis and its changing guise in adults. Dig Dis Sci. 2011;56:3421-3438. [PMID: 21647651 DOI: 10.1007/s10620-011-1769-9] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
578 Bianchi L. Liver biopsy in elevated liver functions tests? An old question revisited. J Hepatol. 2001;35:290-294. [PMID: 11580154 DOI: 10.1016/s0168-8278(01)00155-6] [Cited by in Crossref: 32] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
579 Søgaard KK, Horváth-Puhó E, Grønbaek H, Jepsen P, Vilstrup H, Sørensen HT. Risk of venous thromboembolism in patients with liver disease: a nationwide population-based case-control study. Am J Gastroenterol. 2009;104:96-101. [PMID: 19098856 DOI: 10.1038/ajg.2008.34] [Cited by in Crossref: 274] [Cited by in F6Publishing: 222] [Article Influence: 22.8] [Reference Citation Analysis]
580 Mirza MS. Obesity, Visceral Fat, and NAFLD: Querying the Role of Adipokines in the Progression of Nonalcoholic Fatty Liver Disease. ISRN Gastroenterol. 2011;2011:592404. [PMID: 21991518 DOI: 10.5402/2011/592404] [Cited by in Crossref: 63] [Cited by in F6Publishing: 72] [Article Influence: 6.3] [Reference Citation Analysis]
581 Reid AE. Nonalcoholic steatohepatitis. Gastroenterology. 2001;121:710-723. [PMID: 11522755 DOI: 10.1053/gast.2001.27126] [Cited by in Crossref: 346] [Cited by in F6Publishing: 326] [Article Influence: 17.3] [Reference Citation Analysis]
582 Hickman IJ, Macdonald GA. Impact of diabetes on the severity of liver disease. Am J Med. 2007;120:829-834. [PMID: 17904449 DOI: 10.1016/j.amjmed.2007.03.025] [Cited by in Crossref: 97] [Cited by in F6Publishing: 78] [Article Influence: 6.9] [Reference Citation Analysis]
583 Jepsen P, Vilstrup H, Andersen PK, Lash TL, Sørensen HT. Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study. Hepatology. 2008;48:214-220. [PMID: 18537190 DOI: 10.1002/hep.22341] [Cited by in Crossref: 80] [Cited by in F6Publishing: 77] [Article Influence: 6.2] [Reference Citation Analysis]
584 Abdeen MB, Chowdhury NA, Hayden MR, Ibdah JA. Nonalcoholic steatohepatitis and the cardiometabolic syndrome. J Cardiometab Syndr. 2006;1:36-40. [PMID: 17675901 DOI: 10.1111/j.0197-3118.2006.05523.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 20] [Article Influence: 1.2] [Reference Citation Analysis]
585 Vodkin I, Valasek MA, Bettencourt R, Cachay E, Loomba R. Clinical, biochemical and histological differences between HIV-associated NAFLD and primary NAFLD: a case-control study. Aliment Pharmacol Ther. 2015;41:368-378. [PMID: 25496369 DOI: 10.1111/apt.13052] [Cited by in Crossref: 64] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
586 Sutedja DS, Gow PJ, Hubscher SG, Elias E. Revealing the cause of cryptogenic cirrhosis by posttransplant liver biopsy. Transplant Proc. 2004;36:2334-2337. [PMID: 15561241 DOI: http: //dx.doi.orq/10.1016/j.transproceed.2004.07.003] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
587 Lee WJ, Uradomo LT, Zhang Y, Twaddell W, Darwin P. Comparison of the Diagnostic Yield of EUS Needles for Liver Biopsy: Ex Vivo Study. Diagn Ther Endosc 2017;2017:1497831. [PMID: 29056843 DOI: 10.1155/2017/1497831] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
588 Chtioui H, Semela D, Ledermann M, Zimmermann A, Dufour JF. Expression and activity of the cytochrome P450 2E1 in patients with nonalcoholic steatosis and steatohepatitis. Liver Int. 2007;27:764-771. [PMID: 17617119 DOI: 10.1111/j.1478-3231.2007.01524.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 35] [Article Influence: 2.4] [Reference Citation Analysis]
589 Fernández-real JM, Ortega F, Gómez-ambrosi J, Salvador J, Frühbeck G, Ricart W. Circulating osteocalcin concentrations are associated with parameters of liver fat infiltration and increase in parallel to decreased liver enzymes after weight loss. Osteoporos Int 2010;21:2101-7. [DOI: 10.1007/s00198-010-1174-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
590 Nozaki Y, Saibara T, Nemoto Y, Ono M, Akisawa N, Iwasaki S, Hayashi Y, Hiroi M, Enzan H, Onishi S. Polymorphisms of Interleukin-1beta and beta3-Adrenergic Receptor in Japanese Patients With Nonalcoholic Steatohepatitis. Alcoholism Clin Exp Res 2004;28:106S-10S. [DOI: 10.1111/j.1530-0277.2004.tb03226.x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 21] [Article Influence: 0.2] [Reference Citation Analysis]
591 Ezzat WM, Ragab S, Ismail NA, Elhosary YA, Elbaky AMNEA, Farouk H, Rasheed IA. Frequency of non-alcoholic fatty liver disease in overweight/obese children and adults: Clinical, sonographic picture and biochemical assessment. Journal of Genetic Engineering and Biotechnology 2012;10:221-7. [DOI: 10.1016/j.jgeb.2012.05.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
592 Mignot A, Ayav A, Quillot D, Zuily S, Petit I, Nguyen-thi PL, Malgras A, Laurent V. Extensive lymph node dissection during pancreaticoduodenectomy: a risk factor for hepatic steatosis? Abdom Radiol 2017;42:1880-7. [DOI: 10.1007/s00261-017-1087-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
593 Su Y, Liu Z, Yang L, Li Y, Jiang S, Yao H, Du G. PPARγ gene Pro12Ala variants reduce the risk of obese individuals to non-alcoholic fatty liver: A study in Uygur Chinese population residing in Northwestern China. Clin Res Hepatol Gastroenterol 2020;44:894-904. [PMID: 32505733 DOI: 10.1016/j.clinre.2020.02.005] [Reference Citation Analysis]
594 de Freitas AC, Campos AC, Coelho JC. The impact of bariatric surgery on nonalcoholic fatty liver disease. Curr Opin Clin Nutr Metab Care. 2008;11:267-274. [PMID: 18403923 DOI: 10.1097/mco.0b013e3282fbd33f] [Cited by in Crossref: 19] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
595 Gaya DR, McLay AL, Oien KA, Spooner RJ, Reilly TG. A tale of two sisters. J Clin Pathol 2004;57:439-41. [PMID: 15047754 DOI: 10.1136/jcp.2003.012013] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
596 Jawairia M, Subhani M, Siddiqui G, Prasad A, Shahzad G, Rizvon K, Mustacchia P. Unexplained findings of kayser-fleischer-like rings in a patient with cryptogenic cirrhosis. Case Rep Gastrointest Med 2012;2012:438525. [PMID: 22606437 DOI: 10.1155/2012/438525] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.1] [Reference Citation Analysis]
597 Mehrabian F, Jahanmardi R. Nonalcoholic Fatty Liver Disease in a Sample of Iranian Women with Polycystic Ovary Syndrome. Int J Prev Med 2017;8:79. [PMID: 29114377 DOI: 10.4103/ijpvm.IJPVM_305_16] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
598 Brunt EM. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in Diagnostic Pathology 2005;22:330-8. [DOI: 10.1053/j.semdp.2006.04.002] [Cited by in Crossref: 58] [Cited by in F6Publishing: 57] [Article Influence: 3.6] [Reference Citation Analysis]
599 Bugianesi E, Leone N, Vanni E, Marchesini G, Brunello F, Carucci P, Musso A, De Paolis P, Capussotti L, Salizzoni M, Rizzetto M. Expanding the natural history of nonalcoholic steatohepatitis: From cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. [DOI: 10.1053/gast.2002.34168] [Cited by in Crossref: 998] [Cited by in F6Publishing: 936] [Article Influence: 52.5] [Reference Citation Analysis]
600 Kumar D, Farrell GC, Kench J, George J. Hepatic steatosis and the risk of hepatocellular carcinoma in chronic hepatitis C. J Gastroenterol Hepatol. 2005;20:1395-1400. [PMID: 16105127 DOI: 10.1111/j.1440-1746.2005.04007.x] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.0] [Reference Citation Analysis]
601 Tsai JF, Jeng JE, Chuang LY, Ho MS, Ko YC, Lin ZY, Hsieh MY, Chen SC, Chuang WL, Wang LY. Habitual betel quid chewing as a risk factor for cirrhosis: a case-control study. Medicine (Baltimore). 2003;82:365-372. [PMID: 14530785 DOI: 10.1097/01.md.0000090401.56130.59] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.1] [Reference Citation Analysis]
602 Adams LA, Angulo P. Role of Liver Biopsy and Serum Markers of Liver Fibrosis in Non-alcoholic Fatty Liver Disease. Clinics in Liver Disease 2007;11:25-35. [DOI: 10.1016/j.cld.2007.02.004] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 3.6] [Reference Citation Analysis]
603 Hessheimer AJ, Forner A, Varela M, Bruix J. Metabolic risk factors are a major comorbidity in patients with cirrhosis independent of the presence of hepatocellular carcinoma. Eur J Gastroenterol Hepatol. 2010;22:1239-1244. [PMID: 20505515 DOI: 10.1097/meg.0b013e32833aa19b] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
604 Mendes FD, Suzuki A, Sanderson SO, Lindor KD, Angulo P. Prevalence and indicators of portal hypertension in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10:1028-33.e2. [PMID: 22610002 DOI: 10.1016/j.cgh.2012.05.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 38] [Article Influence: 4.3] [Reference Citation Analysis]
605 Noureddin M, Vipani A, Bresee C, Todo T, Kim IK, Alkhouri N, Setiawan VW, Tran T, Ayoub WS, Lu SC, Klein AS, Sundaram V, Nissen NN. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances. Am J Gastroenterol. 2018;113:1649-1659. [PMID: 29880964 DOI: 10.1038/s41395-018-0088-6] [Cited by in Crossref: 181] [Cited by in F6Publishing: 169] [Article Influence: 60.3] [Reference Citation Analysis]
606 Basaranoglu M, Basaranoglu G, Sentürk H. From fatty liver to fibrosis: A tale of “second hit”. World J Gastroenterol 2013; 19(8): 1158-1165 [PMID: 23483818 DOI: 10.3748/wjg.v19.i8.1158] [Cited by in CrossRef: 100] [Cited by in F6Publishing: 96] [Article Influence: 12.5] [Reference Citation Analysis]
607 George J, Liddle C. Nonalcoholic Fatty Liver Disease: Pathogenesis and Potential for Nuclear Receptors as Therapeutic Targets. Mol Pharmaceutics 2008;5:49-59. [DOI: 10.1021/mp700110z] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 4.0] [Reference Citation Analysis]
608 Nardone G, Rocco A. Probiotics: a potential target for the prevention and treatment of steatohepatitis. J Clin Gastroenterol. 2004;38:S121-S122. [PMID: 15220676 DOI: 10.1097/01.mcg.0000128934.53920.1d] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.1] [Reference Citation Analysis]
609 Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Noninvasive biomarkers in NAFLD and NASH — current progress and future promise. Nat Rev Gastroenterol Hepatol 2018;15:461-78. [DOI: 10.1038/s41575-018-0014-9] [Cited by in Crossref: 153] [Cited by in F6Publishing: 147] [Article Influence: 51.0] [Reference Citation Analysis]
610 Kamiya T, Sameshima-Kamiya M, Nagamine R, Tsubata M, Ikeguchi M, Takagaki K, Shimada T, Aburada M. The crude extract from puerariae flower exerts antiobesity and antifatty liver effects in high-fat diet-induced obese mice. Evid Based Complement Alternat Med. 2012;2012:272710. [PMID: 22685484 DOI: 10.1155/2012/272710] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
611 Carulli N. Metabolic syndrome - cardiovascular disease risk and more. Aliment Pharmacol Ther 2005;22:1-2. [DOI: 10.1111/j.1365-2036.2005.02586.x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
612 Straś W, Małkowski P, Tronina O. Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis - epidemiology, risk factors, clinical implications and treatment. Clin Exp Hepatol 2020;6:170-5. [PMID: 33145423 DOI: 10.5114/ceh.2020.99506] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
613 Bertolotti M, Lonardo A, Mussi C, Baldelli E, Pellegrini E, Ballestri S, Romagnoli D, Loria P. Nonalcoholic fatty liver disease and aging: Epidemiology to management. World J Gastroenterol 2014; 20(39): 14185-14204 [PMID: 25339806 DOI: 10.3748/wjg.v20.i39.14185] [Cited by in CrossRef: 143] [Cited by in F6Publishing: 126] [Article Influence: 20.4] [Reference Citation Analysis]
614 Amarapurkar A, Ghansar T. Fatty liver: Experience from western India. Annals of Hepatology 2007;6:37-40. [DOI: 10.1016/s1665-2681(19)31951-9] [Cited by in Crossref: 14] [Article Influence: 1.0] [Reference Citation Analysis]
615 Jiménez R, Hijona E, Emparanza J, Alústiza JM, Hijona L, Macarulla MT, Portillo MP, Herreros-Villanueva M, Beguiristain A, Arenas J, Bujanda L. Effect of neoadjuvant chemotherapy in hepatic steatosis. Chemotherapy 2012;58:89-94. [PMID: 22377819 DOI: 10.1159/000336133] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
616 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
617 Eiszrich Á, Fehér J. Fatty liver in childhood. Orvosi Hetilap 2007;148:2461-8. [DOI: 10.1556/oh.2007.28270] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
618 Khan FZ, Perumpail RB, Wong RJ, Ahmed A. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 2015; 7(18): 2155-2161 [PMID: 26328027 DOI: 10.4254/wjh.v7.i18.2155] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 6.5] [Reference Citation Analysis]
619 Thuluvath PJ, Hanish S, Savva Y. Liver Transplantation in Cryptogenic Cirrhosis: Outcome Comparisons Between NASH, Alcoholic, and AIH Cirrhosis. Transplantation 2018;102:656-63. [DOI: 10.1097/tp.0000000000002030] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
620 Siebler J, Schuchmann M, Strand S, Lehr HA, Neurath MF, Galle PR. Enhanced sensitivity to CD95-induced apoptosis in ob/ob mice. Dig Dis Sci. 2007;52:2396-2402. [PMID: 17415659 DOI: 10.1007/s10620-006-9148-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
621 Fassio E, Álvarez E, Domínguez N, Landeira G, Longo C. Natural history of nonalcoholic steathepatitis: A longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6. [DOI: 10.1002/hep.1840400411] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
622 Dureja P, Mellinger J, Agni R, Chang F, Avey G, Lucey M, Said A. NAFLD recurrence in liver transplant recipients. Transplantation. 2011;91:684-689. [PMID: 21248661 DOI: 10.1097/tp.0b013e31820b6b84] [Cited by in Crossref: 105] [Cited by in F6Publishing: 31] [Article Influence: 10.5] [Reference Citation Analysis]
623 Gutierrez-grobe Y, Ponciano-rodríguez G, Ramos MH, Uribe M, Méndez-sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, posmenopausal and polycystic ovary syndrome women. The role of estrogens. Annals of Hepatology 2010;9:402-9. [DOI: 10.1016/s1665-2681(19)31616-3] [Cited by in Crossref: 119] [Article Influence: 10.8] [Reference Citation Analysis]
624 Satapathy SK, Nair S, Vanatta JM. Nonalcoholic fatty liver disease following liver transplantation. Hepatol Int 2013;7:400-12. [PMID: 26201774 DOI: 10.1007/s12072-013-9434-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
625 Thong VD, Quynh BTH. Correlation of Serum Transaminase Levels with Liver Fibrosis Assessed by Transient Elastography in Vietnamese Patients with Nonalcoholic Fatty Liver Disease. Int J Gen Med 2021;14:1349-55. [PMID: 33889015 DOI: 10.2147/IJGM.S309311] [Reference Citation Analysis]
626 Merat S, Malekzadeh R, Sohrabi MR, Sotoudeh M, Rakhshani N, Sohrabpour AA, Naserimoghadam S. Probucol in the treatment of non-alcoholic steatohepatitis: a double-blind randomized controlled study. J Hepatol 2003;38:414-8. [PMID: 12663231 DOI: 10.1016/s0168-8278(02)00441-5] [Cited by in Crossref: 86] [Cited by in F6Publishing: 24] [Article Influence: 4.8] [Reference Citation Analysis]
627 Stepanova M, Hossain N, Afendy A, Perry K, Goodman ZD, Baranova A, Younossi Z. Hepatic gene expression of Caucasian and African-American patients with obesity-related non-alcoholic fatty liver disease. Obes Surg. 2010;20:640-650. [PMID: 20119733 DOI: 10.1007/s11695-010-0078-2] [Cited by in Crossref: 34] [Cited by in F6Publishing: 37] [Article Influence: 3.1] [Reference Citation Analysis]
628 Ahishali E, Demir K, Ahishali B, Akyuz F, Pinarbasi B, Poturoglu S, Ibrisim D, Gulluoglu M, Ozdil S, Besisik F. Electron microscopic findings in non-alcoholic fatty liver disease: is there a difference between hepatosteatosis and steatohepatitis? J Gastroenterol Hepatol. 2010;25:619-626. [PMID: 20370732 DOI: 10.1111/j.1440-1746.2009.06142.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 2.0] [Reference Citation Analysis]
629 Hashimoto E, Tokushige K. Hepatocellular carcinoma in non-alcoholic steatohepatitis: Growing evidence of an epidemic? Hepatol Res. 2012;42:1-14. [PMID: 21917086 DOI: 10.1111/j.1872-034x.2011.00872.x] [Cited by in Crossref: 78] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
630 Malik SM, Devera ME, Fontes P, Shaikh O, Sasatomi E, Ahmad J. Recurrent disease following liver transplantation for nonalcoholic steatohepatitis cirrhosis. Liver Transpl. 2009;15:1843-1851. [PMID: 19938117 DOI: 10.1002/lt.21943] [Cited by in Crossref: 80] [Cited by in F6Publishing: 62] [Article Influence: 7.3] [Reference Citation Analysis]
631 Sebastiani G. Non-invasive assessment of liver fibrosis in chronic liver diseases: Implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15(18): 2190-2203 [PMID: 19437558 DOI: 10.3748/wjg.15.2190] [Cited by in CrossRef: 50] [Cited by in F6Publishing: 50] [Article Influence: 4.2] [Reference Citation Analysis]
632 Takahashi Y, Fukusato T. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol 2014; 20(42): 15539-15548 [PMID: 25400438 DOI: 10.3748/wjg.v20.i42.15539] [Cited by in CrossRef: 165] [Cited by in F6Publishing: 140] [Article Influence: 23.6] [Reference Citation Analysis]
633 Ladegaard Grønkjær L, Holmstrup P, Schou S, Jepsen P, Vilstrup H. Severe periodontitis and higher cirrhosis mortality. United European Gastroenterol J 2018;6:73-80. [PMID: 29435316 DOI: 10.1177/2050640617715846] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
634 Dowman JK, Armstrong MJ, Tomlinson JW, Newsome PN. Current therapeutic strategies in non-alcoholic fatty liver disease. Diabetes, Obesity and Metabolism 2011;13:692-702. [DOI: 10.1111/j.1463-1326.2011.01403.x] [Cited by in Crossref: 80] [Cited by in F6Publishing: 80] [Article Influence: 8.0] [Reference Citation Analysis]
635 Nair S, Verma S, Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology. 2002;35:105-109. [PMID: 11786965 DOI: 10.1053/jhep.2002.30318] [Cited by in Crossref: 293] [Cited by in F6Publishing: 233] [Article Influence: 15.4] [Reference Citation Analysis]
636 Kutsenko A, Ladenheim MR, Kim N, Nguyen P, Chen V, Jayasekera C, Yang JD, Kumari R, Roberts L, Nguyen MH. Increased Prevalence of Metabolic Risk Factors in Asian Americans With Hepatocellular Carcinoma. Journal of Clinical Gastroenterology 2017;51:384-90. [DOI: 10.1097/mcg.0000000000000689] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
637 Baffy G. Editorial: Hepatocellular Carcinoma in Type 2 Diabetes: More Than Meets the Eye. American Journal of Gastroenterology 2012;107:53-5. [DOI: 10.1038/ajg.2011.390] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.0] [Reference Citation Analysis]
638 Malik R, Lai M, Sadiq A, Farnan R, Mehta S, Nasser I, Challies T, Schuppan D, Afdhal N. Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis. J Gastroenterol Hepatol. 2010;25:1562-1568. [PMID: 20796156 DOI: 10.1111/j.1440-1746.2010.06371.x] [Cited by in Crossref: 36] [Cited by in F6Publishing: 35] [Article Influence: 3.3] [Reference Citation Analysis]
639 Cortez-pinto H, Ermelinda Camilo M. Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): diagnosis and clinical course. Best Practice & Research Clinical Gastroenterology 2004;18:1089-104. [DOI: 10.1016/j.bpg.2004.06.021] [Cited by in Crossref: 56] [Cited by in F6Publishing: 47] [Article Influence: 3.3] [Reference Citation Analysis]
640 Garcia-Compean D, Jaquez-Quintana JO, Gonzalez-Gonzalez JA, Maldonado-Garza H. Liver cirrhosis and diabetes: Risk factors, pathophysiology, clinical implications and management. World J Gastroenterol 2009; 15(3): 280-288 [PMID: 19140227 DOI: 10.3748/wjg.15.280] [Cited by in CrossRef: 196] [Cited by in F6Publishing: 180] [Article Influence: 16.3] [Reference Citation Analysis]
641 Hanaka H, Hamada T, Ito M, Nakashima H, Tomita K, Seki S, Kobayashi Y, Imaki J. Fibroblast growth factor-5 participates in the progression of hepatic fibrosis. Exp Anim. 2014;63:85-92. [PMID: 24521867 DOI: 10.1538/expanim.63.85] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
642 Siegel AB, Wang S, Jacobson JS, Hershman DL, Lim EA, Yu J, Ferrante L, Devaraj KM, Remotti H, Scrudato S, Halazun K, Emond J, Dove L, Brown RS Jr, Neugut AI. Obesity and microvascular invasion in hepatocellular carcinoma. Cancer Invest 2010;28:1063-9. [PMID: 21077757 DOI: 10.3109/07357907.2010.483500] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
643 Angulo P, Bugianesi E, Bjornsson ES, Charatcharoenwitthaya P, Mills PR, Barrera F, Haflidadottir S, Day CP, George J. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2013;145:782-9.e4. [PMID: 23860502 DOI: 10.1053/j.gastro.2013.06.057] [Cited by in Crossref: 286] [Cited by in F6Publishing: 258] [Article Influence: 35.8] [Reference Citation Analysis]
644 Clemente Ricote G, García Monzón C. Estado actual de la esteatohepatitis no alcohólica. Medicina Clínica 2003;121:102-8. [DOI: 10.1016/s0025-7753(03)73870-6] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
645 Tannapfel A, Denk H, Dienes H, Langner C, Schirmacher P, Trauner M, Flott-rahmel B. Histopathologische Diagnose der nichtalkoholischen und alkoholischen Fettlebererkrankung: Konsensusbasierte Leitlinie der Stufe 2. Pathologe 2010;31:225-37. [DOI: 10.1007/s00292-010-1274-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 12] [Article Influence: 0.6] [Reference Citation Analysis]
646 Fleming KM, Aithal GP, Solaymani-Dodaran M, Card TR, West J. Incidence and prevalence of cirrhosis in the United Kingdom, 1992-2001: a general population-based study. J Hepatol. 2008;49:732-738. [PMID: 18667256 DOI: 10.1016/j.jhep.2008.05.023] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 8.3] [Reference Citation Analysis]
647 Burke A, Lucey MR. Non-Alcoholic Fatty Liver Disease, Non-Alcoholic Steatohepatitis and Orthotopic Liver Transplantation. Am J Transplant 2004;4:686-93. [DOI: 10.1111/j.1600-6143.2004.00432.x] [Cited by in Crossref: 149] [Cited by in F6Publishing: 123] [Article Influence: 8.8] [Reference Citation Analysis]
648 Runyon BA. Ascites and Spontaneous Bacterial Peritonitis. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 1517-1541.e4. [DOI: 10.1016/b978-1-4160-6189-2.00091-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 1] [Article Influence: 1.1] [Reference Citation Analysis]
649 Caldwell SH, Hespenheide EE. Subacute liver failure in obese women. Am J Gastroenterology 2002;97:2058-62. [DOI: 10.1111/j.1572-0241.2002.05922.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 43] [Article Influence: 2.9] [Reference Citation Analysis]
650 Nascimbeni F, Pais R, Bellentani S, Day CP, Ratziu V, Loria P, Lonardo A. From NAFLD in clinical practice to answers from guidelines. J Hepatol. 2013;59:859-871. [PMID: 23751754 DOI: 10.1016/j.jhep.2013.05.044] [Cited by in Crossref: 223] [Cited by in F6Publishing: 203] [Article Influence: 27.9] [Reference Citation Analysis]
651 Wong SW, Ting YW, Chan WK. Epidemiology of non-alcoholic fatty liver disease-related hepatocellular carcinoma and its implications. JGH Open 2018;2:235-41. [PMID: 30483595 DOI: 10.1002/jgh3.12070] [Cited by in Crossref: 22] [Cited by in F6Publishing: 25] [Article Influence: 7.3] [Reference Citation Analysis]
652 Nair S, Mason A, Eason J, Loss G, Perrillo RP. Is obesity an independent risk factor for hepatocellular carcinoma in cirrhosis? Hepatology 2002;36:150-5. [PMID: 12085359 DOI: 10.1053/jhep.2002.33713] [Cited by in Crossref: 224] [Cited by in F6Publishing: 197] [Article Influence: 11.8] [Reference Citation Analysis]
653 Pierach CA. Foie gras. J Lab Clin Med 2005;145:231-2. [PMID: 15902094 DOI: 10.1016/j.lab.2005.02.012] [Reference Citation Analysis]
654 Angulo P. Nonalcoholic fatty liver disease and liver transplantation. Liver Transpl. 2006;12:523-534. [PMID: 16555318 DOI: 10.1002/lt.20738] [Cited by in Crossref: 104] [Cited by in F6Publishing: 97] [Article Influence: 6.9] [Reference Citation Analysis]
655 Takino JI, Nagamine K, Hori T, Sakasai-Sakai A, Takeuchi M. Contribution of the toxic advanced glycation end-products-receptor axis in nonalcoholic steatohepatitis-related hepatocellular carcinoma. World J Hepatol 2015; 7(23): 2459-2469 [PMID: 26483867 DOI: 10.4254/wjh.v7.i23.2459] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 3.2] [Reference Citation Analysis]
656 Yunianingtias D, Volker D. Nutritional aspects of non-alcoholic steatohepatitis treatment. Nutrition & Dietetics 2006;63:79-90. [DOI: 10.1111/j.1747-0080.2006.00054.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
657 Fraisse T, Savey L, Hentgen V, Rossi-Semerano L, Koné-Paut I, Grateau G, Georgin-Lavialle S, Ducharme-Bénard S. Non-amyloid liver involvement in familial Mediterranean fever: A systematic literature review. Liver Int 2020;40:1269-77. [PMID: 32196885 DOI: 10.1111/liv.14445] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
658 Struben VM, Hespenheide EE, Caldwell SH. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am J Med. 2000;108:9-13. [PMID: 11059435 DOI: 10.1016/s0002-9343(99)00315-0] [Cited by in Crossref: 192] [Cited by in F6Publishing: 60] [Article Influence: 9.1] [Reference Citation Analysis]
659 Wang R, Koretz RL, Yee HF, Wang R. Weight reduction for non-alcoholic fatty liver. Cochrane Database of Systematic Reviews. Chichester: John Wiley & Sons, Ltd; 1996. [DOI: 10.1002/14651858.cd003619] [Cited by in Crossref: 4] [Article Influence: 0.2] [Reference Citation Analysis]
660 Dong H, Wang J, Li C, Hirose A, Nozaki Y, Takahashi M, Ono M, Akisawa N, Iwasaki S, Saibara T. The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population. J Hepatol. 2007;46:915-920. [PMID: 17391797 DOI: 10.1016/j.jhep.2006.12.012] [Cited by in Crossref: 75] [Cited by in F6Publishing: 75] [Article Influence: 5.4] [Reference Citation Analysis]
661 Brunt EM, Kleiner DE, Wilson LA, Unalp A, Behling CE, Lavine JE, Neuschwander-Tetri BA; NASH Clinical Research NetworkA list of members of the Nonalcoholic Steatohepatitis Clinical Research Network can be found in the Appendix. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD-Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009;49:809-20. [PMID: 19142989 DOI: 10.1002/hep.22724] [Cited by in Crossref: 243] [Cited by in F6Publishing: 224] [Article Influence: 20.3] [Reference Citation Analysis]
662 Yang YJ, Jung MH, Jeong SH, Hong YP, Kim YI, An SJ. The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES). Int J Environ Res Public Health 2020;17:E9568. [PMID: 33371282 DOI: 10.3390/ijerph17249568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
663 Kumar R, Rastogi A, Sharma MK, Bhatia V, Tyagi P, Sharma P, Garg H, Chandan Kumar KN, Bihari C, Sarin SK. Liver stiffness measurements in patients with different stages of nonalcoholic fatty liver disease: diagnostic performance and clinicopathological correlation. Dig Dis Sci 2013;58:265-74. [PMID: 22790906 DOI: 10.1007/s10620-012-2306-1] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 6.1] [Reference Citation Analysis]
664 M. Brunt E, G. Tiniakos D. Fatty Liver Disease. Surgical Pathology of the GI Tract, Liver, Biliary Tract, and Pancreas. Elsevier; 2009. pp. 1087-114. [DOI: 10.1016/b978-141604059-0.50044-8] [Cited by in Crossref: 8] [Article Influence: 0.7] [Reference Citation Analysis]
665 Álamo JM, Bernal C, Barrera L, Marín LM, Suárez G, Serrano J, Gómez MA, Padillo FJ. Liver transplantation in patients with cryptogenic cirrhosis: long-term follow-up. Transplant Proc. 2011;43:2230-2232. [PMID: 21839241 DOI: 10.1016/j.transproceed.2011.05.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
666 Hamed MA, Ali SA. Non-viral factors contributing to hepatocellular carcinoma. World J Hepatol. 2013;5:311-322. [PMID: 23805355 DOI: 10.4254/wjh.v.5.i6.311] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
667 Margini C, Dufour JF. The story of HCC in NAFLD: from epidemiology, across pathogenesis, to prevention and treatment. Liver Int 2016;36:317-24. [DOI: 10.1111/liv.13031] [Cited by in Crossref: 113] [Cited by in F6Publishing: 110] [Article Influence: 18.8] [Reference Citation Analysis]
668 Charlton MR, Burns JM, Pedersen RA, Watt KD, Heimbach JK, Dierkhising RA. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology. 2011;141:1249-1253. [PMID: 21726509 DOI: 10.1053/j.gastro.2011.06.061] [Cited by in Crossref: 770] [Cited by in F6Publishing: 691] [Article Influence: 77.0] [Reference Citation Analysis]
669 Ma C, Brunt EM. Histopathologic Evaluation of Liver Biopsy for Cirrhosis. Advances in Anatomic Pathology 2012;19:220-30. [DOI: 10.1097/pap.0b013e31825c6bab] [Cited by in Crossref: 11] [Cited by in F6Publishing: 1] [Article Influence: 1.2] [Reference Citation Analysis]
670 Asano T, Watanabe K, Kubota N, Gunji T, Omata M, Kadowaki T, Ohnishi S. Adiponectin knockout mice on high fat diet develop fibrosing steatohepatitis. J Gastroenterol Hepatol. 2009;24:1669-1676. [PMID: 19788607 DOI: 10.1111/j.1440-1746.2009.06039.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 65] [Article Influence: 5.4] [Reference Citation Analysis]
671 Musso G. Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 2003;37:909-16. [DOI: 10.1053/jhep.2003.50132] [Cited by in Crossref: 484] [Cited by in F6Publishing: 450] [Article Influence: 26.9] [Reference Citation Analysis]
672 Yakaryilmaz F, Guliter S, Ozenirler S, Erdem O, Akyol G. Vitamin E treatment in patients with nonalcoholic steatohepatitis: A six-month, open-label study of sixteen patients. Curr Ther Res Clin Exp 2004;65:266-77. [PMID: 24672082 DOI: 10.1016/S0011-393X(04)80077-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
673 Berhane S, Fox R, García-Fiñana M, Cucchetti A, Johnson P. Using prognostic and predictive clinical features to make personalised survival prediction in advanced hepatocellular carcinoma patients undergoing sorafenib treatment. Br J Cancer 2019;121:117-24. [PMID: 31182766 DOI: 10.1038/s41416-019-0488-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 7.5] [Reference Citation Analysis]
674 Wang RT, Koretz RL, Yee HF. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med. 2003;115:554-559. [PMID: 14599635 DOI: 10.1016/s0002-9343(03)00449-2] [Cited by in Crossref: 108] [Cited by in F6Publishing: 32] [Article Influence: 6.0] [Reference Citation Analysis]
675 Argo CK, Caldwell SH. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. Clinics in Liver Disease 2009;13:511-31. [DOI: 10.1016/j.cld.2009.07.005] [Cited by in Crossref: 247] [Cited by in F6Publishing: 224] [Article Influence: 20.6] [Reference Citation Analysis]
676 Keyvani H, Bokharaei-Salim F, Monavari SH, Esghaei M, Nassiri Toosi M, Fakhim S, Sadigh ZA, Alavian SM. Occult hepatitis C virus infection in candidates for liver transplant with cryptogenic cirrhosis. Hepat Mon 2013;13:e11290. [PMID: 24082889 DOI: 10.5812/hepatmon.11290] [Cited by in Crossref: 36] [Cited by in F6Publishing: 34] [Article Influence: 4.5] [Reference Citation Analysis]
677 Judi L, Toukan A, Khader Y, Ajlouni K, Khatib MA. Prevalence of elevated hepatic transaminases among Jordanian patients with type 2 diabetes mellitus. Ann Saudi Med 2010;30:25-32. [DOI: 10.5144/0256-4947.59369] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
678 Lee WG, Wells CI, Mccall JL, Murphy R, Plank LD. Prevalence of diabetes in liver cirrhosis: A systematic review and meta‐analysis. Diabetes Metab Res Rev 2019;35. [DOI: 10.1002/dmrr.3157] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
679 Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, Rivas P, Barreiro P, Mura MS, Babudieri S, Garcia-Samaniego J, González-Lahoz J, Soriano V. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177-82. [PMID: 16688096 DOI: 10.1097/01.qai.0000221683.44940.62] [Cited by in Crossref: 120] [Cited by in F6Publishing: 108] [Article Influence: 8.0] [Reference Citation Analysis]
680 Zamin I Jr, Mattos AA, Mattos AZ, Coral G, Santos D, Rhoden C. The vitamin E reduces liver lipoperoxidation and fibrosis in a model of nonalcoholic steatohepatitis. Arq Gastroenterol 2010;47:86-92. [PMID: 20520981 DOI: